var title_f17_47_18160="Cholesteatoma mechanisms";
var content_f17_47_18160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F56231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F56231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Mechanism of acquired retraction pocket cholesteatoma formation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    As a retraction pocket is progressively drawn in, it forms a large pouch with a narrow neck that traps desquamating cells.",
"    <br>",
"     (A) Normal drum in cross-section.",
"     <br>",
"      (B) Shallow focal retraction.",
"      <br>",
"       (C) Deep retraction with collection of keratin debris.",
"       <br>",
"        (D) Infected cholesteatoma with granulation at its mouth.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reproduced with permission from: Isaacson G. Diagnosis of pediatric cholesteatoma. Pediatrics 2007; 120:603. Copyright &copy; 2007 by the AAP.",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18160=[""].join("\n");
var outline_f17_47_18160=null;
var title_f17_47_18161="Sucking blister";
var content_f17_47_18161=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sucking blister",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A blister is present on the thumb of this neonate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18161=[""].join("\n");
var outline_f17_47_18161=null;
var title_f17_47_18162="Retroflexed view esophagogastric junction and proximal stomach";
var content_f17_47_18162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retroflexed view of the esophagogastric junction and the proximal stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Appearance of the endoscope and fundus during esophagogastroduodenoscopy. The endoscope is in a retroflexed configuration to achieve visualization of the fundus and the esophagogastric junction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18162=[""].join("\n");
var outline_f17_47_18162=null;
var title_f17_47_18163="Marcus Gunn Jaw winking";
var content_f17_47_18163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Child with Marcus Gunn Jaw winking ptosis of the right eye",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    As the child sucks on a bottle, the right upper lid opens due to aberrant innervation of the levator by the mandibular branch of CN V.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of C Gail Summers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18163=[""].join("\n");
var outline_f17_47_18163=null;
var title_f17_47_18164="AVMs APC Endosc";
var content_f17_47_18164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Arteriovenous malformation in the gastrointestinal tract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic views of arteriovenous malformations being treated with the argon plasma coagulator (APC). The top panels illustrate the appearance before and after APC coagulation. The bottom panels demonstrate the ability of APC to treat lesions tangentially. It is important to see the black portion of the APC cathether prior to initiating coagulation to prevent damage to the endoscope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Cohen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18164=[""].join("\n");
var outline_f17_47_18164=null;
var title_f17_47_18165="Vaccinia virus in the research setting";
var content_f17_47_18165=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vaccinia virus in the research setting",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18165/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18165/contributors\">",
"     Stuart N Isaacs, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18165/contributors\">",
"     Harvey M Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18165/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18165/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18165/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18165/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/47/18165/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccinia virus was the live poxvirus used throughout the world as the vaccine against smallpox. With the worldwide eradication of smallpox, routine vaccination with vaccinia virus is no longer performed. However, after the anthrax bioterrorism attack in October 2001, there was a debate about the advisability of reinitiating routine vaccination against smallpox [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even prior to the potential need to revaccinate an at-risk population due to concerns about bioterrorism with smallpox, vaccinia virus has remained important to understand because of its widespread use as an expression vector in research laboratories and because of its potential use as a vector for recombinant vaccines or as an oncolytic agent. In addition, the military continues to routinely vaccinate recruits against smallpox.",
"   </p>",
"   <p>",
"    Infectious diseases physicians may be asked about the advisability of vaccination for occupational exposure to vaccinia virus or other orthopoxviruses. Since routine vaccination was stopped in the United States in the 1970s, current decisions about vaccination are now made when there are an ever-expanding number of students and researchers who are working with vaccinia virus who were never vaccinated as children.",
"   </p>",
"   <p>",
"    Issues related to vaccinia virus in the research setting will be reviewed here. Vaccinia virus as the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40057?source=see_link\">",
"     \"Vaccinia virus as the smallpox vaccine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GUIDELINE RECOMMENDATIONS FOR RESEARCHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controversy exists as to whether to vaccinate all researchers working with vaccinia virus since the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    has had an imperfect safety record resulting in both mild and severe adverse reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CDC and the Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of laboratory workers handling vaccinia virus or other non-variola orthopoxviruses as well as persons working in animal care areas where these viruses are being used [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, the United Kingdom Joint Committees on Dangerous Pathogens and Genetic Modification does not support routine vaccination of all researchers working with vaccinia virus [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INSTITUTIONAL POLICIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many institutions in the United States have set policies that strictly follow the ACIP recommendations and only allow work with vaccinia virus to be carried out by vaccinated individuals.",
"   </p>",
"   <p>",
"    Other institutions allow the individual researcher, after talking to healthcare providers in occupational health, to decide to accept or decline vaccination. This approach is similar to policies that allow healthcare workers to decline recommended vaccines that confer protection against substantially more dangerous or contagious infections. An example of such documentation can be found at the University of Pennsylvania Office of Environmental Health and Safety web site:",
"    <a class=\"external\" href=\"file://www.ehrs.upenn.edu/protocols/vaccinia.html\">",
"     www.ehrs.upenn.edu/protocols/vaccinia.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROS AND CONS OF VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pros and cons of vaccinating all research workers who work with vaccinia virus is discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/3,9,11-14\">",
"     3,9,11-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Arguments for vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the years there have been a number of published case reports of laboratory accidents involving vaccinia virus. From 2005 to 2007, five cases of laboratory-acquired vaccinia virus infection were reported to CDC during informal consultations regarding management [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/15\">",
"     15",
"    </a>",
"    ]. Two patients had no history of prior vaccination, one refused immunization, and another did not have follow-up for a failed vaccination. Of note, all the cases reported were from accidental needle sticks. Because there is no official national surveillance system for the reporting of laboratory accidents, the extent of the problem is unknown.",
"   </p>",
"   <p>",
"    Supporters of immunization stress that vaccination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provides exposure to a measured (rather than unknown) dose of a well-characterized virus formulation, which results in local infection [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      May prevent an uncontrolled infection with unknown pathogenicity after an accidental exposure in the laboratory [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the specific circumstance when a researcher is working with vaccinia virus expressing HIV proteins, vaccination with vaccinia virus may protect the researcher from unintentional seroconversion to HIV antigens after an accidental exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Arguments against vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;On the other hand, many argue that the risks outweigh the theoretical benefits of routine vaccination of all workers in the post-smallpox era [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/4,5,7,8\">",
"     4,5,7,8",
"    </a>",
"    ]. The arguments against vaccination include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If one uses proper and careful microbiological techniques similar to those used when handling other viruses like HIV or HSV, there should not be accidental exposures when working with vaccinia virus. If the worker uses appropriate precautions, the hazard is a personal one and not significant for co-workers, family, or the public health, and thus, the question of vaccination should be an individual decision.",
"     </li>",
"     <li>",
"      The risks of complications from intentional vaccination are greater than the chance of an accidental exposure potentially causing a problem. In addition, there is a potential risk of spread of the virus after vaccination to the ever-growing group of unvaccinated contacts [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/17-19\">",
"       17-19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is not certain that vaccination will prevent an infection caused by a laboratory accident since there is evidence of what appears to be a primary infection in some previously vaccinated people. Most of the known complications of vaccination can also occur during revaccination.",
"     </li>",
"     <li>",
"      Vaccination may give a false reassurance of protection to the worker. The presence of neutralizing vaccinia virus antibody may not prevent infection [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is theoretically possible that vaccination with the current vaccine might prevent a later immune response to a recombinant vaccinia virus-based vaccine. Previously vaccinated workers might make anti-vaccinia immune responses that could negate a superior response to the foreign antigen expressed by a recombinant vaccine.",
"     </li>",
"     <li>",
"      Many do not like the permanent scar that develops at the vaccination site. Also, if generalized vaccinia occurs there is a risk of the development of disfiguring scars on other parts of the body.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RISK OF EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of exposure is influenced by the work environment, work-related procedures, and the virulence of the laboratory vaccinia virus strain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Work environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research with a recombinant vaccinia virus expressing a potentially dangerous protein should be performed in a biosafety level 3 containment facility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Work-related procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational health and safety offices that provide the vaccine at academic and industrial centers should inquire about:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What will the researcher be doing with the vaccinia virus and what titer stocks will be used?",
"      <br/>",
"      <br/>",
"      It is important to know the circumstances of the vaccinia use, since work with animals, or sharps, or high titer virus stocks increase the possibility of an accidental exposure.",
"     </li>",
"     <li>",
"      What antigen will the recombinant vaccinia virus express? Will any foreign genes be inserted into the vaccinia virus that may increase virulence?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to realize that the majority of work done with vaccinia virus in the laboratory setting is done with the laboratory adapted vaccinia virus strain Western Reserve (WR). This strain was selected for its neurovirulence in mice and is more pathogenic in the mouse model than the human vaccine strain, ACAM2000. While the preponderance of recombinant viruses used in the research setting have foreign genes inserted into the thymidine kinase (TK) gene of laboratory strain WR, which significantly attenuates the virus in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], it is not clear if these viruses are attenuated in humans. For example, when these TK-negative viruses are given to humans by scarification, the same sized lesions are produced as the TK-positive vaccine strain, suggesting that virulence in humans is comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/11,23,24\">",
"     11,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TARGET GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is highly recommended that the following researchers should be vaccinated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those exposed to monkeypox or to high titer vaccinia virus (that is, an accidental exposure with a droplet would produce an infectious dose)",
"     </li>",
"     <li>",
"      Those directly working with needles while vaccinating animals with recombinant vaccinia viruses (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Laboratory strains'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Those working with vaccinia viruses that may have enhanced virulence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Informed consent for vaccination describing the relative benefits and risks should be obtained from any worker receiving the vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physicians should also remember that there is a higher risk of serious adverse reactions to vaccinia vaccination in people with the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with immunodeficiencies (natural, acquired, or drug-induced)",
"     </li>",
"     <li>",
"      Individuals with a history of eczema, atopic dermatitis, or other exfoliative skin condition",
"     </li>",
"     <li>",
"      Pregnant women",
"     </li>",
"     <li>",
"      Patients with cardiac disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individuals in the research setting with these contraindications should not receive vaccinia vaccine. &nbsp;Individuals with contraindications to vaccination should probably consider not working with vaccinia virus or other human orthopoxviruses.",
"   </p>",
"   <p>",
"    Relative contraindications to vaccination would be close contact of the vaccinee with people who have any of the above-mentioned conditions, although this is debatable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40057?source=see_link&amp;anchor=H13#H13\">",
"     \"Vaccinia virus as the smallpox vaccine\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS FOR VACCINE RESEARCH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Route of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since one of the major complications of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    is the inadvertent spread of the virus from the vaccinee to unvaccinated contacts, there has been some research into administering a sterile vaccine intradermally or intramuscularly in hopes of decreasing some of the complications due to cutaneous administration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/25\">",
"     25",
"    </a>",
"    ]. However, one study demonstrated that either of these routes of administration induced lower immune responses than standard scarification. While this is disappointing, it is also not known what level of immune response is needed to safeguard against serious infection after accidental exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Attenuated virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Germany, a highly attenuated vaccinia virus (ie, Modified Vaccinia Ankara, MVA) was used to vaccinate 100,000 people during the smallpox eradication program in the 1970s. This vaccine, which was given subcutaneously or intramuscularly, rather than through scarification, was not associated with any significant adverse events. This viral strain is now being used for the development of recombinant vaccinia virus based vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18165/abstract/26\">",
"     26",
"    </a>",
"    ] as well as for biodefense purposes in hopes that this vaccine may serve as a safer alternative for laboratory workers than the currently available vaccinia virus vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1414267\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaccinia virus was the live poxvirus used throughout the world as the vaccine against smallpox. With the worldwide eradication of smallpox, routine vaccination with vaccinia virus is no longer performed. Vaccinia virus has remained an important microbial agent because of its widespread use as an expression vector in research laboratories and its potential role in recombinant vaccines. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Controversy exists as to whether to vaccinate all researchers working with vaccinia virus since the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"       smallpox vaccine",
"      </a>",
"      has been sometimes associated with severe adverse reactions. Routine immunization of laboratory workers handling vaccinia virus as well as persons working with animals infected with vaccinia virus is recommended in the United States, but not in the United Kingdom. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Guideline recommendations for researchers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supporters of immunization stress that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"       smallpox vaccination",
"      </a>",
"      may prevent accidental infection with a virus of unknown pathogenicity. Opponents of immunization argue that the risk of an adverse event associated with the smallpox immunization is greater than the risk of occupational exposure, when appropriate safeguards are taken. Opponents also argue that immunization should be an individual decision since the personal risk of infection does not pose a hazard to public health. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pros and cons of vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Research with a recombinant vaccinia virus expressing a potentially dangerous protein should be performed in a biosafety level 3 containment facility. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk of exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Target groups for immunization include those exposed to high-titer vaccinia virus and those who vaccinate animals with recombinant vaccinia viruses. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Target groups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Smallpox immunization should be deferred among persons at risk for serious adverse events related to vaccine, including patients with immunodeficiency, persons with certain skin conditions (eg, eczema, atopic dermatitis), pregnant women, and patients with cardiac disease. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Risk factors for adverse events'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/1\">",
"      Fauci AS. Smallpox vaccination policy--the need for dialogue. N Engl J Med 2002; 346:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/2\">",
"      Bicknell WJ. The case for voluntary smallpox vaccination. N Engl J Med 2002; 346:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/3\">",
"      Openshaw PJ, Alwan WH, Cherrie AH, Record FM. Accidental infection of laboratory worker with recombinant vaccinia virus. Lancet 1991; 338:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/4\">",
"      Baxby D. Indications for smallpox vaccination: policies still differ. Vaccine 1993; 11:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/5\">",
"      Wenzel RP, Nettleman MD. Smallpox vaccination for investigators using vaccinia recombinants. Lancet 1989; 2:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/6\">",
"      Jones L, Ristow S, Yilma T, Moss B. Accidental human vaccination with vaccinia virus expressing nucleoprotein gene. Nature 1986; 319:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/7\">",
"      Wenzel RP, Nettleman MD. Smallpox vaccination for investigators using vaccinia recombinants. Lancet 1989; 2:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/8\">",
"      Williams NR, Cooper BM. Counselling of workers handling vaccinia virus. Occup Med (Lond) 1993; 43:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/9\">",
"      Rotz LD, Dotson DA, Damon IK, et al. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 2001; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     Vaccination of laboratory workers handling vaccinia and related poxviruses infectious for humans. HMSO Publications Center 1970.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/11\">",
"      Cooney EL, Collier AC, Greenberg PD, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991; 337:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/12\">",
"      Dolin R, Graham BS, Greenberg SB, et al. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med 1991; 114:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/13\">",
"      Fulginiti VA. The risks of vaccinia in laboratory workers. J Invest Dermatol 2003; 120:viii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/14\">",
"      MacNeil A, Reynolds MG, Damon IK. Risks associated with vaccinia virus in the laboratory. Virology 2009; 385:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Laboratory-acquired vaccinia exposures and infections--United States, 2005-2007. MMWR Morb Mortal Wkly Rep 2008; 57:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Laboratory-acquired vaccinia virus infection--Virginia, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/17\">",
"      Centers for Disease Control (CDC). Contact spread of vaccinia from a National Guard vaccinee--Wisconsin. MMWR Morb Mortal Wkly Rep 1985; 34:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/18\">",
"      Centers for Disease Control (CDC). Contact spread of vaccinia from a recently vaccinated Marine--Louisiana. MMWR Morb Mortal Wkly Rep 1984; 33:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/19\">",
"      Centers for Disease Control (CDC). Vaccinia outbreak--Newfoundland. MMWR Morb Mortal Wkly Rep 1981; 30:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/20\">",
"      Vanderplasschen A, Hollinshead M, Smith GL. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J Gen Virol 1997; 78 ( Pt 8):2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/21\">",
"      Buller RM, Smith GL, Cremer K, et al. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985; 317:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/22\">",
"      Taylor G, Stott EJ, Wertz G, Ball A. Comparison of the virulence of wild-type thymidine kinase (tk)-deficient and tk+ phenotypes of vaccinia virus recombinants after intranasal inoculation of mice. J Gen Virol 1991; 72 ( Pt 1):125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/23\">",
"      Baxby D. Safety of recombinant vaccinia vaccines. Lancet 1991; 337:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/24\">",
"      Graham BS, Belshe RB, Clements ML, et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis 1992; 166:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/25\">",
"      McClain DJ, Harrison S, Yeager CL, et al. Immunologic responses to vaccinia vaccines administered by different parenteral routes. J Infect Dis 1997; 175:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18165/abstract/26\">",
"      Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 1992; 89:10847.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8324 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-D91D1357DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18165=[""].join("\n");
var outline_f17_47_18165=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1414267\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GUIDELINE RECOMMENDATIONS FOR RESEARCHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INSTITUTIONAL POLICIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROS AND CONS OF VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Arguments for vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Arguments against vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RISK OF EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Work environment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Work-related procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory strains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TARGET GROUPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RISK FACTORS FOR ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FUTURE DIRECTIONS FOR VACCINE RESEARCH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Route of administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Attenuated virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1414267\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40057?source=related_link\">",
"      Vaccinia virus as the smallpox vaccine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_47_18166="Percutaneous transhepatic cholangioscopy";
var content_f17_47_18166=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Percutaneous transhepatic cholangioscopy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18166/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18166/contributors\">",
"     Hiroto Kita, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18166/contributors\">",
"     Osamu Togawa, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18166/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18166/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18166/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18166/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/47/18166/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H31817743\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Miniature intraductal endoscopes have an increasingly important role in the diagnosis and nonsurgical treatment of biliary diseases, complementing diagnostic imaging modalities such as computed tomography and magnetic resonance imaging by permitting direct visualization of the biliary tree.",
"   </p>",
"   <p>",
"    Intraductal endoscopes can be used intraoperatively and during endoscopic retrograde cholangiopancreatography (ERCP). In addition, intraductal endoscopes may be introduced into the biliary tree via a percutaneous, transhepatic approach.",
"   </p>",
"   <p>",
"    This topic will review percutaneous transhepatic cholangioscopy, which is most commonly used when anatomic considerations prohibit a peroral approach (eg, after previous Roux-en-Y gastric bypass surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Percutaneous transhepatic cholangiography and peroral cholangioscopy and pancreatoscopy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/39/37491?source=see_link\">",
"     \"Percutaneous transhepatic cholangiography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=see_link\">",
"     \"Cholangioscopy and pancreatoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31817750\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in percutaneous transhepatic cholangioscopy (PTCS) is the creation of a cutaneobiliary fistula. Percutaneous access to the biliary tree is typically obtained by invasive radiology under ultrasound and fluoroscopic guidance. Once the fistula tract matures, usually after seven to ten days, and has been sequentially dilated to at least 12 to 16 French, PTCS can be performed (",
"    <a class=\"graphic graphic_picture graphicRef80343 \" href=\"UTD.htm?9/1/9246\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PTCS is time-consuming (procedures can take up to 90 minutes) and requires a well-trained team of an endoscopist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    invasive radiologist skilled in this exam along with assisting technicians. Thus, it is only available in relatively few tertiary referral centers worldwide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31817756\">",
"    <span class=\"h2\">",
"     Instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous cholangioscopes are specialty fiberoptic endoscopes unlike the peroral cholangioscopes that are used during ERCP, which are videoscopes. Percutaneous cholangioscopes are also shorter and wider (length 380 to 450 mm, external diameter 4.1 to 4.9 mm) than the peroral instruments (",
"    <a class=\"graphic graphic_picture graphicRef54112 \" href=\"UTD.htm?8/14/8416\">",
"     picture 2",
"    </a>",
"    ). The ratio of external diameter to length allows for better scope control than is seen with the peroral scope used during ERCP. In addition, the tip of the scope can be deflected up-down.",
"   </p>",
"   <p>",
"    Percutaneous cholangioscopes have a biopsy channel of 1.7 to 2.2 mm in diameter that permits passage of catheters, biopsy forceps, and brushes. Therapeutic instruments for electrohydraulic lithotripsy (EHL) and tumor ablation therapy can also be passed through the channel.",
"   </p>",
"   <p>",
"    Narrow-band imaging (NBI) provides enhanced imaging of certain features, such as mucosal structures and microvasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/5\">",
"     5",
"    </a>",
"    ]. While it is available in peroral video cholangioscopes",
"    <span class=\"nowrap\">",
"     (CHF-B260/BP260,",
"    </span>",
"    Olympus, Japan), it is not currently available in percutaneous cholangioscopes. However, one study reported using a peroral video cholangioscope with NBI through a percutaneous route [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31817762\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should fast for at least eight hours prior to the procedure, and antibiotic prophylaxis is routinely administered using the same agents that are given prior to ERCP in patients with biliary obstruction (",
"    <a class=\"graphic graphic_table graphicRef54121 \" href=\"UTD.htm?13/60/14285\">",
"     table 1",
"    </a>",
"    ).",
"    <strong>",
"    </strong>",
"    The procedure is usually performed under conscious sedation.",
"   </p>",
"   <p>",
"    While standard GI endoscopes used perorally only need to undergo high-level decontamination, the percutaneous cholangioscope must be sterilized and handled under sterile conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31817768\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to cholangioscope insertion, a percutaneous transhepatic drainage catheter is placed through the cutaneobiliary fistula. A guidewire is then inserted and advanced to the ampulla of Vater or the bilioenteric anastomosis under fluoroscopic guidance. Once the tip of the guidewire is in the small bowel lumen, the catheter is removed.",
"   </p>",
"   <p>",
"    The cholangioscope is advanced along-side the guidewire into the biliary tree under direct visualization in most cases. Alternatively, if a stricture is present or if there has not been sufficient time for a mature cutaneobiliary fistula to form, the cholangioscope is advanced over the guidewire after backloading the guidewire through the biopsy channel of the scope. During the procedure, the biopsy channel is continuously rinsed with sterile normal saline. To prevent cholangitis due to cholangiovenous reflux, it is important to maintain biliary tract pressure as low as possible since cholangiovenous reflux of bacteria occurs with pressures greater than 30 cm H2O [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/8\">",
"     8",
"    </a>",
"    ]. In the absence of obstruction, the guidewire is followed until the cholangioscope reaches the lesion of interest, the papilla of Vater, or the bilioenteric anastomosis. Once the papilla of Vater or the bilioenteric anastomosis is reached, the proximal bile duct system can also be inspected. At the end of the examination, the transhepatic drainage catheter is usually reinserted to drain the biliary system and to prevent the fistula from closing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31817774\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous transhepatic cholangioscopy (PTCS) has both diagnostic and therapeutic applications. Diagnostic PTCS assists in the differentiation of benign from malignant bile duct strictures and in the preoperative staging of bile duct carcinoma. It can also help clarify nonspecific findings on other imaging procedures such as endoscopic retrograde cholangiopancreatography (ERCP), computed tomography, percutaneous cholangiography, and magnetic resonance cholangiopancreatography (MRCP).",
"   </p>",
"   <p>",
"    Therapeutic PTCS is commonly performed to treat complicated cholangiolithiasis (eg, recurrent pyogenic cholangitis) or cholangiolithiasis in patients who have failed or are not candidates for ERCP. Other indications include the passage of a drainage catheter through a high-grade stricture and retrieval of a broken biliary endoprosthesis (",
"    <a class=\"graphic graphic_picture graphicRef55883 \" href=\"UTD.htm?3/38/3694\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14472?source=see_link\">",
"     \"Recurrent pyogenic cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31817780\">",
"    <span class=\"h2\">",
"     Diagnostic cholangioscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of PTCS in the diagnosis of bile duct and pancreatic carcinoma has been described by several groups [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/10-18\">",
"     10-18",
"    </a>",
"    ]. In addition to visual inspection, the procedure permits tissue sampling with biopsies or brush cytology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Illustrative studies have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study included 385 patients with biliary or pancreatic malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/12\">",
"       12",
"      </a>",
"      ]. A total of 328 biopsies were obtained, which detected malignancy in 82 percent of cases. When histopathologic examination or clinical course was used as the gold standard, PTCS had an accuracy of 96 percent in patients with bile duct carcinoma and 67 percent in those with pancreatic cancer (",
"      <a class=\"graphic graphic_table graphicRef72892 \" href=\"UTD.htm?7/58/8108\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In a second report, 46 of 52 patients (88 percent) were correctly diagnosed as having malignancy with PTCS, using histopathologic examination or clinical course as the gold standard [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/7\">",
"       7",
"      </a>",
"      ]. False-negative results were observed in six patients (12 percent).",
"     </li>",
"     <li>",
"      A study comparing PTCS with MRCP included 99 patients with hilar cholangiocarcinoma who underwent both tests [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/18\">",
"       18",
"      </a>",
"      ]. The overall agreement between the two tests with regard to tumor extension was 88 percent, though PTCS appeared to be more accurate for the characterization of polypoid or diffuse sclerosing lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity of a single biopsy for detecting invasive carcinoma is low due to the superficial nature of the biopsies, but it increases if multiple biopsies are taken (up to 91 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/17\">",
"     17",
"    </a>",
"    ]. Some authorities recommend a combination of PTCS and intraductal ultrasonography (IDUS) to obtain a more accurate assessment of intramural spread [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/13,17\">",
"     13,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33353?source=see_link\">",
"     \"Intraductal ultrasound of the pancreaticobiliary ductal system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31817785\">",
"    <span class=\"h2\">",
"     Therapeutic cholangioscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest experience with therapeutic cholangioscopy has been for the treatment of complicated bile duct stones that are not amenable to ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/17,19-21\">",
"     17,19-21",
"    </a>",
"    ]. Although long-term follow-up is limited, PTCS appears to be an effective and safe method to treat complicated intra- and extrahepatic bile duct stones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31817790\">",
"    <span class=\"h3\">",
"     Choledocholithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complicated bile duct stones can be treated by combining PTCS with lithotripsy. In one series, 50 patients with difficult bile duct stones were treated with electrohydraulic lithotripsy (EHL) under PTCS control [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/19\">",
"     19",
"    </a>",
"    ]. Complete bile duct clearance was achieved in 46 of the patients (92 percent). Severe complications related to the rapid dilation of the cutaneobiliary fistula occurred in 11 cases. Other groups have reported similar experiences [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PTCS has also been combined with a pulsed dye laser for lithotripsy. In one study of PTCS with laser lithotripsy, stone fragmentation was successful in 12 of 13 patients (92 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/22\">",
"     22",
"    </a>",
"    ]. The stone fragments passed spontaneously in two patients. When sphincterotomy and stent insertion were added to the procedure, the success rate for stone removal increased to 100 percent. Bleeding occurred in two of the patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=see_link\">",
"     \"Laser lithotripsy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another group reported success in 24 of 25 patients (96 percent) with complicated bile duct stones using laser lithotripsy with a small-caliber cholangioscope (3.4 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/23\">",
"     23",
"    </a>",
"    ]. Only minor complications occurred, including chills and fever in six patients and mild hemorrhage in one patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31817795\">",
"    <span class=\"h3\">",
"     Intrahepatic stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTCS results in high initial success rates for the treatment of intrahepatic stones, but recurrence is seen in up to one-third of patients.",
"   </p>",
"   <p>",
"    Illustrative studies have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study included 165 patients with intrahepatic stones treated by PTCS who were followed for up to five years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/24\">",
"       24",
"      </a>",
"      ]. Complete stone removal was achieved in 80 percent, with a recurrence rate following successful stone removal of 33 percent.",
"     </li>",
"     <li>",
"      Another report included 92 patients, 68 of whom were followed for a median of 42 months [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/25\">",
"       25",
"      </a>",
"      ]. Complete clearance of stones was achieved in 74 patients (80 percent). The rate of complete clearance was significantly lower in those with severe intrahepatic strictures compared with those without or with mild to moderate strictures. Patients with severe intrahepatic strictures also had a higher recurrence rate compared with those without or with mild to moderate strictures (100 versus 28 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The influence of treatment with PTCS on the natural history of intrahepatic stones and survival is uncertain. The benefit of extracting intrahepatic stones depends upon the underlying disease and the clinical setting. For example, in the report of 92 patients discussed above, the recurrence rate was significantly higher in patients with advanced biliary cirrhosis (Child class B or C) compared with those without cirrhosis or Child class A cirrhosis (89 versus 29 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, successful clearance of intrahepatic stones by PTCS must be considered in the overall context of the underlying disease and other therapeutic options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31817801\">",
"    <span class=\"h3\">",
"     Other applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapeutic applications for PTCS include dilation of benign bilioenteric strictures, facilitation of endoscopic sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], and treatment of bile duct malignancies with laser therapy, photodynamic therapy, and microwave coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31817806\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications related to percutaneous transhepatic cholangioscopy (PTCS) are mostly related to the initial creation of the cutaneobiliary fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/19,29-31\">",
"     19,29-31",
"    </a>",
"    ]. Subsequent dilations of the fistula and the cholangioscopy itself are less risky. However, overly rapid dilation has been associated with increased procedure-related mortality.",
"   </p>",
"   <p>",
"    Reported complications include hemobilia, cholangitis, bacteremia, catheter migration, catheter blockage, and bile duct injuries (including perforation). In one series, complications were observed in 47 of 364 patients (13 percent) who underwent PTCS with biliary drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/29\">",
"     29",
"    </a>",
"    ]. The overall incidence of severe complications was 8 percent, and there were no deaths related to the procedure.",
"   </p>",
"   <p>",
"    In another series, severe complications occurred in 11 of 50 patients (22 percent) with complicated bile duct stones that had PTCS performed within three days of accessing the biliary system [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/19\">",
"     19",
"    </a>",
"    ]. The complications included hemobilia, requiring transfusion and bile duct perforation, and there were four fatalities. A significant reduction in complications was observed after adopting a protocol whereby the biliary tract was dilated in two sessions three days apart, followed by a waiting period of six days for the tract to mature.",
"   </p>",
"   <p>",
"    Adequate biliary drainage must be achieved after PTCS to reduce the risk of cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/30\">",
"     30",
"    </a>",
"    ], which in one series occurred in 6 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/31\">",
"     31",
"    </a>",
"    ]. Finally, when PTCS is performed for biliary tract malignancy, the possibility of tumor seeding should be taken into consideration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18166/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31817811\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Miniature intraductal endoscopes have an increasingly important role in the diagnosis and nonsurgical treatment of biliary and pancreatic diseases, complementing diagnostic imaging modalities such as computed tomography and magnetic resonance imaging. (See",
"      <a class=\"local\" href=\"#H31817743\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic percutaneous transhepatic cholangioscopy (PTCS) assists in the differentiation of benign from malignant bile duct strictures and in preoperative staging of bile duct carcinoma. It can also help clarify nonspecific findings on other imaging procedures such as endoscopic retrograde cholangiopancreatography (ERCP), computed tomography, percutaneous cholangiography, and magnetic resonance cholangiopancreatography. (See",
"      <a class=\"local\" href=\"#H31817780\">",
"       'Diagnostic cholangioscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapeutic PTCS is commonly performed to treat complicated cholangiolithiasis or cholangiolithiasis in patients who have failed or are not candidates for ERCP. (See",
"      <a class=\"local\" href=\"#H31817785\">",
"       'Therapeutic cholangioscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications related to PTCS include hemobilia, cholangitis, bacteremia, catheter migration, catheter blockage, and bile duct injuries (including perforation). (See",
"      <a class=\"local\" href=\"#H31817806\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/1\">",
"      Takada T, Suzuki S, Nakamura K, et al. Studies in percutaneous biliary tract endoscopy. Gastroenterol Endosc 1974; 16:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/2\">",
"      Nimura Y, Hayakawa N, Toyoda S, et al. Percutaneous transhepatic cholangioscopy. Stomach Intestine 1981; 16:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/3\">",
"      Ross AS, Kozarek RA. Cholangioscopy: where are we now? Curr Opin Gastroenterol 2009; 25:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/4\">",
"      Jung JY, Lee SK, Oh HC, et al. The role of percutaneous transhepatic cholangioscopy in patients with hilar strictures. Gut Liver 2007; 1:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/5\">",
"      Itoi T, Sofuni A, Itokawa F, et al. Peroral cholangioscopic diagnosis of biliary-tract diseases by using narrow-band imaging (with videos). Gastrointest Endosc 2007; 66:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/6\">",
"      Itoi T, Ishii K, Tsuji S, et al. Diagnostic videocholangioscopy using narrow-band imaging and recanalization by rendezvous technique for difficult benign biliary stricture. Dig Endosc 2009; 21 Suppl 1:S108.",
"     </a>",
"    </li>",
"    <li>",
"     Martin WR, Riemann JF. Perkutane transhepatische Cholangioskopie. In: Gastroenterologische Endoskopie, Fruehmorgen P, Springer, Berlin, Heidelberg (Eds), New York 1999. p.151.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/8\">",
"      Yoshimoto H, Ikeda S, Tanaka M, Matsumoto S. Relationship of biliary pressure to cholangiovenous reflux during endoscopic retrograde balloon catheter cholangiography. Dig Dis Sci 1989; 34:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/9\">",
"      Sato M, Inoue H, Ogawa S, et al. Differences in fine mucosal structure between superficial spreading carcinoma and non-neoplastic bile duct mucosa detected by percutaneous transhepatic cholangioscopy. Dig Endosc 1997; 9:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/10\">",
"      Nimura Y. Staging of biliary carcinoma: cholangiography and cholangioscopy. Endoscopy 1993; 25:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/11\">",
"      Tamada K, Kurihara K, Tomiyama T, et al. How many biopsies should be performed during percutaneous transhepatic cholangioscopy to diagnose biliary tract cancer? Gastrointest Endosc 1999; 50:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/12\">",
"      Nimura Y, Kamiya J. Cholangioscopy. Endoscopy 1998; 30:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/13\">",
"      Tamada K, Ueno N, Tomiyama T, et al. Characterization of biliary strictures using intraductal ultrasonography: comparison with percutaneous cholangioscopic biopsy. Gastrointest Endosc 1998; 47:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/14\">",
"      Neuhaus H, Hoffmann W, Classen M. [The benefits and risks of percutaneous transhepatic cholangioscopy]. Dtsch Med Wochenschr 1993; 118:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/15\">",
"      Van Steenbergen W, Van Aken L, Van Beckevoort D, et al. Percutaneous transhepatic cholangioscopy for diagnosis and therapy of biliary diseases in older patients. J Am Geriatr Soc 1996; 44:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/16\">",
"      Seo DW, Kim MH, Lee SK, et al. Usefulness of cholangioscopy in patients with focal stricture of the intrahepatic duct unrelated to intrahepatic stones. Gastrointest Endosc 1999; 49:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/17\">",
"      Sato M, Inoue H, Ogawa S, et al. Limitations of percutaneous transhepatic cholangioscopy for the diagnosis of the intramural extension of bile duct carcinoma. Endoscopy 1998; 30:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/18\">",
"      Lee SS, Kim MH, Lee SK, et al. MR cholangiography versus cholangioscopy for evaluation of longitudinal extension of hilar cholangiocarcinoma. Gastrointest Endosc 2002; 56:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/19\">",
"      Bonnel DH, Liguory CE, Cornud FE, Lefebvre JF. Common bile duct and intrahepatic stones: results of transhepatic electrohydraulic lithotripsy in 50 patients. Radiology 1991; 180:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/20\">",
"      Takada T, Uchiyama K, Yasuda H, Hasegawa H. Indications for the choledochoscopic removal of intrahepatic stones based on the biliary anatomy. Am J Surg 1996; 171:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/21\">",
"      Simon T, Fink AS, Zuckerman AM. Experience with percutaneous transhepatic cholangioscopy (PTCS) in the management of biliary tract disease. Surg Endosc 1999; 13:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/22\">",
"      Brambs HJ, Duda SH, Rieber A, et al. Treatment of bile duct stones: value of laser lithotripsy delivered via percutaneous endoscopy. Eur Radiol 1996; 6:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/23\">",
"      Harris VJ, Sherman S, Trerotola SO, et al. Complex biliary stones: treatment with a small choledochoscope and laser lithotripsy. Radiology 1996; 199:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/24\">",
"      Yeh YH, Huang MH, Yang JC, et al. Percutaneous trans-hepatic cholangioscopy and lithotripsy in the treatment of intrahepatic stones: a study with 5 year follow-up. Gastrointest Endosc 1995; 42:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/25\">",
"      Lee SK, Seo DW, Myung SJ, et al. Percutaneous transhepatic cholangioscopic treatment for hepatolithiasis: an evaluation of long-term results and risk factors for recurrence. Gastrointest Endosc 2001; 53:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/26\">",
"      Kim JH, Lee SK, Kim MH, et al. Percutaneous transhepatic cholangioscopic treatment of patients with benign bilio-enteric anastomotic strictures. Gastrointest Endosc 2003; 58:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/27\">",
"      Itoi T, Shinohara Y, Takeda K, et al. A novel technique for endoscopic sphincterotomy when using a percutaneous transhepatic cholangioscope in patients with an endoscopically inaccessible papilla. Gastrointest Endosc 2004; 59:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/28\">",
"      Itoi T, Sofuni A, Itokawa F, et al. Salvage therapy in patients with unresectable hilar cholangiocarcinoma. Digestive Endoscopy 2006; 18:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/29\">",
"      Oh HC, Lee SK, Lee TY, et al. Analysis of percutaneous transhepatic cholangioscopy-related complications and the risk factors for those complications. Endoscopy 2007; 39:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/30\">",
"      Maier M, Kohler B, Benz C, et al. [Percutaneous transhepatic cholangioscopy (PTCS)--an important supplement in diagnosis and therapy of biliary tract diseases (indications, technique and results)]. Z Gastroenterol 1995; 33:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/31\">",
"      Chen MF, Jan YY. Bacteremia following postoperative choledochofiberscopy--a prospective study. Hepatogastroenterology 1996; 43:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18166/abstract/32\">",
"      Yamakawa T, Itoh S, Hirosawa K, et al. Seeding of gallbladder carcinoma along the tract after percutaneous transhepatic choledochoscopy. Am J Gastroenterol 1983; 78:649.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 677 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-F42F8ABDFE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18166=[""].join("\n");
var outline_f17_47_18166=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31817811\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31817743\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31817750\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31817756\">",
"      Instruments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31817762\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31817768\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31817774\">",
"      CLINICAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31817780\">",
"      Diagnostic cholangioscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31817785\">",
"      Therapeutic cholangioscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31817790\">",
"      - Choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31817795\">",
"      - Intrahepatic stones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31817801\">",
"      - Other applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31817806\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31817811\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/677\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/677|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/1/9246\" title=\"picture 1\">",
"      Cutaneobiliary fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/14/8416\" title=\"picture 2\">",
"      Percutaneous cholangioscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/38/3694\" title=\"picture 3\">",
"      Endoprosthesis cholangioscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/677|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/60/14285\" title=\"table 1\">",
"      Abx prophylaxis regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/58/8108\" title=\"table 2\">",
"      Accuracy of cholangioscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21897?source=related_link\">",
"      Cholangioscopy and pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33353?source=related_link\">",
"      Intraductal ultrasound of the pancreaticobiliary ductal system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=related_link\">",
"      Laser lithotripsy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=related_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/39/37491?source=related_link\">",
"      Percutaneous transhepatic cholangiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14472?source=related_link\">",
"      Recurrent pyogenic cholangitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_47_18167="Chromosomal translocations, deletions, and inversions";
var content_f17_47_18167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chromosomal translocations, deletions, and inversions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18167/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18167/contributors\">",
"     Iris Schrijver, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18167/contributors\">",
"     James L Zehnder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18167/contributors\">",
"     Athena M Cherry, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18167/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18167/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18167/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18167/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/47/18167/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this review, we will describe the most common structural chromosomal anomalies, give examples of disease processes resulting from these germline or somatic alterations, and discuss the mechanisms underlying these disorders. Due to the important role of chromosomal abnormalities in the pathogenesis of many hematological disorders, a general review of these specific aberrations is presented separately, as is a review of cytogenetic and molecular genetic tools used to characterize these abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=see_link\">",
"     \"General aspects of cytogenetic analysis in hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosomal aberrations are due to either numerical abnormalities or structural defects. The normal diploid number of chromosomes in humans is 46. There are 23 pairs of chromosomes with 22 pairs of autosomes and two sex chromosomes, the X and the Y. Human females have two X chromosomes (46XX), while males have one X and one Y chromosome (46XY).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Abnormality of chromosome number",
"    </span>",
"    &nbsp;&mdash;&nbsp;A numerical abnormality in a cell's chromosomal endowment may be caused by the gain of one or more complete haploid chromosome sets (polyploid karyotype). An example is the triploid chromosomal number (eg, 69XXY) in a partial hydatiform mole. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13816?source=see_link&amp;anchor=H8#H8\">",
"     \"Gestational trophoblastic disease: Pathology\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More commonly, there is a selective gain or loss of an individual chromosome (aneuploidy). As an example, trisomy 21, which causes Down syndrome, is characterized by the gain of one additional copy of chromosome 21. All mutations that change the total number of chromosomes are considered to be",
"    <strong>",
"     genome mutations.",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Abnormality of chromosomal structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural chromosomal anomalies, also called",
"    <strong>",
"     chromosomal mutations",
"    </strong>",
"    , comprise those changes that are due to one or more breaks in a chromosome. Following a break, the separated fragments are likely to participate in chromosomal rearrangements. Structural chromosomal changes can result in a displacement of chromosomal regions without any loss or duplication of genetic material (ie, balanced rearrangements) or they may be unbalanced:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Balanced rearrangements are frequently inherited and are not commonly associated with phenotypic abnormalities. Two exceptions to this rule include a breakpoint that directly disrupts a gene, and the displacement of chromosomal material from an X chromosome to an autosome or vice versa.",
"     </li>",
"     <li>",
"      Unbalanced rearrangements result in a partial trisomy or monosomy and are a frequent cause of congenital abnormalities or developmental delay.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On a submicroscopic level,",
"    <strong>",
"     gene mutations",
"    </strong>",
"    such as single base-pair substitutions, insertions, deletions, duplications, nucleotide repeat expansions and inversions are usually too small to be identified by standard karyotypic analysis, and require DNA analysis for their detection. These submicroscopic mutations can be as small as a change in a single base pair, or as large as megabase stretches of DNA sequence in very large genes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=see_link\">",
"     \"Overview of genetic variation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MECHANISMS OF CHROMOSOMAL BREAKAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosomal breakage is caused by double strand DNA breaks of endogenous or exogenous origin. Endogenous breaks are associated with DNA replication, recombination, transcription, and repair processes, all of which require temporary double strand DNA breaks. Permanent endogenous breaks occur in programmed cell death due to aging of the cell, cell damage, or regulation of cell numbers. Exogenous causes include exposure to irradiation and certain chemical substances, as well as other types of DNA damage.",
"   </p>",
"   <p>",
"    The repair of DNA breaks occurs with high fidelity as long as the damaged area can be removed and replaced by a DNA sequence that is copied from an undamaged template. Double strand DNA breaks, however, need repair across the damaged area on both strands and are more susceptible to errors. By altering gene structure or expression patterns, such mutations can have pathogenic consequences, including malignant transformation.",
"   </p>",
"   <p>",
"    Chromosomal breakage is also a requirement for subsequent translocations, deletions, inversions, and other chromosomal rearrangements [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/1\">",
"     1",
"    </a>",
"    ]. These will be discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TRANSLOCATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals with a balanced translocation are phenotypically normal. However, early studies demonstrated a significantly higher incidence of \"balanced\" rearrangements in institutionalized individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/2\">",
"     2",
"    </a>",
"    ]. It is theorized that, in such instances, the translocation directly disrupts a gene (by &ldquo;position effect&rdquo;) or elicits the loss of a small part of the chromosome.",
"   </p>",
"   <p>",
"    There are three types of chromosomal translocations: reciprocal, Robertsonian, and insertional (non-reciprocal).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Reciprocal translocations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital reciprocal translocations have an incidence of 0.2 percent and originate from the breakage of two non-homologous chromosomes that interchange their separated parts. Rarely, more than two chromosomes are involved in a reciprocal exchange of chromosome segments. When this occurs, the translocation is considered to be complex.",
"   </p>",
"   <p>",
"    Normally, genetic material is not lost in a reciprocal translocation. During meiosis, the normal and translocated chromosomes pair by forming a quadrivalent structure, from which one normal, one balanced, and four unbalanced products could be generated (",
"    <a class=\"graphic graphic_figure graphicRef58692 \" href=\"UTD.htm?13/55/14207\">",
"     figure 1",
"    </a>",
"    ). The unbalanced products can be subdivided into two products with correct and two products with incorrect centromere segregation. The latter situation, in which the gamete contains two identical centromeres, is very rare and less compatible with a viable outcome. Contrary to the theoretical expectation, empirical evidence demonstrates that almost 90 percent of produced gametes are either normal or balanced. The general risk of having abnormal offspring, therefore, rarely exceeds 15 percent.",
"   </p>",
"   <p>",
"    Reciprocal translocations also frequently occur as a somatic mutation in hematologic malignancies and other neoplasms. The reciprocal translocation in one cell either juxtaposes two genes and induces upregulation of one of these genes, or causes oncogene activation by creation of a novel fusion gene. In both scenarios, clonal expansion of the affected cell directly leads to tumorigenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41049?source=see_link\">",
"     \"Genetic abnormalities in hematologic and lymphoid malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first situation is exemplified by the translocation of an oncogene to a gene that either encodes an immunoglobulin heavy or light chain, or a T-cell receptor. These genes naturally undergo extensive rearrangements to ensure the necessary diversity in cell-mediated or antibody responses. This process, however, increases the risk of erroneous interchromosomal rearrangements. An example is t(14;18), which is present in nearly 80 percent of patients with follicular B-cell lymphoma. In this translocation, the BCL2 gene on chromosome 18 is adjoined to the immunoglobulin heavy chain gene on chromosome 14, which is constitutively expressed and causes overexpression of BCL2 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the second circumstance, the breakpoints occur within two genes and a hybrid gene is created. Expression of the chimeric protein can change cell signaling pathways due to the altered activity of transcription factors. One of many examples is t(9;22) which causes fusion of the BCR gene on chromosome 22 and the ABL gene on chromosome 9 (",
"    <a class=\"graphic graphic_figure graphicRef72417 \" href=\"UTD.htm?3/31/3569\">",
"     figure 2",
"    </a>",
"    ). This hybrid BCR-ABL1 product is present in all patients with chronic myeloid leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41049?source=see_link\">",
"     \"Genetic abnormalities in hematologic and lymphoid malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it is currently unknown which cellular processes determine that chromosome breaks will result in a reciprocal translocation, some pathogenic mechanisms of juxtaposed and chimeric genes have been elucidated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The BCL2 gene encodes proteins that are oncogenic by prevention of programmed cell death rather than by promoting cell proliferation,. B-cells with t(14;18) escape apoptosis and are thus predisposed to the accumulation of additional mutations.",
"     </li>",
"     <li>",
"      The PRAD1 gene on chromosome 11, which is juxtaposed to the immunoglobulin heavy chain locus on chromosome 14 in many patients with mantle cell lymphoma, encodes the cell cycle regulator cyclin D1. The t(11;14) directly interferes with normal cell cycle events [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These examples illustrate the functional diversity of genes that undergo translocation to the immunoglobulin or T-cell receptor genes.",
"   </p>",
"   <p>",
"    However, the genes most frequently involved in oncogenic translocations are transcription factors. Their dysregulation gives rise to inappropriate target gene activation in one or more cellular pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/6\">",
"     6",
"    </a>",
"    ]. An example is the widely studied BCR-ABL1 fusion gene, which encodes an oncoprotein that is involved in the activation of multiple signal transduction cascades by constitutive expression of the ABL1 oncogene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=see_link\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While cell proliferation and survival become independent of the cytokines that normally regulate the differentiation as well as proliferation of the hematopoietic cells, phosphorylation of several substrates activates signal transduction pathways including RAS, JUN kinase, MYC and STAT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/7\">",
"     7",
"    </a>",
"    ]. The induction of additional transcription factors may upregulate or reduce the expression of a potentially large number of genes. Finally, the BCR-ABL1 fusion protein may also influence the cell cycle directly [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Robertsonian translocations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acrocentric human chromosomes 13, 14, 15, 21 and 22 have very short p-arms that contain only chromosomal satellites and the genetic code for ribosomal RNAs. Their centromeres, therefore, are very close to one end of the chromosome. When the long arms of two acrocentric chromosomes merge by translocation, their short arms are lost and, depending upon the location of the breakpoints, a dicentric or monocentric fusion-chromosome is created.",
"   </p>",
"   <p>",
"    Loss of the short arms of acrocentric chromosomes does not have phenotypic consequences, because the lost sections do not contain unique genetic sequences. The only consequence is a balanced karyotype with 45 instead of 46 chromosomes. This is identified in approximately 1 in 1000 individuals.",
"   </p>",
"   <p>",
"    However, unbalanced gametes of heterozygous carriers are common and give rise to a monosomic or trisomic fetus. Most monosomies and trisomies are lethal and spontaneously abort early in the pregnancy. Surviving fetuses with trisomy 21, however, can be viable and affected with Down syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/9\">",
"     9",
"    </a>",
"    ], although about 85 percent of trisomy 21 conceptuses will not make it to term. When this syndrome is caused by a parental Robertsonian translocation, the carrier parent typically has a fusion of the long arms of chromosomes 14 and 21 (",
"    <a class=\"graphic graphic_figure graphicRef81746 \" href=\"UTD.htm?23/3/23602\">",
"     figure 3",
"    </a>",
"    ). One of the three viable gametes will be balanced, one will be normal, and one will contain the fused chromosome [der(14;21)] as well as the unaffected chromosome 21. Normal fertilization of this gamete results in a fetus with trisomy 21. The empiric risk for a child with Down syndrome is 10 to 15 percent for a carrier mother, but only 2 percent if the father carries the Robertsonian translocation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Insertional translocations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insertional translocations, by definition, are not reciprocal and are caused by integration of a segment from a \"donor\" chromosome that has incurred two breakpoints into a recipient chromosome that contains only one breakpoint. The resulting zygotes may be normal, balanced, partially trisomic, or partially monosomic. The phenotypic outcome of this anomaly, once considered rare, strongly depends upon the location of the breakpoints and on the nature of the translocated sequence.",
"   </p>",
"   <p>",
"    With the advent of array comparative genomic hybridization (aCGH, also known as chromosomal microarray assay), it appears that insertional translocations (IT) are not as rare as previously believed. In 2000, the estimated incidence of microscopically visible ITs was",
"    <span class=\"nowrap\">",
"     1/80,000,",
"    </span>",
"    whereas more recent studies have shown them to be more common with one estimate of",
"    <span class=\"nowrap\">",
"     1/500",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/10-14\">",
"     10-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DELETIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletion of chromosomal material may or may not be detected by standard chromosomal banding techniques (ie, macrodeletions and microdeletions, respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link&amp;anchor=H9#H9\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Genotyping new mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Macrodeletions",
"    </span>",
"    &nbsp;&mdash;&nbsp;To microscopically see a chromosomal deletion by chromosome banding, the deletion must span at least three to five megabases (Mb). Considering that the average gene density approximates one gene per 50 kilobases (kb), it is not surprising that the loss of such a large region is likely to lead to phenotypic manifestations. Perhaps the most well-known example is Cri-du-chat syndrome, which is due to a terminal deletion of the short arm of chromosome 5 (",
"    <a class=\"graphic graphic_figure graphicRef66560 \" href=\"UTD.htm?32/23/33150\">",
"     figure 4",
"    </a>",
"    ). Congenital abnormalities in this disorder include cat-like neonatal crying, microcephaly with dysmorphic facial features, cardiac defects, hypotonia, and severe mental retardation. Even though the size of the deleted fragment differs from patient to patient, chromosomal bands 5p15.2 and 5p15.3 are always included. These bands, therefore, encompass the critical region for this phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another example of a variable size of the deleted fragment has been described in patients with multiple myeloma. In 106 patients, all but eight had a deletion of the long arm of chromosome 13 which included the 13q14 region (",
"    <a class=\"graphic graphic_figure graphicRef64638 \" href=\"UTD.htm?16/3/16446\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Microdeletions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytogenetic developments, such as high resolution banding techniques and fluorescence in situ hybridization (FISH), have enabled the detection of relatively small (\"micro\") deletions. If the FISH probe is designed to localize to the region that is deleted on one allele, only one double signal will be present in the (pro)metaphase chromosomal evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One example of a microdeletion syndrome is Smith-Magenis syndrome, with an incidence of 1 in 25,000 and characterized by a microdeletion of chromosome band 17p11.2. Phenotypic features include intellectual disability, a deep and hoarse voice, self-abusive behavior, insomnia, short stature and brachydactyly. While most deletions span about 5 Mb and are cytogenetically discernible near the centromere, the remainder must be diagnosed with more refined diagnostic methods, such as FISH (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67417 \" href=\"UTD.htm?35/21/36191\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/17\">",
"     17",
"    </a>",
"    ]. The interstitial deletion in this syndrome is facilitated by the presence of regions of low-copy repeats that flank the common breakpoint regions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/18\">",
"     18",
"    </a>",
"    ]. These segments are highly homologous, which makes them prone to unequal crossing over in meiosis I. During unequal crossing over, two non-sister chromatids recombine at an incorrect location due to inappropriate alignment of highly homologous DNA sequences. Thus, one of the chromatids acquires a duplication of the intervening sequence, while the corresponding segment is deleted on the other chromatid (",
"    <a class=\"graphic graphic_figure graphicRef63004 \" href=\"UTD.htm?31/12/31951\">",
"     figure 6",
"    </a>",
"    ). This is called non-allelic homologous recombination (NAHR), and is the basis of most",
"    <span class=\"nowrap\">",
"     microdeletion/microduplication",
"    </span>",
"    syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34025?source=see_link\">",
"     \"Microdeletion syndromes (chromosomes 1 to 11)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/44/11978?source=see_link\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another example of a microdeletion syndrome, which is the consequence of NAHR, is Williams syndrome (or Williams-Beuren syndrome, WBS). Phenotypic features include cardiovascular disease (most frequently supravalvular aortic stenosis), distinctive faces with full lips and periorbital fullness, and an unusual and intellectual disability with relative cognitive strength in verbal abilities. Over 99 percent of individuals with Williams syndrome have a contiguous gene deletion which encompasses the elastin (ELN) gene at 7q11.23. Approximately 95 percent of individuals affected with WBS have a 1.55 Mb microdeletion, while the other 5 percent have a larger 1.84 Mb microdeletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34025?source=see_link\">",
"     \"Microdeletion syndromes (chromosomes 1 to 11)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Homologous recombination during mitosis is both rare and abnormal. Nevertheless, unequal crossing over can also occur in mitotic division and leads to unequal sister chromatid exchange. The basic mechanism of misalignment between repeat sequences is the same as in meiosis. This abnormal event in mitosis, however, results in a somatic mutation and can predispose to cancer if the deleted sequence contains (or is part of) a tumor suppressor gene.",
"   </p>",
"   <p>",
"    A subset of patients with hypereosinophilic syndrome have a novel FIP1L1-PDGFRA fusion due to a large interstitial deletion on chromosome 4q12. This results in a fusion protein with constitutive tyrosine kinase activity, eosinophilic proliferation and end-organ damage. Patients with this fusion frequently respond to the tyrosine kinase inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate. Diagnosis of this fusion protein can be made by demonstrating the loss of the CHIC2 gene within the deleted region by FISH, or by PCR demonstrating the presence of a fusion transcript [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\", section on 'Myeloproliferative HES variants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INVERSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosomal inversions are characterized by two breaks on the same chromosome, rotation of the intervening segment by 180 degrees, followed by chromosomal reintegration of the intervening segment in an \"upside down\" position. Inversions can be subclassified based on the location of their breaks. Breakpoints on just one chromosome arm define paracentric inversions, whereas pericentric inversions result from breaks on both sides of the centromere. Inversion carriers are typically phenotypically normal. However, inversion carriers may have reproductive issues. At meiosis the inverted chromosome must pair with the non-inverted, normal chromosome forming a loop. If crossing-over occurs, unbalanced or abnormal gametes may result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Paracentric inversions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paracentric inversions (",
"    <a class=\"graphic graphic_figure graphicRef63995 \" href=\"UTD.htm?5/60/6095\">",
"     figure 7",
"    </a>",
"    ) are relatively rare, but have been observed in all 23 autosomes and both sex chromosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/21\">",
"     21",
"    </a>",
"    ]. The chromosomes in individuals with a paracentric inversion are more likely to be ascertained because of infertility or repeated miscarriages by the carrier, than because of phenotypic abnormalities in the offspring. The risk of an affected child is generally very small, because of one of the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The transmitted chromosome is normal",
"     </li>",
"     <li>",
"      The transmitted chromosome is inverted and compatible with life, as in the parent",
"     </li>",
"     <li>",
"      After recombination in the inverted region, the transmitted chromosome becomes acentric or dicentric.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gametes with acentric fragments or dicentric chromosomes are not typically viable. In general, inherited paracentric inversions are innocuous. However, there are rare reported cases of abnormal offspring in individuals with paracentric inversions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pericentric inversions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pericentric inversion (",
"    <a class=\"graphic graphic_figure graphicRef51808 \" href=\"UTD.htm?12/16/12559\">",
"     figure 8",
"    </a>",
"    ) not only causes changes in the banding pattern of the affected chromosome, but may change the position of the centromere as well. Telomeric to the inverted segment, recombinant chromosomes will be partially duplicated or deleted [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18167/abstract/22\">",
"     22",
"    </a>",
"    ]. Larger segments are more susceptible to crossing over in meiosis I, since generally at least one cross-over takes place per chromosome arm. Hence, larger pericentric inversions are associated with an increased risk of phenotypic anomalies in offspring because the duplicated or deleted segments will be smaller and more likely compatible with life.",
"   </p>",
"   <p>",
"    In cells with malignant transformation due to somatic mutation, reciprocal translocations and deletions are much more commonly identified than inversions. As a class, inversions are encountered in only 2 percent of all chromosome aberrations seen in cancer patients who have one or multiple chromosome anomalies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6203102\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chromosomal aberrations are due to either numerical abnormalities or structural defects. Polyploidy is the gain of one or more complete set of haploid chromosomes (eg, 69,XXY in a partial hydatiform mole). Aneuploidy, gain or loss of an individual chromosome, is more common. Trisomy 21, which causes Down syndrome, is characterized by the gain of one additional copy of chromosome 21. Polyploidy and aneuploidy represent",
"      <strong>",
"       genome mutations",
"      </strong>",
"      . (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Abnormality of chromosome number'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Structural chromosomal anomalies, or",
"      <strong>",
"       chromosomal mutations",
"      </strong>",
"      , are due to one or more breaks in a chromosome. Structural chromosomal changes can be balanced (without any loss or gain of genetic material, and typically phenotypically normal) or unbalanced (with loss and gain of genetic material, and typically phenotypically abnormal). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Abnormality of chromosomal structure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three types of chromosomal translocations: reciprocal, Robertsonian, and insertional (non-reciprocal). Congenital reciprocal translocations can result in gametes with unbalanced genetic material, although most viable offspring carry normal or balanced chromosomes. Reciprocal translocations frequently occur as a somatic mutation in hematologic and other malignancies. Transcription factor genes are most frequently involved in oncogenic translocation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Reciprocal translocations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Robertsonian translocations involve acrocentric chromosome with short p-arms that can be lost in translocation of the long arms, resulting in a balanced karyotype with 45, rather than 46, chromosomes and a normal phenotype. However, unbalanced gametes of heterozygous carriers are common and give rise to a monosomic or trisomic fetus. Trisomy 21 can be caused by a parent with a Robertsonian translocation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Robertsonian translocations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insertional translocations are caused by integration of a segment from a \"donor\" chromosome that has incurred two breakpoints into a recipient chromosome that contains only one breakpoint. The resulting zygotes may be normal, balanced, partially trisomic, or partially monosomic. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Insertional translocations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Macrodeletions, which can be seen microscopically, must span at least three to five megabases (Mb) and therefore are likely to have phenotypic manifestations. Examples are found in patients with Cri-du-chat syndrome and some patients with multiple myeloma. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Macrodeletions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Smaller deletions can be detected by high-resolution banding techniques and fluorescence in situ hybridization (FISH), as well as by array comparative genomic hybridization (aCGH). Most microdeletion or microduplication syndromes result from non-allelic homologous recombination (NAHR), in which highly homologous repeat DNA sequences lead to unequal crossing over and erroneous recombination in meiosis I. Similarly, unequal crossing over in mitotic division can result in a somatic mutation which can predispose to cancer if the deleted sequence contains a tumor suppressor gene. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Microdeletions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inversions, in which a segment of the chromosome is rotated 180 degrees, can be paracentric, involving one chromosome arm, or pericentric, involving both arms of the chromosome. Chromosomes in individuals with inversions are likely to be recognized at the time of evaluation for infertility or repeated miscarriages by the carrier, or found incidentally during prenatal diagnosis. A pericentric inversion causes changes in the banding pattern of the affected chromosome, and may change the position of the centromere. Larger pericentric inversions are associated with an increased risk of offspring with phenotypic anomalies because the duplicated or deleted segments will be smaller and more likely compatible with life. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Inversions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/1\">",
"      Vamvakas S, Vock EH, Lutz WK. On the role of DNA double-strand breaks in toxicity and carcinogenesis. Crit Rev Toxicol 1997; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     Warburton, D. De novo structural rearrangements: implications in prenatal diagnosis. In: Clinical Genetics: Problems in Diagnosis and Counseling, Wiley, AM, Carter, TP, Kelly, S, Porter (Eds), Academic Press, New York 1982. p.63.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/3\">",
"      Rezuke WN, Abernathy EC, Tsongalis GJ. Molecular diagnosis of B- and T-cell lymphomas: fundamental principles and clinical applications. Clin Chem 1997; 43:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/4\">",
"      Melo JV. BCR-ABL gene variants. Baillieres Clin Haematol 1997; 10:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/5\">",
"      Griesser H. Applied molecular genetics in the diagnosis of malignant non-Hodgkin's lymphoma. Diagn Mol Pathol 1993; 2:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/6\">",
"      Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007; 7:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/7\">",
"      Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/8\">",
"      Warmuth M, Danhauser-Riedl S, Hallek M. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Ann Hematol 1999; 78:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/9\">",
"      Mutton D, Alberman E, Hook EB. Cytogenetic and epidemiological findings in Down syndrome, England and Wales 1989 to 1993. National Down Syndrome Cytogenetic Register and the Association of Clinical Cytogeneticists. J Med Genet 1996; 33:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/10\">",
"      Kang SH, Shaw C, Ou Z, et al. Insertional translocation detected using FISH confirmation of array-comparative genomic hybridization (aCGH) results. Am J Med Genet A 2010; 152A:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/11\">",
"      de Ravel T, Aerssens P, Vermeesch JR, Fryns JP. Trisomy of chromosome 16p13.3 due to an unbalanced insertional translocation into chromosome 22p13. Eur J Med Genet 2005; 48:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/12\">",
"      Shinawi M, Cheung SW. The array CGH and its clinical applications. Drug Discov Today 2008; 13:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/13\">",
"      Bi W, Sapir T, Shchelochkov OA, et al. Increased LIS1 expression affects human and mouse brain development. Nat Genet 2009; 41:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/14\">",
"      Carvalho CM, Zhang F, Liu P, et al. Complex rearrangements in patients with duplications of MECP2 can occur by fork stalling and template switching. Hum Mol Genet 2009; 18:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/15\">",
"      Marinescu RC, Johnson EI, Dykens EM, et al. No relationship between the size of the deletion and the level of developmental delay in cri-du-chat syndrome. Am J Med Genet 1999; 86:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/16\">",
"      Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000; 96:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/17\">",
"      Juyal RC, Greenberg F, Mengden GA, et al. Smith-Magenis syndrome deletion: a case with equivocal cytogenetic findings resolved by fluorescence in situ hybridization. Am J Med Genet 1995; 58:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/18\">",
"      Chen KS, Manian P, Koeuth T, et al. Homologous recombination of a flanking repeat gene cluster is a mechanism for a common contiguous gene deletion syndrome. Nat Genet 1997; 17:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/19\">",
"      Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/20\">",
"      Gotlib J. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies. Curr Opin Hematol 2010; 17:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/21\">",
"      Pettenati MJ, Rao PN, Phelan MC, et al. Paracentric inversions in humans: a review of 446 paracentric inversions with presentation of 120 new cases. Am J Med Genet 1995; 55:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18167/abstract/22\">",
"      Kaiser P. Pericentric inversions. Problems and significance for clinical genetics. Hum Genet 1984; 68:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4490 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18167=[""].join("\n");
var outline_f17_47_18167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6203102\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Abnormality of chromosome number",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Abnormality of chromosomal structure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MECHANISMS OF CHROMOSOMAL BREAKAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TRANSLOCATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Reciprocal translocations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Robertsonian translocations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Insertional translocations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DELETIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Macrodeletions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Microdeletions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INVERSIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Paracentric inversions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pericentric inversions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6203102\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4490\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4490|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/21/36191\" title=\"diagnostic image 1\">",
"      Smith Magenis syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4490|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/55/14207\" title=\"figure 1\">",
"      Reciprocal translocations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/31/3569\" title=\"figure 2\">",
"      Reciprocal translocation CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/3/23602\" title=\"figure 3\">",
"      Robertsonian translocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/23/33150\" title=\"figure 4\">",
"      Cri du chat syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/3/16446\" title=\"figure 5\">",
"      Chromosome 13 in myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/12/31951\" title=\"figure 6\">",
"      Unequal crossing over",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/60/6095\" title=\"figure 7\">",
"      Paracentric inversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/16/12559\" title=\"figure 8\">",
"      Pericentric inversion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=related_link\">",
"      Cellular and molecular biology of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=related_link\">",
"      General aspects of cytogenetic analysis in hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41049?source=related_link\">",
"      Genetic abnormalities in hematologic and lymphoid malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13816?source=related_link\">",
"      Gestational trophoblastic disease: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34025?source=related_link\">",
"      Microdeletion syndromes (chromosomes 1 to 11)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/44/11978?source=related_link\">",
"      Microdeletion syndromes (chromosomes 12 to 22)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=related_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=related_link\">",
"      Overview of genetic variation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_47_18168="Irritant asthma Early";
var content_f17_47_18168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Irritant-induced asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bronchial biopsy taken three days after acute accidental inhalation of high concentration of chlorine showing almost complete desquamation of bronchial mucosa (upper part) with fibrinohemorrhagic deposits (dark pink) and inflammatory influx of neutrophils (dark purple spots in the middle and upper portions). Normal smooth muscle is shown in the lower portion. Weigert-Masson stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lemiere, C, Malo, JL, Boulet, M.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC1PrWua5pMdx4Ks0SN2Kvdamvl4/65oeWxnqeM9M1n+JdKsINVtoruzTW9Y1G3JuLzUJjFDGMbGMSLgKvcnqABXeb3Y/MSTjAyegqRfLZdrqrqAQcqDgEYIAPtXgRr8r91WX9bvd/gvI3Ukjg/E3iHQdL0XSLVNauZYLC4gi1K40mbzJkieGTo4PClgBwchRjqRUVz4l+HiItz4d1ax07VbOMC0ntLOUvJk4CSJt/eg55zkg8itC60TR9KigsL7xFerI7ptAtoEKLlioban+rJBBycN0qODw1Gnjmyv9JtrXQbW0tzBJLCkbyzDccNGNrKj5+UksG2npW8HT3bkt3vZP101vtttuOST2f4HVTajrMvhWxurXSvK1i7RIZbWZSfJduGkIz90D5sE55GazPDfhWw8P8AjS1jtnuZ7q20ySWC9knzJcSmQrK0y/e2gFQvbrySOIPGPiG6F1H4Z0OK4GqXsbETJKN0WTgBl5YKc8u20Acgmq+tW+qeF9RkvtCsdMutPESmIzyAXLyhMNGrs25lBG4Lz941nCEmuVNLmvZfl1+6/mHwxv3PRkkPnFZDsbBABP3sdSKfKiPE8bltkilWGe317GuCt9K1vSWGv6cYrrWrm1VtWtJEMrSEYOy3GflIBIwDzgYzW/oOtWviXw+NR0q6QCUPHuUEmCUAjDBgDkHnBFYypq14u6/r+l3/AAIcLanRONyDa3Ixy3cCpocuURE3MeiqMk1wl5beM721S2ttUt9Na3gYvftGrrfT7htUJkmNABnceSSeMVi+MdK+IGteHbfTodb0W2cYa4a2EqSXJHXJVcf8BXqT0pqhG+s0vv8A8v662HynoHi7UtR0K0huo9OeewRs3tyhVjbxZA3BM5brk47CuU1248HatJb3V43ibWYpSEitrWWZ4GLDjITADY569q5fSpV8OxX+hXWh6mNXS0SS0gsmLQXU4BDOSH3cnDfPyB1A6V1fw10bV9EuTdXLXWn6Z9j8iHS5Z97iUsGeZlX5UBxgKDkZPSt1SjSi3fXydr/i35aaGjSirjJoNT8XRz2dn4bg03TbRn0+zle3Md3FCirlldvlQHoMZ6fjVfUNAmh8SeG9It9L1eZDA08zalqANvhUYeVK0Ybc2QGI5HNekNJuI8xidvI3EkA1574+vksNft5NL1GePxNJbo8NjcTbbPyg/wB5t3y5yG4X5j9KmlOTlypWVn3+96hGbk7I6KbRL1rqOC28OeEYbKOLKyAOH3jlU+VcgAkk9Qa0fDOhJpazTXl02oahOAZTIP3MX+zEh6D3PJ4zV6yuVu9Pt7jzLZvMGGaGUNFvGchWPUDFR2d9bahbifTruC6g3lPMgkDqWHUZHcVjKU5Jrp1MnK2hoCQszlmLEEBj+GaqazeSWWk3VzaIZJYE8xUWMyEgEZ+Uctxngc1z99Hq0d9qE9hdeTE8iQxjyxIWDAfOc9NrFuByelb1u06QRRTv5lwkY8yZUKK/q3t/Sk6Sik7piemp5Zdad4nhutc8SyOTZTxQXdr/AGrp5n8tlzsIiRiY9o6Dafmxkd69X0OG0sNN82DzIku1+2XMt2+JCSu5mkJ+7jn5ei1HPqNvZRST397b2sScs804XAPGeTzk8fWuX1mS68d6HdaZpIuNP0e5cQ3OpXMJV54errDGcNzwNx461rJyqpKSsu/3ff8A1oiubm8h2lafYeKdct9YttPvf7DjujqXnXzsBdXO3bG8KE5WMZLYIAJA9K7iSZ/tEhkARMAo+7AP97I7c964az8OReGNKNxf+NfEBsLABIHeVIY7aPhQpGCGPOMkdxgd61IfDmmSwK0Woa1Pbyssnz6pJJHMM5G7PUc9AQKU4qWrbtstP83v/WisObjsmb7qGYZIHHG054pS2QR+HvVG0ubUEwQRG2CthY2TYrZyfl9e/wCVTFwcnPU54rJ07GfMTRSAq2AfUCqupatFp8qo0NxcXLW8k0UUEZJcJj5N3RWYkAZpjNnkcMOpqul9KswhkyrPuKZPB24yPrg04x7oW5NLd6tP5Mf9kS2cbxMZ3e6j82JiBtUbSRwc5OfpmqWqy6nZ6VMuhpbXPiG6jzEt5dgIkmBubB5ZF64A+vWrk80nkN5LgS/wkjcPyJGaxbiJ9TvTDcajOrpBskOnQLFNAXOQfOOSgIxhQORyeK2jG/RJfP8Ar8RIdJJd6d4OlvvGt601xbxZnisWMcckmRsVQo3Es2FA965zXLTWtE8B6NLqRgv0F2smr21/M0gjWXhYw452occDPPqK6h7BLp5UudSvJzbzpPBnaDaEIVHOPnzySW5yKittEtkulur+7vNYvI4/KSS9K7Av+zEoCg+/JPrW1OooO773tby2Xbff0ttq7om0vVIbXxRe+GVZVeOJbvTo1UkNbHAOGJ7PuGOuK2LjK582Mbhycr09/rWZqFlZaj5Zv7WGd4s+WzoN0eRg7WGCAQeRnFcH8QNVg0CG207w9ZILyR11C9WEPst7ZDhpmTOCxwMZ646GsY0VVkkt+v8Anf8ArUd09EekNOSqZY4xwe34VnT39woj8ixeSdyxETOFyoOM7jwCe2feuR8P+KrjWNOj/wCEO0hb20thsnfUrs20xlOSSEKnIAwc5AOcdq6XT7V7OxiiuZRcXOMzTEkmRvXJ5OOn4UOh7N+993+dnoS3bcYFv7vVJ7i+It9MFusUWnkq7PKfvPKRkcYwoU9zmofFN7dW3hq/fTRcC4EYRTaxh3jUkAsqnqQOlXWkVZVj/wCWjJvAA7A45NJvKvleD6jrRbVO3+QKVnc8d0R9TvoojZeItTlbT7gyFr5Gfe7D5Y9uQB3BD4AYdcV6poOmmxtJpWmW6vLlhJdTBt5D4yEPJwBzxx3rM8Z2dt/wjuuammmw3GoR2rP5yqUkfGPvOuD079apz+EtB1LT7aSyil0qRxHPFd2DMkycZzjOCTnvXRVmqsbttL0T7PyNXJS6WOraUdR0zUMk2V5zj1FcLoPiW50eW907xOL6SC3mK2+otaviSME/PI3OcnGMfTmtu3122ezW5u3eFpnPkWogkM4TPBaMAsCcE8gcEVDw8lpa5jJOO5qzhS3Kgg9vaqWoana2AhNyzgzyCGJVUlncjgDHT6ninPPdzR5t7B7cEgbr1lUkY+8EQk/gcGuJ8ZXF7LpdrK2oiQfaRB5cCBI5Vc7T5Y5ZpeAcE4wDVUaCnNRb/r8RanVXyf2pbz2V9YbLeVQv78JIcHrjBO1sdD7186ap4XW01q9tJ5XtJ5Hc2yMCkaoG6sx7BR2zmvVvHHix/DtzaaP59y13LGEkuJPkUDbzKJMHc2c8Adc1w8l9aa9qsF74s1y/uLS1Cw21vYR/vnGM7S7AANzyeeWrsw1OVOPOl7r7f1+ZrSvazOy+Ft3c3HhPN3ePeGGdo4pssTsHTGRn6A0VTuvHmk6ZZ2lpoumXWk2MUbO73sH8K5ULEu753ZhyxPHNFEqVSrJzjpf+umhnyqLtJf19x6bbeItOmhnaf7TayWh23kUkJP2ZsdGZcrn6GqLeKm1IrZ6BYavJezny0uzZkW9vzzKznjA5OO+MVD4Pv7SPT1g8N2Fzb6fFHNerNfXDJFE7MdwmO3KnjdgbuKis/iTZPLaweIo/7NknjaSKRXaWPaOASCNy7iPlBHI5OK4PY6y5IXt5/pv8r/f135bI6GbQ9Pls7q3khMouJEluJnY75pExtcnPGDyAMAeleb/EPSbrTpE0nQri4l07WD5s2kbi5km3cOhxu28AkZ4I54r1W3uLO8O2wv7G9YAkrbXCO/AyRtBzmucsLnWdbsrXW5LKx0FLG48+1nuL7Jlt2TD+YgXlCp7EYI6cZrOjOcZavT1tr0/Lpqh0puLu1deexWtPDuoadaK0Wu3E2vK/myXDgGCeQAKBImNxUIAo+YDjOKmvLy+0XUby/nzqWqXdlHBYrHYsIopVk5QbSTzv3Egg4X0qnpHinUvE2q6ja6BptlZwwgmO61KY7WHAG0Rk7jnJ4OBgA8mukS28UoY1Or+HbMOQryR2ckkn0jDsFLfWtnzRfLUt6P5Pom7eRnfW7F8VaXO3h+6tNR8XTWCjcr3UCRW6Sn+GMA+vIGGyeD7VR+E+hW2ieD7SaKw+yahfAzXG5nMhG4lA+7+IA84AHNa+m6XDYvJPetLql7PKGkubuJXJOMKFQDagGOw/GpfEuvWXh7TpNR1q4ZP4liUb5pjn+BMgnHcnis+Ztezjrd+n4f1stEF3ayNXI3ZPt2rmPiPq0Np4fk07MX2/UQVgDXotTHtORJvxwAwA7ZPGapWHxF0a/lijtLHW5DLIkce60Ee8sD93c3OMHIFXY9Cvte8RR69feZpEf9ny2UFjndOxcEb5xkqACSVUexNNQ9nJSnpbX59PMqMbP3i/4G0waJ4bghmtreHU5VEt7JAd3nSH/loGyc5B6jg1vAtxkc452muK+G/iK11G0/4R4yLBfaLALIkj5LwRkq0kR9AR0PJzn2rtW37GEbLvPQkZC/UVE0+d824qiaepKDxjJJPArM1vRtK1qeybUbd2vLGRZ7aeByksRDZ+Vh2z2OaTxLe3Ol6SbuzSOVlYAhm+cL32qeGP1Iq/aOzRxyNFJD5yCXY2Ny5H8WOM/SiMWkpInVanNP8ADfwxO4kvY9QvZCdzPcXbHzP9khcAAY7Y962VtrzTntE0+XTNP0K3WSS8t47f9445OYz/AA4A69frWozsijI6nHFcz4rmu0mjT+xdQ1KxUrIP7P2GQuCd27eQMYx8o6561ac6krN39f8Ag6DU21Z7Eni7UNV0/wAGT63pscQgihS5laQnz7eMkZZFxtkfacjcRg+tT6fpOl6xoml3kk+o6lDLGl3FLe3Db33LlS6qQOh+70FZGvpAktjP4xttUltprkSuhvzLb2gPKLIiIu8DhSuDz64q7qvirQrTT4xouoQS3M4MVtFZws5j2Yz+6wDhR/D17VtGM7KME7t7rb70Jx0ujS0rw1oek3st3YaPaRXLYxIVMhHHUBiQPwFbUru+Xcl3A6luT+NRpISIASxklVcArgk4z0/pWdqWu29oZFtbW91hoVL3CaUizmAAgYbBHzf7A5wCeKwtKbvuyW29zO8XXF3YXtpqD6Pea3oiWksN1ZWyrKySbg6y+UfvDAIyOnpTvCetXOsapdPf6bf6TNHaxmGymZTEYjjDDADFugPAAORzU994lWxdg+ja+7LGsw8ixMnBOMDBxuB6rnimxu95rA12KG00i3tIXhnvNVCo1yCPljYg/LGGIJOeuAK1StC0orbf8e/y2KSujoZHJJVucYODzg1GzbuM1leEzqUnhixfXWlbUX3mVnG0kF22kDHC7cYzzjGa1CqhwT90H1rGUeVtdiHpuRvKoZIy215NxRD1bA5I9h3PvTbl4oI0e5Kx7AWVmGMcc4/CsqGw1aC/1a9W8tDcXc48lpkaUwWq42RhRgDncx9zzmnXUD2Np5ltAdSRpXkvVuG3TXG8EEoPuhs4wvAxxVcivv8A1/Wg7a2H21xd3l3K9vJCltFyhMW8Tb0BUg5HCnk469OMVNpNiun2ZiZxPPJK89xPsCGaVjksQPQYUegArO0jVJkuLPT7nRrmyN0Hlt1aVXMVuhxulXjyz2wM59a3I5EmRZIXR1IP3Tz17jt9DVSjbS2ny/ruEroRjlemQRxmmnqCCPb6U914GD+faquo3NtZWU91e3EVtbQrmSWY4VcnA/EkgD3NTYnd2BpF87y2AyRke9YfjpNXuvCd/b+HordtQZCf3hCsVAP3Tg729FPHNZV98QNC0mKabxCb/Sp0z5Vtd2+2eZP7yICeOT1x0NaK+LNK+wS34GoGyRVdZEs3YOGUEFSMg9QPrVqlNNPl/AtXT0PLNM1nxb8PfDenWdylnqsZ3SmCL95cW8H3iSB8wwSclgQOADXqXhfWv7atElY27uEy7QnhT2BHODgjjNc34r1e08TXem6dpmlalcagbiM/a1i8pBCwPmLJIuSY8HDKe/T1rp/B3huDwvoradbyowe4kmLpHsX5sYUd8AAda6a/Lyc042k/6/ruOVrW6mk5xJHEMkyBmyAcDHr6Vn67fQ6Ro11f3kipDEhK7m2mRscKvqx5wAO1c/r174m1jXIbHwlctZ6Uu6O7vVVMxyqeCCc5X0AAzW7p2jtZ6jFf32p32rajEG8qe6cbY2YYdkjACqTzg9QDjNYKCjZyfy6/PsS423OZ0rT5/F8UOq6958GjsA1hpQdl+UH/AFkxGMkkH5cdK7CU7s8jA9Knkd5HZ3Yl26k9TULnC5Aziic3N9ktl2/rq+vUjYg+0KlwLYS5nMfmmLOSEzjJHbnp+NBlkGSGIZ/vN3PsT3rkdcV9B1trvQfDd7f308JU3O4m3RS4ZweSdxOPpjim6TqHi3XD56ix0K025VJrFp5CwONvzsOD64FP2N1zJ6ef+SuynHS51RGF6cegrmtWmg0nVvDiywPPDNPOkflxb2ilCja5x2AZh+Oe1QWus6udbnsJLq3uhazCCWaW1+yRyyuMqi4LHI6D8/St5baZL+a4ujGJSghjiiyVjTq3zHBYs3sOAKrldJ+92++6/wCDchqyOG+KdlreuaVb6bpGnK1hFKs09xMyfPx8qx87hjnOOuR6Vi2fg/w+0BGr6PfoiAK7w2s0JD8ZKDLbl7ZPOa9XI5Xuc/lUZDKnBIwcsc/59KI1+WPIl925UajSscVZadZWlrbXuleFL/UlkYxganchZIFT7rCOTOAccdDRXTSqF6ZK/wB73oolNSd5K/rzf5gqj2/4Bj+FdfvdP13UNOuJLS20XSIHuJrKdQs1rG2WWNGBO+UcBge/ANdZD4oSfWbezmsb2Frzd9llmiUF0ChmeRTzGuCoyf6VbtND0iGK2Eek2CmBFRf3YYjaQw+Y8sQecnnPNcR420Zo9ejs9IN/Jqnim4P2iV5T5MUaldxcAZZcdicDB9a54qlWltbT/h3+b6328zq5lJ7nV3+k+GdRmMmo2ug3Ekcu4uRGHEjf3iuCScd+uK5/XLafxV4pGhS2Hm+HobcGNlYrBHIUJSSbAB+XgCMEcYJ9Kgj0e98A+EL24hh8MMIZWlmv5DLubkBWCEfe5wFHdu1dlpmoSeI9Ee7sDc6fu4Q3CKzAkAh9mTkEEYzg1SXIrxd1sn2emqX9eZN7O+5laRf23hm2bw8NOuri5sYllhj063eaORZGztQtjZ8xyQTxnPsNZJde1G3lePw/b6dNDIpjF/frmQj73CocDHfOaS2sNdlmtzqviFls4QB9m06PyvtBzyZGbkAjIwuMetYev30vhW4QS69qWq3pkWG10iNEyC2WVpto3FAO/BIAo5FN2jZv5/8AA+d9PMhPW/UdqM09pdXWn3d7earr11bmJLHS0b7LZIxws7gkNwTySeewrb8O+H10aS6urjyZNTvIY7e4aEs0IiQYVY9+WCnqcnk1RuPC95qmovqo8QzWd5InlkaQhihlVePvPlyDjB/StG2SfQvDkdtFZi4v2M0sVukv32yWwXP3Rgjk8U5tcvLGW+62/wAtFb9WPyQ0eEvDZkjkbRbeSVOksjuzevdsdeeAK3t5jkV05wRj+lZ2jS6pLZtLrsOmQXLMRGmnyPIuzA5Zm6nPpWgSVbBGR6VhNuWknf53JcnfU8o1fRJPCHjHSJrfzLvQ7q7M8FsztGFnLY8uRuQSM5U4BboelesQzfalne2BVhtLF02kgeufTJH509Wb5lIO0gZU8g49qyvFWinxFpi6fJczW6tOkhmhG5lC5OGB4YHpg55wcVonGTSlp3f62/q5c6zq25tbEOlzS+JLzU5JVjPhu3ufKtSh2yTzR4EmSOsYbkEY5B7V0u4EgdCB2HFcXa23jDSvFFhPqOsR6p4YbetxBZ6aFkgAQ7AyoNxUcZZe/UYrrLW4t76CK6sp47m1kG6OaNsq46ZH405q2q1Xlt+KWumpnLUsY4PGfwxSDaVJO0ANwXIHPrk0ENtaR2UIilmd+AAPUngcVyevR2XiXTLO+0cXupraiU24tEVreVyAAW83CHaehHPJ61Cjf0CKvo2W/GOvafb+FNSnt9atVcRAjyHZhISceVleSWGR8pB96v8AhFIJfDunX1tpkOnCYNNHEIPLcAkjeQcsC455JPPJrgrCz8SS3McXijVprXS0ltI3S3YMsTAZ2NwFXBALPyCWwDXdjRo9LihEGo3yLFdC63NcE+fn+BwOHQjj8sVvOMYR5b63v+HyLkuVWTGeJ5Lm60+4tbG/fSXUqZNTH/LsOOQO4PQ4xgGpNIsksJrLTbazSzsFVpYFtj5aFicdiSzN1ySc0/8AtW3tvPmmEtxJtO6PhV2gfMvoox1z+tYOhebIkVpbvahwjxrDtbzrBvmYMDn5FwdoB578Ukvdfb+tf6/zuknYm8VStq1tqGmadrz2MP2YpH5TYLTI68rIOSFAIIHU8VF441G01TwwNHXF9q9+0UEFqsXmOTuUm4ZDwYwASSeM1o+DNPs7a2TUrGBIxOmIypDKRnG6Nh0QgD5RlcjI9ahl1SLRfiLDb6lFbx2+uReVa6nhi6MuD5EjdACc7QvU4Jqo6StFX5dem6/4YbaWi6HR2dnDpllb2NoXMNugjDSOXZ8dWLEknJzT2PZug9aWMSbQZUMb5IZdwOMH1qrqN7Z6bayXWp3UNpaREB5ZTgKT0HHPNYpOT7tmDv0K+orFuEsgU3NvHJLAzHBXjDkHp93r7VBp99aa1ZFdE1mxe5lBwYmDtDg53MhwQOOpHQ1BrGlQ+M/Cstlfpeadb3ZDxtkeaFB+V2Tphuuw54xn0rgjYeIr7xfeW+sSQ3H2yAadcukcO6WHeo3tJFh49+wHawPcDgGt6dKM003Zr+vn+H46XHU7rwJNbXmgy6hDJ52o3FzJHqEzSCR3ljYqAWHGwD7oAAAPTOa2mhHmSTBVWRx87AAFvqe9ZWh3FrcwSaRocUlhFpkjWzWptfLWPB42ngNnBO4euTWjp0pvdPguAQTKD2IKnJBBB7ggj8KmprJvb+tP+B5EPQmXkA59sVyHjXVVuLhfCdjpUWsalqcLFVmb/R7YqckyEc7lwGwMY4Oa6u6WTyHFuSj8AHbnGeMgVwPiLwpeSw6lJbtby6o3ywpDctGGHOZJN5YMwPUHgjgU6Kje7e35/h67mlNK92bC+BvDb/Zm1bRLDVL9IUjmvLlXZp2AwWPzd+tIPh54IQ7h4VswSMYWecL/AN878Y9qb4P1PUl0bTLTV7a5uJI4cz6w8yOsj4J4UcjH3efQV0pZHLKjqWXBODyM8jP1FKTqwk/efyf+T/AmTaM/R9E0jQ4JINB0yHToZCWdIWY7icZzuJPYcVl+Odek8PaDNPBbtNPL+4jdfnaBm4Egj/jAz0zwcetdE2FXPIwK4nXozr/irT/DrytAlsF1K7mXG6RVPywoO2f4ieMYpUkpTvPVbv0FF3d2ULPRbvwJe2c8+pXepaddMUvpY7f5gwH7tpFGTjkgYJ9Oetb914m08XemWlm/2y8vHCPbwn57UEZDS5xtHY9SPSuimlcTPcKziTlsocHPXis/UbOy1m1WLVbWO9ttwlCOxU7v725SDn8ap1PaNSqLXyt+Wn5ofPfclIKllOMjjr/Ko5MDPHTms281E6EJn1KIx6BGAy6gJfM+zDgBJVOXPPAYZ461Jo2r2Ov6al9pUwmtXYrnGCGHYjsehx71PLK3N0/r+rEPct8qQBxzwBUTHcxBJznknmpmAIyOciosbsZyRmpDdHD/ABYS0tvDEd/LZv8A2sbmNbae3y8sJX5mfAI3gAAHjuOa0/BipF4Q0kRtIVeHePMfewyScE1DpLQJ451f+0Sh1xyWtPMjO9LQAKNjfd2nngc9ck10MhY/MfmPc1vKTjTVJ+T/AA2Xl+twm1axF2POf60jANkcY6dOtLLnB2KN3YE00EsvPTHPHB+ntXPJEIzroYk9jyO/FFPuRsUySuPKUFmdmAUDuSe1FbwV0DNaLX7KTTmurJbnUHA+WOzhaTe+cbQwG3rkZ6cVj+NbjWHgSbw/oviMapETEksIWOPYSCSwIO8ZA4GCRnPFa9pqzaW6abHoWsRadZWUfz21uXiibosUeMmUk4BYdO/c1ga34wbVbyz0/wAJXU9xdRyJPqCWLA3KQ5IaJP8AbGCSR0wBnJFc1OD57xjp5vT52OyK1ViS9sLxvDMOoalo174m1ho8NZXaALbuzbWVLdMKAAMkjLdOeOOd+Fyvo15rOrazPc2WkpmDbbW7G3hcclJxgujJkKCcfU1X1D4paNBcSwLF4gtRC4jt7aDVGi2bWIJY5AGQSSDzkYrQsfE2rzx3d2+g+M4dHgdnklF4cT9OGwgYkgjoTj14rqhCpJOLW/ml8lrby/zNJRcYO63O+1/VjaaZcNpEttcasYVa0gTMzSMwymFXJ5XJBPHGTxmsLRvBk8Vrcz6xftBfaiim+jtv3srf3g1y+WywwGC4XAGMVNp174c8GF9I0mxvDqMwSa5igjMsqo2SvmzH5QFXOFyMYPc5O3Lqck1ksmhaXf3zykrFJPCbWDg8lnfnb16ZzWfvw0irJ9XbXtvol1X5nNeysizd2UU8NtDBJNZ28LqVjs38oFB/yzz12+w61zviXSdF0i9s/Es++zlFxHHdSGV2WeEna+5Cfmwp7flWjY6j4gW/aDWPDiLbqxxfWF2siKnYmNvn/r7Vk6vG/wDa2na7Aya9pJmcSSXMZeHRiFG2SMZxyfvcHGOxpQUoStzfc9/K6utfP7r2Khds7QBWX9zzEQDGAMZXscduKzfEF1Pp8NpLbmGa6luEt47ByBJdliARGeoKg7jxjHWqNvZ6rIXudY8WBoroqIF0xPsysCCQwflx9QckZ5qZPD9jLcRXS3t8+q26Okeo+eJZYt67TjcNuceozxzWajGL1d/k/wBbfPr21DRbnQGH955cfzckDB61XvNQs9ODyX95Fb28Z2yTOwCocfd929FHPIqrLpuoXEcMV3ro+zoNriytfJkuRtwTI5JKH/rn79Kp23gnwzDMJxpMU8o5Rrp2mCHIJIDcA5AOaIRh9p/cv87fk/0JdrFGxeXxhcz32n3mq2OiIv2dZbe4EMguFJ3jGMj5SvzA5B+X1FXtch1jTNEtdP8ACNtAirIi/abiYF0XO6aRt/33bnnqWYmrdxos8lzqU9lrt9YyXxV5Vggi8tWGB5iqw4cgYLc5/KrVtpwE5lvb67v9o3bZ2EcEZA5kEKAKD7sSR61q5q6atZdNf+Bf+tOgadDHgbStY0yG7lN1JDeSs8VpqzvPEAOCiKflbJUHLZxnit9bj+0L4wwC5MVrhGR4zHGQB2BHQYwMcV5/4m8c3NhdaG3hXS1m0e+uEhXVLmAlJ1LbSkEZwx25yDxnHHFdvqFzo9s8y6trenTG2ASV5rmOPucZQNxznilUg1Z2et7dWv6+8o5vVdeh8Qyaxp2gtfXyRWb27bot9mZyTmKRSuMY/jJwDitDwlLb2cOn6TCszRafZwBmkl3mGRsbVYkknjOMcDGBUt94g022trTQ9C1aws5p3YKtg6TPbRhWkd1VchGPAUsMZfIBrC8B6pZLo8mvT2V7cSTyzSzXEcbSixiUknfIQPMPy7jtBOR+FXGL5Hpp0/zf4/1vTV47G7DrU9u2szwSabBpMF81vJqDSZaNgBuZwPlIDHA3H6ntVLxdbx2enJY6VZLq15rIl3xSMC942FO+SQkHyhwWC9RgV0Nve6PcaBcX1vJYvoEqzXE06oPIYEkyM4I6k9c85681UsrY63rGl61PYSWdlZWrNZi4fEkskg27lVTgIEAAJ67uOlTCSUua1rfnbTs99+2+hN7G3BALS0gtVcusEaxKxG0EAAcDoq8cAcAcVjePbiytfBup3GqIr2lsFlBcORG5YKr/ACEMMFuoIrcwTzjAxwK5L4o28l/4esLRLFtRhvLz7O9uLoW0cgMbFd7n0IBUHgkDPappr3437kRu2bl5epovh21nmluNWn8tYIGhjJkvZvLLqAB93IUkk9ACSa818KeKIPFXiSz1TxVNYWlssBltbaZTFb7xIV/dyHHmkEAneSuW46V6ZpOnfZbCCK/vLvUbgRgO14VBGUCMuxPlAxkd+pwea4+/+HGlWmh3a6bcXUJiinkMcaLK8mQSkcSn5YwPmGAMtuycnmt6EqSvGe76/wBf5FRt3NLxh460/Q4b+K3la71KCFm8qFNwTKnZLu+6yKQQQOcjHrXnuv3Wsaf440uwvtcnF/qtvEtldW9slp5js2fmyMhlbIUtwMnjk1UubOx0nwfc/wBnyxy3Vq8dz5tlCALdPLB+cH7+F2hgflDMcjNc5ocvirxNDDZ6xp0sltdlJbTV7618x7ZZHI85WyDjP3QOBkkYroVKNJ2j87/p/X6G0IKMbns+g/2rpWpah/ampWc6RP5X2e4vUlvWbf8AM0r8YYqAQgwoHAArpl1axE7wz+dHOoV5IxGTgPyD7knIHqa80i0OE2Gm3n2m2TVDNNc3sMlvG97qLqQQ0Sr82QAGVD94HPcmr1/8UVjtdMhm0mw/t5pCkiXNwIbe12scHLfNk44GeO9YyoupK0Fd/d/W39bEOm2uYr+MviGllb3KxK76jaSNE1pBcL5SjpuuGAzhc/cU5yOayvANn4wZb3aGhsAm5Jrw7AZcggAH5wmOvHPHNK/xplsr9IX0/QY7i8k/4/Y9/lxfNhhMDyTxng8Utx8RvEUUc63Fl4UTUbp0kmeC7DvMvIUfKxXOF4OcgfWupUKsVyRgl6vf5eQ4uy5UkdibmbT9d0PTNXvrCOXVY5Li7gFsiR2xClm2MPvfMMAHr8x5rehu7E3UUC3Vqt7cRCQW6zKzuoXhgoOSMDOfTpXEWniCXWtdi8Q6WlnaaW6RQ313qDKWtTtwYw5+aFeAAcbWbuKseNdOk8O61FrWlw2umNdMlpLf3axvFaDBbzFYjKl8FSCdp3DpgVySp3koS0dvx87fLu/mzOUbnT+J71tL8Ma3qEW4TWdm8kbLglXyFDc8HBOefSuO0KfUPC91cpdeHtT1O0wsl54ghgEs06lA+4kEl0BYnPoQOMVvp4x0G40yeDW7iKG7uIZYpLVIHeCfKn5I3GVkJ4+UEn9KsfD+TWF8H6YNdgls7+JSghddjRxg/uwR/u4/lUKLhTlzR69b/h3tb019CPh0ZHa+KNFvzEILqeCSWEzot5bPbbowMl1LgAgDnI7c1Npd3HqM93DZnzAmySNo/mSWJ1yroRww7ZGRmrPiHTbTX4Y49WRpvJLGOQNteLcNrBWHIDDgjuK5Dwx4ej02HT9N1TXNR+1r5sMdkLnYk8CsHKxqvMSZVScHJ244qIRi0+/3/dsNqLjdHUa5pA1TSb3S7yNhFdwmFlZtp9ev4ZrlNHvr/SNNitF8P2FlpFvJt+3RSeRbyAkBdinLNIx7/drfm8M6K0UsZsWVJJWmJE8hKuf7pJyoxxgcY4puoaBp99rFvqE4m3whP9HSYpAxQ/IWQcZH696cZRWj1Xp/k/68+gpKzTM+fWNbF1cxWnhK8eGMFo5rm6SATfNgYBBKnvhucVZgi1u8hWTUZbfSFXhre1IuZJGz1MhG0JjsBkn2rZd92dwwSeOetRuSvPpQpq2kV+P6tr8CLnH6lqF7beMdIsb25trrTITK5lFsVntyUOd23gpnAJAwOM81Jp+r6nq0kj6bo8cVgkjxGe/n2M5UcFUXnBOOTV5vCmgE35TS4op79WjmnjJDfNzlf7vPPHXvSeHNUl1XTXe4jeK7tp3tLhHXB3pgbsehGDWnuuN0r2010+dl/W3ccpKydinLdar/AGTE8+mOt/HKpkgtnDRyJ/EFc8fg1Vtf1i9tyyabpmoZFk8iNJbkAT5wi4x846D5ema6RvujqRwSM1mvqNvba/cw3d9FbhbVJR50oQBcsWwD1wBk47VHMm/hvb1JjZ9DlNe1G1Dxf2jezNNZQefq+lnDQoPKB8sngElzxnOSKK5nUoNFn1vVtUSyt9Rg1GcZkdS32NVIzIfaQDIY9AaK9CnQTj70L/evya/HU6I8sVZux6p4e1y7OsXC30d7b6hqk6i0066jeNYraMEeaGwRuI5bGATiuomks7EXWoNHZWh2/wCkXgjWN2QHgM4wTzXnuuwXtyloLTUbzTb2WSW9sDK/l/Zoiqh437GRmOQvRdxrqtLtbt5LS/8AEGpWt1Paqwhgt4wIlJUDzGJ5klwCc4AHOK8qpTjpPv8Ap28tLa+uul3NaXILrS7LUvEls40OD+zHX7XfXV1Y7RdTLxEihsE8MzM2PrWhp17a65cXVxuc3Vm72joJiy7A3XbwOvHTjpVyO7huIxJDMsyE4Vw2Q30PevPPH2j3ml64PFPhdZbfUjEY7mSNBKqZwNwjx94jgsKSa2eltv8Ag+v+QU4urJRvr0PS3hguIJIbm0t7mCT/AFsU0YZJP94d6y7Lw7aabceboUs+kuRtMau01sVznBgZsfiCDXnHhb4ra7q3iS00+XSrCdLuQQDyVZGjYcM2MnGOWJPHFetW7XJ3rcxQK6sRvgYsjj155Bpe/FNd/wCtuoq1GdF2kYOpSavcSaok1u6GxKfZZtNRil2HH8Kuc707nJXmq+m+A9ItRLNO1xcX0gkHmFhEFD/eyqfIzHk7sd+nSusxjd2PSnKhyDgEdznOapVZRXLF29P6/r0M+fsZml6Tp+mF0hglLOxJaaUykE+megx0A7VqrGif6tEQHk7BjJ9ainV3TbG+xs9e9TEiNFDNzwOe9ZuTk7tibbF6j0x09qljAdxGNokxnBPb1/Wqep3tvp2n3N7fymG0gTfJJjcVHsO59B3rD0q3XxPNBrGsLBPpsMjx6dZLnbKg6SXAOCX77OAMc5qkm1foNRVrvYy/Efi6xvNVk0Wx1aK0hSFbqTVLMNdujBtojSOP7xycHnI9MVZFr/atnax+KLzxnMoeSd9PGkPCLjceFkeJWG0EfdLcA812MCx2yGO0iitoz83l28SxKffCgc1IJHDDBYHuN38619okrRVvuv8AfbT+rWDn0sjMaTxJqnh3URdR6Vo+qXNs8cECSNcmBiCATIpVQcHjaOD61yWh2Wo2k2l6PqGgafY2d65hj+zx25ZikYaR5FYPkZIxhsnnivQDzwTg9cVhXFrqMnim8u7W0tpIoLeO1try4YgWUzKxdkXB8x8MpOMDGBnOcTTlZOKStv8Ap/W/4lRmU/8AhX+jT6hPe6vLeapNKqIA7LBGiI25UVI1HGeuSa6+GUxMnlIscUeBHEoxGgHQKOwrk9QOq6Bq+m6jea/dajpM8q2moQTQKkVuHACzJt+6A2M7ietdVflNPt7ue8Zo4LRHlnk2ltqoCzHA5OAD0605tySu7r8Pu0/IiXN3ON1TSvDvh6O6v9ev9UvdPaWa9j0u5ufMilkYF5FVAB5mT82GyAean+FBhk8KS3NvFdwwXE7XAhnVo4oHbloIVbkRoAvPQkkis/VLm78cS6RFoCfZbKNP7UW5nYCQvlkjTy+2QC2CeQRVC1g8UaU2q3fhgrOYmS0uYbxJn824B+/GzHDZLZZuBwACcVs6d48spWk+703/AF/4c2SvC19T08DfhV3En+7XJ+K9W0vVPDl9aafq9u+pJOIbRbaRTOl2jrwidSRnBOMYJ5qHUdR8WaR4dxaWJhvkmVRqOr3kZZ1LAkrFFkk4yNo6LzyRXkWg6/Npes2NvZavNqVvYCVlXTbMCTyiWLMxdAzN8x6YIAB5xVUMPKV5p3tt8vv/AKuTGlfVn0cSZNzAq7A+XJsYEeYMbgcdDnt2qJdjOArAP/sn3ryPwp4k0T4c+AtKlm1MalHrN/JeXEmJBKqZCNsDD5mQhdwOCd3GcVuf8Jrca1qHn+Bbe3ura3tXuHv9Sjkhily5G2JB8x5BG5uMg9MGsfYS1stO702/4IpU3ewzV10nVvGupWerTXX9jf2S1rdmCP8Adq7SM2GYf6tlA3d9xI/HzRZLnxH4jh03w7Jdafps1pG8EIvGbYsbIqlV6LJ8ikhjj0A4zb8c+KLxNWisLLSpYvEVzqbXNzBflZ4hhdsCKBkDIw/PGec4r0D4QeC7/wAO6bdXniCVn1C/bebZ0XbESckjH0X06fSvRXLhqftJb2Vlf/L779vUpy5djiNY8BeM2N/eG2W61VYHj+1Fle4c7srITncZAowu0cdqq+Cvhfd67pap4n086YqOWa7l3JOwJyWIb7428DoPWvcLPUpN1y0xiPlS+WdpJdOOFf8A2vp2q5eXkghY20EdxIm3zGmOI4VPd/4ifRRyfasvr1ZLlSSfdGbnd6o81uvhr4Q1XQ3kOuzTQRDyZbiIBowyncVUdevYHNQxfA/wxFaRSRalIbdkDOZYQwkBI+ZTuGOOlelafbeXdTRXc011dxQRSebMAAVJIyqjheR0H51zPxR8cWPg60jtWiW+164USWunjkEdnk9FGCcdTjsOahYmvOfLCTf3f5Apyb0PGpdOHg7xZq+iPq0MdmlpJMtvdTb45FWTcISBxlxzjqCPxr2XwTPeW1xd+HdSsGudDeHz7Wa4PnKquqs1s5P3lAbKk+hxXjvgXwl4l1bWZfFepQWV/wD2hJPaTGZ97ROy4ZlVf4wrZUe2a9f0SeOz0yHXdSuGs9N0qzks/KkkVI3UvmJ3JP3ygA28kZ7nit8VPnhyuzf69Pnp+JpU0WpevPB+nT30N1pf2rR5IkWNV0yXyU2Ancu3Bxu4BIwTgVW1LULnTvHdhbWlybq3v1YXGmLKkkloAAVnAJ3BOSCPbI61hifxX4okBhsyNKhmCyzWt6bZJCTlvIkIJkUKRzgc8V2dro+naFa3Nl4es4bQI/zALlyTg/Mx+Y5BB64rjneDtN8z103t69f63MmujZPdymECTY7oGy+zllXuQByT6AdTXNaVqTav4r1iS8gjih0NVjtZtmxkSZcuJmzy3y52HG0dea19f17TvDkNrJqks6NcNst4YIjNLM46qijqfyFcvqNl5WozG7tmk1vVkuLqw0GCJSIRs5muTuw0jLzz0OQM1NKOl312f5/hdN7IUVfQ7NWVhlSrKeQynIPuKhlGW4A5rG+GrJP4K0+CKQPJYobadQxfyXDH5SxA9fp1AJxmt2e3uJIWW0IS4JG0suVIzyDnHXkZ7VE4qE3FvZk2ZAeB6+lZl9rmlWN9b2N5fxW95OcRRyKwDH3fG0fQms1te1+8by9D0GO1vpYZJ7O21dW33EanaXAXARgeitnPXNcfBruj6o0Bhn1jWJLeFYdSMzpFaxbnwXILY8wsQowTxznitqdDm+L8P6tvpvvoUond6vdWmlQJJJdxRtPP5cUO/c00mRlIwvO7JHB455rnfEep3fh7VDqU80NpYX5JNsy+dK8safcCL93fwN4yBgZ61ee3bQNLvtSs9H0mwjtWBEpnNxHaqCEcnau7dg9Og9cdeM+JnjOxvL200nSJzFBdxFhfjO5o2ziPgbkU4yxH5HFEU1pFX3XT16XX53NaVJSlZ/D1MvUfiX4jvr2NNK0qG3eIec1tkzHYBku5GMr14wMe5r0aO20XXJPMMkF/cXMUMspiJ2EqPlKE9OCwwO3WvK7eyuvD9vdaNeRbNSuY1i2wzqHt1IU8MRtZWBBK8n02kV7K9jpd7pkdh5Vvd2lsqwLtODGVULlWGCrD1FJtKKcdPNfL+lr8zXFQhSaUdDJ8Vf2fpujX89/ILCG4jWLfCoR1Cn5Sg77Tz0ornfEHw50/U9aW/vNQv5LWFEjS0dy+AMcFyScd+nWiuzDToU4+9KXy0OPm+Z6BqttdS3mmXcGkRatLbMwWZnAaBWHLrnjPsfw5q5Jaz3EsRS1SHzObjz0DbDjl0wcnPTAxkdadeaTHePZ3L3V9BdWjGSEWswCO/UqYjxIDjG0889RWTqA/4SDw6mrf2rNaNZ75hHaXZtovlPzLcYUspCggr2z3rxo+9az8uvn52/I6i7N4i0aDXU0Q3kA1Yt5b2sUTERsFz8xC7VGPU1shFk+SSR1RxgmJ9rYPoR0+tcVDqVroOnwa3aXDz6BGxm1GGCBXVY5E/dy27kKSoYBWDFj83rxWx4K1WPxNpM+sQsws7y6f7FArfNHCgC4cY4csCTgkYI5rScEldbfr9yt39OplKNh/huO+SWJL3T4kuYhLDJcyKomWMOfLUMuSQVK/eIOAc9q6EblGQAR+lc5ZRabB4wuY7O41ObUpo/OugJmktY8YAV/4VfHQcmt+5ZI7K4kuJza26RsXuAwTyhjqCeM+g5+lOolzaLfy/r5Et82ol5NcQhXt7Ge8UfNJ5TICiDkt8xAJ9AKbpd7Fqen2t/aB/st1GJovMG1yD0yvbis3/hH7O8ntr3UrjVbwhUkFtdTkQO20BXeDAG7HbgZPIzWzEFVVSJFRE4CqMAD2FS+Wytv/AF/WyEyK7SaWSKOGRoU3bnZV6/7JNWkj+dERC56Duc1ja7c31npszxPZ28mMRT3EpSBH5I8044U4xnjkgdTVfX7XVNV+Hd9aXEXla3dWWx47E8JIcZ2ZPIx2zyO9Pluldre3/BKSbsWNbjudbvLvQbULHpyQq17qSsGaNzysEanh2OAWzwF461uIXWMCaZp5V5aVwAX9yBxWB4O1HU9Vk1CO802G0s4ZUSxKo8UjRleA6OOW4BLA47VqaXf2mpwvPp9/a3sQbaGtXDKvsfQ/Wk01pbYc7rQ0CcEEcmgcrgdOnFZ+t6pZ6Jpcuoak8iWkW0OyRM5GTgcAZxk9aoReLvDklubiHWbaWEP5ZZEkcBsZwSF681SpzkrxTfyMzoMA8DOO1VIdPhh8QXmrxu5uLy1jtJI8/IQjEh8f3sHb9B703SruPUrm5ks7y3ubUorQRxAh1VSVd2BAOC3A7cVfXcShPA53ADr6c/n+dJ3i7BqY/jRbKbwbrseqLI9iLRnlEblGyvKlT2IbHJ49a5Xw94d/tK/TRrjxD4wvI7aAXdy8k3kwxeZGCR9p6yD5hhR05OeDXc6veSafYzXEcSSHHlqZmCQoxB+aZieIx3wC3oDXO+HPDo1TTru58UR299JNOoWCBHis02qRmFd2SrbiOQM+ldFKfLTetvx1/rrdFRulcteC7G2aa41G3Sf7JDEulWEjzljcwwkq07DgfMRgH0BPeuo3nbjPTgcnikjUIiRxokcUarGiIu1VUcBQOgAHaooSSpMi4OT+I96wnLmdwb5nc57xj4RHia70y7fUbi2bTvMe3jjUFTM2AJST0Ze3BrHv4NL0jxxZWOlajOdcci/isUcOC+wq0jHGNxG4nJGcGupN2w8YxWVu8jn7Hm8KIdtufvRHf0Dkbht9OeK4XX/BWpX3jDU9YsdljDbNF9nxP5ELRxqNwdgCQwLMwP3SAc9a6aMm1yTlZW0+b/p+nYuPusz/AIbeFNKuNbWW7tp72aC5mt45JgTawyAFhHFz8xO7ezHCk4Ap3xB8UWPhKe5tLTXYZXvbT7G6Q4Y2MA3AuhQbd7HK7ewUZ7Vs/F/XF8NeD9Ns9MvbERTjyJMSie4aMAH92g+U7j1Y4AGABzx4RcQahrCw6Db6XGCbkBVhi/49y3zHYVJJLAjcGyuQuMdu3DUniH7aXw9vR/1/mU5tta6mj4X0KLxN4rii8OPdTAtHG895IG4I+eRVABUADgnPYV9Nfapts6SQbJI5jbWmCW89EUfO3Ax7gcVw3ww0KXwXot1FdOViuZfItbVX3XDShjvQkZGBkDI7gk4AFdhqLpaQ3NpY2aanfxbZbmJ7jy0jjY5LFmOABjKqME4FY42t7WoorVLb8Lu/4GDd9CRYFgWGTesshaSSJmQHa2ATnHJA4A70sk8Vlp5vtaeGKKJS0pIJXJ5YherE9uM9KzbK9vokiub55b66njcwwWNmGCrnIXJYdRgktjoQCalbzZru3uwq3U0ab/mkHktOfu7ST8sa9c+vJzXI4a2kxblaK/vtPvVvDBDCk9k+xNVn2bth3iSUjIXA4CjJwTnmvFNF8J6jqng7XfGl5eGfU5rx/NCDzXEORuaM4++C3AzjbnPOBWj8WNbg8Z6nDoenvLK6sGDuG3Mf+Wki9QqYBCqcZzk9q3/BniSw8HySQTrqdrp7XWx4o4N0doiRn90y4JaRshiQF+6eflIPowpyp0+eK97TTy7fNHRGMqa5luYksmheFLzU9MtdaltZVs2N9KGeCUHCBFQ46gkHABY564zixrY1az8F6dpk9jPDPDGn9o3sMTPHBby52Snfk+c4xuZQdqnHU4r1q+0+21y8g1KCSSJEg2xajbRoZWDHO1WdWAXGMkDPbNQWvhjS7OyeGzk1CKRt/wDpX2pjMCwwcE/KRz0IxnnFY/Wo6OW/6/16/hrLra3Zl6Lp+tQaQdKsL6RLeM+Ut5LIZ7iNtoCxAYACDGW53DdxUeg2GuaHa3ENo+n31/vUX1vcSziFJiTlopCC2SuMqR/CMVe0nR9V057vTrjWku9IuDJIsxUx3ql+GVWHy4ChRuA6knA4q3a6NplqdLNvalm01GjtWlkZygJ5J5wzc/eIJ+lYTnurp38t/XZ/19+bmjC8JT6re65rWqalb28nlXYtYnlDIkHlZVkgTbng9XzyfStyy06KG21BCN76hNLPdSjhpS5Py567VHyqOwFaDln+/uPpnpUbDgkdRxWcpczulbb8CXK5zOo+D9OnW2aweXTriJDFJcRku1xGQQI5AThgCcjjIxXEalZTeFTZ2GqeMr3ULt7hr22t4UleeeNQVCGQvtGOSQc9K9YYnP0/Wsa+Gh+HFv8AW7q3traWZgzzeXukd8YCR+jH0GM961pV5p2bb8tP1uNS6MgTT9S1fQmOsalOt3chzGYV8l44JB/qnGfvAZGRXHeJtBFp5Z1FVFpJLaubiC28mJzErp5U5TP94Nv28n0rvINZiu4IbuyttSvLWaIPHJbwoUcHoSzOCCOQQRkelZ15retPetZ6d4curXyZcTT3jq8cse3P7vYcbicdTgc048zdrafJWKhUlHU4XxJrceparfaaYr6+uhIIrGDTsxRKV+VXEn3uScHcu3HO45rPHgu88LaSp1SSOOeaRpYreKVEaKNOZj5uMsUypVV45616hFBrEquL/U4dOt5Uy0Wk2qx3CEgZQzNuGM9SF7cEUsGn2cEU0QjknSXO9ryRrh2B6gs+ePYYHtVKcadkv8/8kvknfuVLEu1kedLpngfSbs6rb62Ly9khK27ySvLD5z8By2Cd45OGx716NZ2sdhp9vZwNvihjCBiNpf1bA7nrT0SGOHZbw28UfDBYolVc+uAMZ96S4ZlgbywGkxwOgNYVKnMlHX5v/gLzMZzc9SrcEsygFSRztbvRTJgTgnAzyT6H0FFEEmiCp42t7mbxD4XmtrC9vPsks0im1O3ypSoCMW6Lg4OSCMDv0q3bWWmeCPh7OmvyCeFVaW/YNzdSv1QZ6luF9xXVRg84bj0Fcr8QRYzaJLaX+n3GqzzqWtNOgVg7soO+UuOFRQRlj0xxz05YTc+Wn08t92/wu/zO7mukkcFc+LbjWfA92viTTr26sGlWCz0+3h+yWgXnYzyBcvh8BVXAOCTk8ib4eajrNjdan4asbmyjdUjuUtIVMsiOxHmRxNnqq4DA5IIJ9TUGtaf4X8Iabpdxqr67rurbA2+0v2jit84YrEzHIUHoRkkjORXe+F1tm8OaO1hILHSZIc22nW67W3uzM37/ADvd8ZBAPOOfSutKMVdrTppZfd/mlfubVKkeVqC0b1/r/hzR0y70vS9NfS/CsP210kYpaxyHa8zH5nllPAAOSxz2wOcVNb6D50dnL4quYNZ1C1mM8ZVClvG3G3ZH/sgAZbPf1rZGI0WJY0jiBz5aIFBJ5JIHc9SfXk0iqhzwCAORWDm221169fv/AK8zj5kth7ytIDI0gfqWfOee5NQ2dxHd2dtc2+9oLhBIhZSpKkZGQeR9KwPEq3ul+D9QltZRceW4eSNYQXkhLfNGueA2Dw2Dj0roL6JomtYYw0Q2gKoJcLgDgt3x0yaTiktP6t/w4rFXXtG07XtP+xaxaC5td6yeWzMo3DOCcEZ6nirkMccEMUUEYjgjQRqi9FUcAc/SpOwBPFRzh9p2HDDmp5na3QPIkdg67Xyy+5NZ2gaXpmgW7abpNvHbRuxnKAkl88FiT17CryAlVyAPUetQzkRTpMYy8r/u1wCfrmiLe1w8i+NroVlQOjqUdGGQwPUEHqKm06Q6fbrb6cFtbdMkRQjaMk5J46n3qorK0rKu1tvBIOcH0PoatIpJAHXsBRutSdjC8e21vdafDq17e6hYXmnuJEvrGBppQh+8joo+ZDgZz0xn1q94b8Q6X4ltFn0i8N00aAyrImyZewMi4AXPJHY1g+NfFlxpN+2k6YZre9eMYvVKk72U4hiU/ekwAT6A1ifDO/XTLq+fxHc2p8barZmUl7gsJgmdiO4wsZPA2jJ+XOe1daoydHmfTb+rbdd/lqaKN467mx4/8O6tq2sJqmnJNOumWXn2lq7qUlvN/wDDHn/nnkHd1zhcHmuZ+G18+g6tqW24tk8Isryu9zK/mwuPlijRW+ckgAbSueD6VR0Pxh8QtOiml1CPTpbCxYO8PlbWnjIBJjmyQTk4BOctkda6i78RWdr47iiTw7Pb6rdENPeSWW4Sy7MeX5pH7sxtjMq5Hc1r7Golyy1ST2fpv+nZvttopNR5Gtyx4n+IcMDJbaJaXVxbzx4XXUiaW1tpdwByuBu2ZGeRycY4o8Haj4uvp7mTWbqSdHl3WaxaesLmHJBZ0LAqxwMKenXNczB4i8Rprlpb3OkTyAziSGw09/LtI4tocF227CQ4J7bmyD143LSWCwvtM1LRoY9XtLZZRcTXEjySvJJnKrKTsLl85IBwOBgU3RjFcqir99H+PS+3Z9CXHlL/AIe1OVpr6bSruOErfq2qT3KkzSBOCi7vkHXhgCCoODmuZ8X/ABEOn6sll4W160v7J1kCW2oQtGLeXJDPLKQNyMCwUHruHsaxvEV5p1zdSaFPqGnWF/cW6S6ndtGs1uzFgQm1ThCjbDhew5zjFM8M/DLVrlhB4hney8PTxi5u+oF2/Y9N2c87SQOhFdMaFJL2lV/Lv/n5JdN97ESavZC6b4L1jWr22aJLIalZRy2l8gj22LQvsIy46ybXYFFORtQjHOe8XRdK+Hd1bxeEo7ibUZovs7NOweQoc7F+X7iluSSOQuAcnNXfErTWHw41y20G3VLWw0u5zcOBGzHyifMATA39ST3NeJ+BNW1ay8R+EJxd6rpUGoI0U13qMnmw3DMuAYwFyvOSCxwDg9jnP2sqt7vTt39evorGerVz3+OUWtwRp2XvLONkO8BvIEpywOPl85yBwPujrjvlyuAZIEUzytNvuGSIszS5wQ7fxMDxtXj2FYl7q+l6Jp2n2ukrfPYxTPJbi2iM81zKxy85U8gY6OeuflA4NcvrHxKfTtPMGji5h1Rh5dvbxbZJBgeozsVj/Cvzdcms4YectYr7/wBf609Sorsek20ls2ry6bezSG/aIFrC2wsvlnGTMxIUA8fKCSM1zfxD16LQrK5sb17NRcMCbW3xi2tsAbN2fnlJ4yBjHb15SLw/qM2h+G9Ru/EVyvirzpbh5DMssNuGO1IRklBJlidvqzZIIrO0vwXb2MbxWUNzqOryyJceUfkkWFJWVvLmyQxZxjeoGBWtOlTUlKUtF087/gv6v31hBpcyLHgPQEu7qW8ubm/s/FrM32OaUokMDbgU3cgZ4wAwPT7tewzaToejeHB/bcUMdpbIPtE7Fxl2YMSSvzct/M9ia850SOw183NnL513Fbai8Z0qSDZA92o/1srx8rGQMLkksy4z2rqviTqejGa1S8u9UkudMuFmeHSUDs7v8vluOQpIDHnnCsOpqK8pVaqim/l+H9bK/XUJJXSRi6v4p1SLX9M8S2t091Yi3SEaFB8tvJE+QJRNjaOxxjcCMcdK9FF3B9tjtkkH2iRGkEY+baF65I474z3NeZ6Fr+kReILqyvjeaiTeqtnDbQIsNw7DAKQdUC4PI6Yz3r0p7Fz4hmvWBPkWwtcDnBL7z0/Dr61hWjFNJq1l/wAMvlf17k1kk7EzYLluMYxgjpz2pjfNn26VKYZGAXa25unHXHpVW7uoLK2kmvLiKKJF3FnYDj29ScEAd65077GFmOHGfUn9KiZhk4AArKm8QWifZw9tqatOwQZtGwinPzuf4VGOSelXRfaeZBGNRsRKV3KjTqGIHfBPvWnJJdBND2A4+9z09653W7O51jxNY2cd1BJpNh5eoXcCyIdrEkIGA+YsSDxkYHNSXeviTxhp+gaZewLM8bzXUq7W2qBkJEehk4z3ABBrU0vSrDSLD7LpVpDa224uxHWRj1d3PLH3J49qafs9Xv8A1r/l/V7V4akhIG0IqoigKqqMBR6VGxBBHOCfypUdZYlkiYNHIN6OpyGB7g+lIVBJZf0GanYh6kTEjpz29c1DJ0Bxn2zUrc8c/wAqiYcdefamQ2RjJ/u5PIGeSPYen+NV725jt4WVlFxcMp8u1EqRyTn+6pbj8fauW8W6ZNqnifS5tFjabWdHdWcuwjtY1cghZWzndx91ecHPpXRQ2dw0kM+syWV1fQmTyWt4dsVuHxnYWyxPA+Y/hiplBJKTfy/L7/l5GiSRzNuvjT+07q41FdK+xsg+zael0B5XtvC/e9WOR1/ArprpMZcctjpRWinpsv6+YKSfQteHdfX/AIR6S98RXECPbeas1wmI4rrygS7W4J/eKAMBhgE9BWLot5ql7pOreIriF7y8liPl2e05Ma/NDbx4xhVJy/djxW1oGgKLW3m8RW2n3V/BJvtI0UyxafFgBIYQ4wNoGM85xmtue9htVe7vpY44FbLySEBQM9z/AFrk5oxb5VfX9dl/XodfNbY8Q1q507TZzY+JG1y4v7m3D6nJa7RN5jkN5Ks52xQrx8oGWOM8DFb3wl1HTvEGl6v4N1S1mvNPtT9rt98axts3jPKE4YMRyDjrWX4v8M3MXh+bVm8S6RdQxXktxkQPI95csOIyASNwUYwOMDJ4FcZbXsnh+7tryDWLyBoZkYNbxrG8QZRuCk8bQCR0wenFdM6knon+e67dv026HfRw1OvSbW6+493upfE3hmwa6kZfFGnQt5YtlhZL6OLk5DjKybR1LDJxWz4X17TvE+mm/wBIM5gWQxOJovLdHABKkeuCKbaeJtPbTrm7vpxaNawxTvvddzpIqlJEA5+ZmAAIHPtXBeB5Z/FvibUZL2dgi28UV5LasIZJ5UkdldtgAHyPsJ4ziinH2sJTatbqv8tv6R5sqUle6tY9B8U6Naa1o81tfF0jhIuI5UkZDDImSr5UEnHpjmqPg3QnsLQanqUEw8R6lCjapLMxDSODkBkB2qQDjApviCXUfEOsah4W08Q2FnaxwyajqLnfIVY5EEQHAYgcknI/n1lzJ507y7cFmLYHvUc8ow5b7/8AAt9+9vJGXQrso4xjHQgdqTZlx19hip1jJZflIycZxXAt4qur34kan4PvdIEVhbxlrq+iupklt41TcsuR8sfO3P161klzbFwi5HbYX5vUDOM1yWuTeMp9eNj4YykaSxhZGhQQSKRk7pGBwykAEDrnird/4u0Oxlcy6lC0cC75mZ/l29uRyfw57jNef23xpt7eRWTQ769t1nZJCp8vGMk4PIz0PPbPStqdGq7yUL+v/BNYRa1sdv4K1fXtQ1W9GqXNvfaPAsrXGoQW/kWySqyqscLkAuRg7ieB65pni7xmqtdaH4b02bXNXmf7JmNN1qjMuW3OrZO1SDxxnvXn+qavD4/ubq1n0KXTr2b5I9Q1S8lZbeEcrFEkSbQTk5JBzzmu88MXul+HfDNjolvFcQanBbFw9xbmBphvLH58bSpJO1Ax6AHkGun2Ki+Zx17bL1uv+AKcHe5X8G+HdE8LXNnY6fYf2pPBbpeXl/Id+11Y7yuThCpbAwMnnk1jX1lq3jbx1qd3MEtNYTSGQQXFsxhtGRiYSrkjcWBYqwHDK2RjFddZ6r9jvLuCytJ3FzO8VzMoQx/cBjR2YgtIegXH8Vc78NtdtNU8RXdlcWsNyl0ggju7gxpIm4kvalQcsCyErgkjnsTWjlP3qr1dt+v9eX3dhpWTkuhW8Fx3OtaRo8msBL6wsrPdJZxqPsj7yWMkhAOZGJyenOc13Gsa7Cvh+wt5bJp5mlS1gtYCYozledpOcJtG3PPWtDxVPDpXh2PSNISG1vb/AP0HTbeFAibj1OMYCqMkmuK1i5eC2tbjVdYurqys0SdPIVII7fyj89xkn99I+1iiDpuBxwKiLVZqTWl9P6Xf5Xs1e4r8zvYPE6QfZ5E1u5F5o00olTTorh2gDqyrvuZBz5aHGIo/qea848e+KH1TWprO2la7kurlo0uo5PJjtpUIRDDjBCKCfQHPU9aj1vxzrfjS+TS9D+03VpGmNPjljKTK+RtkbZkPIx4yeOT0rtPhx8OL7TLi21PWI4LPU7SaSUzSYn8xnXAV488FCc4B5713QjGhHmqvXov6+V/+AS5WWh29t4Z0O38G6PqOt6PNc6s1rDLJbWUWyeeVeMeUMbm5yxPXua39SguruBj4hkla2aXcllYAhpiQcKzDDOwz91cLxnnGana4EbyTt9pa5kUK0kgAmcDsoHRc9hgc1kX9rtubOy87dqN5ul2eaQ5QnLuxDZWJQNue/TvivL5pTfvP/gena39WMXqY3iiwuvElpPoX2Z00aOSJHjjfapZuFhDAZkZc735AHAHIJrA1TwH4V8MmO9tlmmltD5VuJpmnjmn2/LFGCcALj5z0wQvB5rvbNZGE1hbxyf2RZ8y3COVQhQWeNWbucjLDgLnvXk3ivxDc3viBbKW+TS5PK8uSMwkW1ra5LMUGMrI2QM45AB4zXTQ55Pljolr5/rr/AF2HGPM7GLqf2vUDdG31i523Vw0U2vFWjjuHZmDhMHDJyV4ABIGOMVdg02x8N6fBJo1hdXtuSETUTBmzhlztDSSD72M/MBxzjtW0sAvTFbQC10GGNYgltcTiJNPQghQSxy8jDD47bvc11tzren2U1leaRe2NvoWm23l6lpEKeXEiksfNjI4fOACRu4Oe5roqVZWSS/rpt32XT5Wv1X5NEcxovh60ntoBFqBvr+9kkP2TSfuGVVwzuzDbbKAeAR+taZ+F+pKUhj1TSrFLWMpamK2Msw353mWTgyNz649MdK62w8d+FW0yJjrVhp8ErH91JmJA3B2lioUtgjnvXQxSRzwxTwvHJDMokjlVgVdTyGUjqCK4amJrJ6q3qv8AgfIydacXoczF4G0vybdbu71OVoli3iGUWyTOnRn2Dc5zz8zGtzSLOy0xJotJsILRJX8yURJjzX/vHuT1q63JyucZwarXVvHdQPBcJ5kUgwy5IzznqOe1c3PKStJ6f10MZTk3dsq65pmn63p32LU7SGaEEGMhAHiYHIZT2INcSPDHiO11CXyzaXWnXEgknkjvTDPdyABY5WH3U2KBuAGDjjk5r0Bjhuo+lRk8DpVQqSgrReg41Gjz+58FSzW+oz+KfE+parqV0CIY7d/LjZ8grtiPPUAHGBjk11cGh6dDcTXU1lbyX1ysZuJGG8MycgKDkAA5IxTL1dVg1k6hGkF3pkNsVS1jfbcCQ53uPlIYYx8oOcA4qxpmoWWq2MV3pt1DdWsufLnibKtjqB0OR3BHFU5y5d9P60/D+rBKbZblkJclmJPcnuKgk2ZmZo4mMgVXLIDuAzgH6ZOKVmJHBzz27UxhhM44zk80kZXZUv7Gx1C1jt7yxtZoI1KRo8YwgPXb6Z74qg+kTQXds2lajNYWbOn22zI82O4jXoqBv9WSMgkcEHkVe1LUbDSYFm1S/tLGIkANczLHuJGenX9KbZX1pqdt9o068tr2AMUMtvIJFz6ZHQ005W8vw/yKuxsMCWmnW9paoNlvEIohwMgdM44FY2oWOtXcwJ1mS1gimM8K2iqg6jEcpPLoBu6Hkt7Ct5tu5QxAyduCcc+lZ9reC4uI4ZIJ7V5QxjS4hKeaV67c9eOcdcAnFNNp3QJsc93Gb2e3OEZQGDNkI2fQ+2a5p/F+3WbjT4dHulltzjzbqaO2Dvzjyg/EnTIGRniuoYbuqnapwoI7+oqKYeagSVVdAcgOARn1Ge/NF49V+Ik4p3aOY+Gsl2fCECaklyl6ZpZZluIvLfc75yf72Qev4dq6OQLk49Mc96UAoAB0Xjr0pkqkqRn8V4xUTlzScu4m76lGdtxIJOB16jqKKbKu3ABJkYYywzg+uO/0oq4zcVo7BZHYvFJED50TqegyKzdVkuGtpra0sbe9lljICXThYTyAdy4+YDOcd6pXGiCw0i4j8IxwaXenBU7iY5W4/wBaGzu+vX3rQsiwtIBNGI59g8xASQHx82CeozXFFJe8nf8Ar+up0s8e8f6aPDdroOnaNFLJL5s2pXEpuDELqRSEYbR0JDYAX+FvqawW1jwXpF/axQvqOoLIhinhuIRG1nGxyYlYnl1YEZI24PHNe8alpWm6mY/7T0+2vPLDCMzRhim4fNtPVScDkelR6Z4f0PTpreWz0awint4zDFN5AZwpzkZPXOTyeea6/axnFKabfrubUsVKkvdZ5Do/h22+IniMahpcdxpekJELe4ManzJWHJOeg+YDGf7vsK9pvLyx8G+GUhsrQwabbW0oWWA/LA6plGdfvNuYnJHQ9etT6PYWWj2b2ukWyWls7+a6J/E2MZOfYDis/wAcraXPhS+s9TvDYWV2gikuApJXPIwPcjHPGKc6kakoxt7q6fr6/eZSqOpIb8N5dJTwxaWWj6pb6jcCMXl8UmEsnnS8s0pHfPHPpRfeJNdj8aPpWi+HIb+ysGiTUJJpjFIfNGQUJwvAz0yfWua+GOgazHH/AGlqKN4ftmg+zQwWcvl3M0eAVJcA/uurAghiSecYrvNJ0yx0a0aDT45AZZTNPLLIZZZ5CMeY7tyxqJNc0m9W/wCun6d/IdVRhLR3PPdG8SavrHirxbp+p6hJ4blTEOmiR9+xjITuXPy5VFILgYGcnkitTVvC7z+HLbSU1eHRLq73ma7Zw0N5IwHJZyHlyPr16YxXUeKNMtNV0S9S72wyx2svlXiriW3O3duVuo5UZA69K8c0bw5rnifQ9E1fxf4gvJrSK9Dixm3ygwA4aUA/db/Z79MDpXTS5Ze8ny2fa+ttLf8AB2Dm5lob2v8AwmtxpsbxXfn3zIq3dzcRlocIMFguc5wOp4rY0/RRpFkNPg0eO3tZpU3200hnE8rr96T7y4O0dOa6x7y4068+zRfZmtomQSQvvM4jJC/Iehweu7k84qj4l8cw6ZEBoNsmrXscp+0Wrl4dkYyMh8YDZ28HnGeM1KnVqJRtzf116feWpz2K3hnRd+hXH2hpEmyVlnndNuc/cBBA+8pAzjjFZKanaR2TWZ1m1EFtcea8iQs64YHEajvtbO50BAwc1yfiPXL3xDcW17eW9tvgxElkrKls7sTy/O4uOAM8cCsGzuJpoZZbrU7qMWmUurBgqSWrE7Rw2G25IBK5xnniu2NDW9SSV+n9X/Q0jTlbU9bSxB0NNUtJLC9hntpnhlafbE0yHEYLnjdksQe5ABpui6RpKXmnW2qadbqZZQ8M4gKEXZw+crjy3Ygexxgd647wtcRaVaae9uN+mSXoWeGT5kt2kIBkQfwnIHt616rrnhRp7ozvPK80EiusKHY6rnkBjwTjPB65rGrek+Vy3vr/AF2Mp6PlkzlfEusandeNPFE7W07ppcFtp+nkfKIWuf8AXTpnq3BGRzjiuF163/4SOHTfC+lXOlCJ1EjQi/DzoWUHPzcFcNwiEnHOAa2rjUdZ8LeNdRuxDcNb20cbW9u6hVubFJCPl5/hA4yNwIyK5fXdck0XxfpvibRZ7O6sLxpZJYtkUXko8hkEcjj5gCOFJwccL0IroowcLcttlb1t/nr6thKNo3T0Pbvh74U0jwRpVpbCG2fWyjSTXEasZHxgER55AA2jt+tU49V1keMJoPscltpOyQrPMIz9qu85HlDO5l24HA69eK39L1MeIfBlrrNqEWSW2aZChYCORQQQpYZwCCMnrXPtcXV38QvDkEdwDJBby3EwmBxMjKuTHgfLt3cZxlvXFedHmnObqavW9/L+rf8AAOdvubOr3i6Nbahf6tZXV/L5TOEs0BMYxjy07knJJIHSsjTNKkvJ7zULto/t5txZ3uEZWhyFkaJWHKqq7VGOGJYmug1Se+iku2s7FLy5WCSKCAn5JAVyGIJGT7elYWg3enOsHhi0mnvL5ovNmEsDxSuuVP7zcARk8c9vwpU2+Rtb/p+n6/ITsYvjDUbnQL5Jr+dH0G2iIKQk/KxQ+UpGcttXOR0bAJ7VwHhKGfxFfaZp2u2zNJJcNeXksiks9mApVpRnCggDknHIz0q18Q9WbWfGVtoF1NcArcD99Ywq8RLAZUg8uquIV2N2BzXc/DfSbifTNZvL/wCzz3FxItteQsfME8ka5ZAw42MWAPYbcY4rvv7GhzS3a/4b87/cbwfKrl7wboUWpRLrOtTPfI8rzaZYTIRFZRFmCMQf9Y5THzNnjGDiusutM06c25nsLJzA2+EvbqfLYdCuRxiua0bxBLpdjrUGv2032rTbqCEmOVZXuJZ0VlT0UjcBnhfStPUNZfR/KvNasGstJeQx3VwZhK1px8ruq5GwnKnB4JHrXnVFUc9Plr5X0+T+d+5nK7ZsXYhv4xFqcEF7bZDGK5iWRcjvgjFefaFrreFL6TwreWxuLK2umaK+ecCSK2lzIhMQGXVScFlyF/CrvhLxJL44m1q60LUrax0/T5zawA2BlFxuGVlkZmBHTOxcY75rSk8F6NeTNca7aWmsXbEu01xAc7zwQvzfLEBhVj5wB1J5qYJU24VNu2uj/BdStIppsueHvEWkeIYi2kX8E7q7RGEuFkBBxkLnkHsRWlKrhv4gfcVUu9I0m7ZDc6bYOyLsQvAD5YxgYAx046Vk+E7uaOafRNWubm61uAkC4nt2jN3CnCuGxtY/NjgknHNDUXdw6dP+D/wxm0mro22HJ/OsfWNettMv7HTza3l7qV8jPa21rEWDheCWfoijuT0GTWy5O7DADPPNcHqV7rmn/EXVLrSPC1xqDyadDbW1y0wijbawY4kJwg5OVHJKg0U4qT17egoK71OhFlrU+pW9xqN9YWtvETIlrpqMzBuMZmfBOOegwc1mJ4f1LT0uodC1Gwt7UyPNaCSErLAzgGTewBDhjjsMYFZ1p/wkfhLT4oo9LXVbF3EtzdXNwltHal8s/wA7NlzuyNz4zx2Iq94X8daR4lilNhDfGVOEiSBpN785Xco2rjj5mIXnrWvLLVws4rtb8Vv/AFvYq8o6lW3XxEmtWukat4msP39s84exs1ErOuNy/N90YOQcZPcCteW1aZpo7DWbqC4RtzMUWYZK4GQwx74Hce9Z+n6Pq8ut6vrrxaPbajM6R6fFfB5Ps8IXa7OYyRvcAcDPviuhVZUjC3EsMs//AC0eFCiM3cqp5A+tNy16fJL/AC17evkTJrdGdbeHNPfE95YW+q36w+XPeXdusskqkYbdwQoOSMADjiq2kaDpXhwtHoVg1vHcDbK3mluhyBg9hnAxS+JNAbXzZMmtanpbWjmWP7G4VWfszDqSO38q0VjYv5k7Ey5Krlywx+Pc9TScnb4t+mv9f5E3BwG3A4INcdr2g6teeJrDVxqssiaa+baxViiSZGN+c4WQbmDEjkBcdTXYufmOBUM2TjDBORliM8dxilGXK7oIy5XoVVuc/u33NKp2nHOffNJNIqlB3J6D09ajijY3UuTIrHLheCGUd/wpl8+yNdqgszBAx/hzxn3oa1SIZl65banLdaZqHh42LSwM4njuiVFwrbQBntj5uetXWn1dkbfpmjI4bAZbyYqB6425/CrvA4TGBUcjfe6nBwazcrpJopS02Odv7TXbhSh1awsoWTbutLYvICT/AAs5wOKK0ZSm75cs2euODRWqlb/hl/kPnaNXXdfttGws1vf3UxAfyLGAyylc4JA4H5kVMmqaVeSRi21KBhNGHj3ExttJx0bGDnsefauaOkeKJPEXh24dXig0sukl49yN0sOeFXactuHLZHXpXY3dvaXqul3awXKMeRJGGJ5yOeuQeetcbUYpfozrlGMSs19aRGVZp1gWGYWzNOfLBkI+UKWxnODgjgkHB4q2pJ2MqsyMoZXGNpB5H1znjtXNzeGrKx8UQa5ZaVvg+zPbXVtAgl81iylH2OeoweRznGBVzwz4h0PVlt49Lmmt45lYwC+i8hXRDtbYSSPlxyM5ArZRTXNG7/r+vkYyXY3jFM1vKIJRCyoW85lDeWO7HJA4Hc8euelcvYfbNQhj0rSbq91HRLiZm1DxBdSoxmGf3luikfOCNq71wByB0NalhFHrcH27Uonks5JPMsrGXiIxrkLLKvVmY7jtPAGODW2pwsYO0BQAFUYVR6AdAPYU78mm7/r7/wAvUnYflQEWNEjjRQiRoMBFAwqgdgBgfhSEYfqQBxRkgH0Pr1pV4QAAbQPX0rMncpeJFabw5qSpaW95mAlre5crHKoILAkEEfKCRyOR1rn5dZ0qO2uLePVptahe3E6QpbiOOxh2AoquBjeB82SSePxJ4r8VWMcs+gxWI1G6uGgtZorhGFsn2jOwyMPmI4HAweeoxTPBHhtfCXh69ufEEW6e2aaR4kfMAiCYPlqR0Kjb83pXTCChC9S990u9/wCuljaKtG5j6jf3dnpU4jYW+t3AitxLdo29VJyZlY8OABkEZ564rh7rWZbC4u7JL23jRMIr7WwshzkO55LdSTggepNXvF/iO41yc3twV2WpS1WCCXciOT/CDwGxtB5xxUXhzT5PFPie1srWbT7i8iw8FtNZPcW0qDOTM6su0KeQDnJAz7+jpQpOpUXr1OyELLzNPwV4F0vxDov9oPd6nZm2druaWKRPs52kYdZF3cgZOGwevFdH410bwx4SaLX5/t1w95O86bY/ORg6knduG3ac7ySc4GAKveC7rS10lGtJrG40nQ7+e61J2Xy5JG2utu6qMKcgnAzgYAPIrkfhL47u9e8Q6lpetW1le6fqyyX1pZlY8LiQqykHowUFhnnCZHWvKqe0xKdWT2/r/g69GVOq6FXljt16GZ4djgszd6TLqNpcpd2+C1sD5bo/KMpwNoBGMY42kGvbfA2rzaloMFtqU4fW7CNYrxNx3YyQkhJAyGUZyPevK/HPg+Hwdb2t7odtJeRQbklngbc4jbGFkjC/IPl++D65AzzmL4p1PSZ7fXbG68qcbY3gHzQ30QywU9wR8446jbjHOe6C+u07J+8vz/4K/ToicVTUlzw2PZtf0X7RDK8EIWVwEd4RmZ0OQyITwpwTz0rxj4i+HL/wZ4PEMMVpMhungS8ZAft1oo8xRIvIBQ/J0HU8969z1fVPI0iw1KBBLYXnlOJo24RJFBDjI5AyD/hXmHxTunm8K6vYSr5/+hG+89oSUIVwnyZPysC4JPP0NZYSc00ntf8Ar7v67rlg5NWOu+AlzdXHw3tlvoZBFHKUhd4wnmKw3MQMnjcxAzjPWrl5DHblPEdi2ZdOQRXNvCgBmUEhlV2O0kLgbeASOtcr+zX9tPw7v7O5CTxC4Y2p80sNuNrKccjkAgY6ZNeixaAscIt5NQu0mO4r+8WNMk5wFx2PQnmssRJU6879/wAOv9dzFq5j6RqUurXt5NeyRfZHH/EvkijPzxfeyV6g9c5wajNxo3/CXxeR5jXbQCS41EthmgPLYc/eQFRk47gCr/iOfRfDKqNYv7a1kJEqLcfNM3J9OSpwcmuQ8QfEfQLz+0dJ8PF7q6htbhTJaRKsaqi8qgPVevIwMjgGnTg6mtOLs18vX+uoON2eZ6Xq8Fz4z1zxBptvK32O7kSRDECmJGIh8s5yHdvlII4ABznp654Pxp2lQ6FPd/ZfEdlbtdywTRHYJZV+VCBjftwMnJxn3rz3w3Dpmk+F0t9XiFnrlzq1jdG3hhYRpEQGiIPPJLZJOeh6V6OYNO8V6vIllqN1bmxuzqmotDIAkkYJRY3c/dUNHJleR94967MXJWs72XX8vlq/XQ2k3axZ1HwtfeIVjutZ1iO0LeRP9is7YPHFPGciRZMqzcZGGBAz3wK6LXdRh0/SdT1C4jD28MLu0XlmQP6IVHUEkD+orAl8eaZLNpsv2LVDpmoMfL1MWxS2UbsBjnkIT0JA456Vb8Y3Ev2nSvDcMSmbXTLFNK3KwWyAGYjplyDhRnvnnofLmpvlU1Zf5b/dbrqZxTclcqfC828vguGO0/s9Z1mllurawKslrI7lhGSCdxUHGST0xniumYbc9evPNYd94S0NtKuLPT7CDT3eMJDcwptkgZU2pIMEZI6+5zUAlvfDkGk291fvq8V3drbPNdfLMhZM5TaDvGVOFPI9TVStUk5Re/f7/wCr/iKSUndG8QCTjgfnXO+KtP02/vdLuNU1CS3ntgy2sTSlYXbOcun8QGDxkdTXSXTRwJJNczRQW8QzJJMwREX1YngVy8Pi+z1Ce8g0bRda1K5t1DIRZCOOVc4JWSQgBQT35PYYyaVPmvzR/r5kxTTuiOOTxbd+I40lbSbPRDbea1zFaicSyZOFTMit8wIbkADGMmptX07xENPuzpviOSe8PzxQ/ZYoY2ORuRPvFCRkKSTgnJ9r8N/crfxWN9pV1ZSzpI0Em9JoX2dVLr91sYIXHIzzxVp3WGMyyukUaY3SO2FUkgDJ7ckD8abk01ovuTv+f4MTlYxobHSPEFtItxG2rpCf3qXlw1ysTn7yEZAO0jHIwDV6NbexhS3s4I7W3kY/JbxBELH1Cjv6niuP1CDQF+JlzPMjWK6bHG81zp58mCa8ZjujuH+6cAIcZ6k9zXRR63pcMd2Dq1pNHZ/NNIJd2wHnLY7dcEcHFW4Oytdrf7xyT6F9vvMF/I9qilVpV8pGdWbo8Zww+hqnoeuaZrpm/se9ivWj2F0jzu+YAjg47H8O9VfE11dJbrpmmtAdcvMxrFxItuuCC8uGBUeh9ccU1B35Ho/MzSbZoxypMhaJlba5jOGzhgcEHFNl3hhsw3ODk9B7VW0jTn03Tba1MqSmGNUDIu0E4+YnPUlsnNWnzxu4Hr3pu19BMhWVZN5ikSTa2w7WDYPcHHQ+1NcnBHY/pUkVsA5FrDCjSMWYRqqeY56k46seOetYN14r0GLUbiy/tFLi6g4ljtUMu3kDluF4JA60oxc3aKuO3Y0biBJjH5y7/LO5BnAU+vH/AOqquqxSTabeJFn7QIWeFtoYiRRlTg9eRirw34PmReU2eULAkfiKZgk4HeltqTc4zwdqGvtezL4rkt447iCOWyIiEQZs/MgIOC3PKnngYrrZF4HGDXFaro9t461G5cD7A2lyLDFejMrTuMsCmGACr6453Y7V0TTeJnWR7jSdMlkbBAttQIM3qBuUbG7806qTldWT7ben4G84p7bj5so+QOCeBjv64orGl8Y6EryW1/dtYahEwSW0njbzI39OAc57EZ6iiqjSqPaL+4xafVHQ61N4svNMaLw5pdvpM0qFWutWnUPDnjKRpuyfc5x6VkW/gq6UyRN4w8TEtAI5LgXjBjNnLMFPGzoAM59+1dwp4B7N1oIz2yOoz2rkhUlH4dPT/g3Oly6HN6f4QsbZUGoX+sa0QDuXULxnjZj/ABeWOARzjB4ya2NT0a11fR5tKa2WK1eExxm3hUfZf9qPj5T7jrz61Y6kgH8KxvFmixeI7KLTZ7i6t18wPJJbylGVR94N2IYcY9TntWinLmUnLbr2ITvoWdL1e7l1t9I1FtImmjj3CXTp2LIFUf62JhlPTIJGcDvW+ATxjFcd4ZWPRPE9x4X0e3SWxtoVvLq8kUCUBgAkTMoAZ/unn+EE9as+M77XdP1HwxFol5ZwRXl0yXFvKgea5jG3IQEHgDOSMYyOaco3kox0uv0/AbV3odQ5EaSSyMFjjBkcnsAMn9KkjxJbRXKgtBIodJB0YEZByPY1l/Zb++N2Nelgt7CQNGLDTndi6nj95OQCQQeVUAe5rh5NF1jwTcXmt2GrwT+H7W1xi+ld3jhUZCIgGwHI2L/vetEKalpza/1pfuCin1PQLy4tI9UsrCW2hlbUYJ5GlRFL/uQpCvgbujHGemOOtc34q1S0TQtdthfzNb3Vl/oxfkJIDyik8kcdD34q5pHie0vvCR8WyaVPpXm2plMshV0aJZNowyktnOOqg49RXJ+PoimhWsrfuwvmyyxyNtJleTIeMDIZTg5HGMZrXD07zSl3t81r6dkbU4XkkzzaO8tEm+0kyx2USllBwELg/NIQB64x611nhfVLaw8Dz6jYy3q2d1qccd26WyqkbFSV+RW3MGGeRtBIAPHB5R7wmxcWiSyW8sypNB5zQg7G+8SDjI7ZyATnFeqjw5HrejwLDNpkMkZiW5gtEJg+1YfH+rK7QUHzHOcqM1rm9VpKm1o/0PWoqMXzS2Of8KRaVeaF4g07U7rWlt5v3jRaZGoMvmYCp0KhmIOAchcP0zTxb+FPDVhpF3qdhJpOvaI8qWg09F3ai8YCt5z7B8pOUJPXDkHBqHw9bG98Waho17pz6haQl2RYm+ytZyDbudfLIXZuI6k8YYclszXMcU/hy81p7Kd9Ou2ZrS5upC0lldgrmPeMlg2cBm468A9fJjXlBKF3b/M6K+Gp1qrlLrb+l/wxsfE+PUJb/Rtci1S30bS7yNJAdrkxz+SSwJAIyR8ucDOMYNcyiDW7L+0tM01f7HMZbUREpFvbzLne8atyAqhCcHALnb3qLTdYi1PwxJ4a1nUJY0u7gXlvOshligkU7QJNxz5ZIO4AnhgfWur8O6BHp51Gz8b3EXnTm3gtYI7wWbsFLf6QBwCoBAUkZOGB4rTD4h0JXW/6f156W8yatDkp8kum3mv63D4bX8b6wLGa5uIbe+jAjs5Jy8CshLfIv3fnz1GAfxrQ8QWduddSGJrq6028u5Ir37UC8f8ApMRjCI3Gxc/NgfxAHOcV5xf6b9g1Py9ZE0On20s9uZRHthMYfZui77lYc9R0I45r0zTr3ZYLptjvuJ7SUpqc07Eq435j+QZB3rgADBHPpXt1Um1Wp6pr+nf7vO9jyKkFGRw7/DzX/Dd2sXhLXbldL3RvKqyiKdnJxsVOjPjO35lBHFMTwnrniHSwms+PX+zR3TrGdjSqSzHcQwwSw24I6A8D1r0q70n+zdJ1Kee9uhYriaEwKGms1DZEZGGMpB+7uGcHB6ZrJ1x9S0/RpdUawRLa3mWK5SKBQYYX/wBbIIhkFnIRdpBCNknjNTHFTkt1fa9kn/w/9djFJPY8s17wjp+m3lvZ+KfFTta2ySnT4Q6LNKrdnc5ER3kZVs4UHr0qj4d13QPDenzyaJb3l7rkO1P7T8j9wkZkAfbwW3FTt3EY9B3rsNV8d6TbWzWegR6XmRJDcRXOmxzyCViFMmcYOEU7jjrj73OPTPh1calqOi+YrJatHIIpRZW8YS0g2qVhTcMeYMq2CDgMec1EsROzk9vPT9P+HN503ShzOxwUes6ffXuowXWumxlW4S8ieyhYrJM9s2yMSP8AcjULyCpGSenStT4O+GLO+8IIpnu7uwublL6+v3Dx/bXT7lrh+WjU7ixIwcgc547238EeG7RLSGHSbSa2gMjgXa+ezu5yXJbqSfX0GMYrornzXtZltpRDOIXELhRiJsHaduMYB7Yrnq4qPLaF1tv5f1fyOaVS+h55428URyeNB4b1I3FnplrHBfXUotnl+3R53GMbSAsQ4yTnJBGK3DKfGOsaHfpbXFpaaNdy3TSzgBp5ChQLGRwUwQxP0GK81+Ger23iLxYYfEAbXdRvgJTeWcp2SNG23DIwQCNcBsDHB6HNe5NdQyy3KJcwSvaEiaOOQMYyBnbgd8c4FZ14xpNQtqlv+Dfz8/L0KneKSW4yRvMyQv4DvWLqer2i6i2jx2VzquqxxrdLbRRYiVuqB5j8sXY56gcj0qXVfE+k6Jb6dc6hJM51GXyrKCNP3lw/cANgKBxktgCqfhTUdUtvAdlqx06TULwzTPNEhWPzP3jBWLchhgAbz2GemKzUWo8zXkumuv5W8vUyjB7lXRfCN5ZW1lD4h8R6nrAgcXE1nchWgklweuRuZFJyAeMqDgV1E0srj53Y+26uH+HEfiHTtHWLX7gSQwK6eXKxklExbcSsuTujA4GSfauvFzFKcRvlumDxVVdJu7T9CanNexQ8Q20t3ozm0uDbXNk32+CTzDGgdATiQgf6sjIYelc94durzxXfXc2uw2cNrbJA40mIs6v5sOVkkJGGRgxIHZlHpWX8X31GFbQ399JZeCZAsd9LbxeY/mlzlX2/OEK4wRkZ6g1hXXiS90bxTbXk+q2Igi00W8jSwNGtyRKNqMqjduWNsKR1YehNawpNwutW9t9P6/C6fU1pwbjoesR29vDZC0jtoFswNv2fy1MRHuhGD7kjmmlI1VgsMKrt27VjCjaOg4HQenSi1vrXUYWmsfPeAHaGmhaNumeQwB//AF0S48vGSKys76o5ndHNeOrfU5tIsbfRo42u5bgy+VHP5NxKqJkrEffOGzj5emSa0LS20vSIbULa2Gn3FyEgL7FE0shGfLL9W5B4zjiuM8bXlh/wkWraaJruzuksluo5rF9kk90FOEZjkqu3aPk2+/rVv4Wa9qGtaVLbayPPvdPEQkZ4irxqwbbuY8s3y/ewPxrb7Fl01+/+v6vY6ZUZqmpvY7Vs4JIPGc1BLy3/ANerDY27lO7I4I70xvlqEchSvbW1voTDe2sVzDuDhZBnaR3B6g1zniu803w1Lo2rxwwQpDMbeawsrYBp4pARuEaYBZWGQW46962NZ1uw0aIQySLeX5JiisY5186STHAb06qSfTNGjadLp/2i6vpln1m9KvezxcICPuxxjsi9Aep5Jq43VpPb8+//AA/9LRe6irZ69pd/I6QXJRlUswnQpt/2Wz0Yd161U1m+K67aeHYGlhvb9Gd55AUVIgvzeU3eX0HbrWnrhskspJ9SsTeptMe2ONWk+bqdzEBRxy2eOtcI2pf8I/fokNnrct4vlR2kV5cxyiC1kIPDYOC7sRkEsVUdBxVRipPRfl+f3FRhzXaO6s7O1sbZILG1htbeMcJEuPxPck+pqV8AnJPvUyBH3PbSpNCGZN8bZGQcEfUelRyZXjnGe1c71dzJ36lGdUMiy+XGZV6SmNTIo9A2MgewoqQQSSI3Ru2SQM/nRReOzFZs3YxweSQagnnjtgXcOVJ+bYpY03TtRsNQi8yyvYJkwrllPQP93dn7ue2etc7rPiGK5aLTtHuoPMl8xbt2VjJaIuB5hTg4yeD+PTNZU6cpStY6bXdi5BrslxdSmHQtVjtYm2rPIgD3S9/KjOCevBPHOaxdCtvHtjujZNHaxiika1tbmcvKWZ8qsrqMkgEjIOOma7SRMEFWLsoG0k43EDue2aSSaK0hhmu5oYFdxErO2A0h6ID3NaxqJaRitfVk3MCDS/EVz4gXVnuLXRkaxFvLZozTF5c8O+DtOBkAjnHGea2tA0ZdHku7x7qfUNTuhtkuZT85QdEUdFHXOMZ71fIeJmyh+VdxVeWxnrjr1qVmWJDJLIscS4LNIdqr7k9qUqkpKy2/r5i5mUtS1vTLPSLi+u763hhjjdgplAd2XIKKOpbIxgd6zb6KbxD4LgU6LLFZ6lAI7nTZ5tk8UZP3wcfeBAYDHTtUFjpOga54gn1pvJvLzS9QKQrFKTDFIET5mTAy2eeeM+tdbklyz8kncSTkk0StBqy18/y/4I7pbHGXfhm20TwKdI0z7YbSzha4jdnPmTbG8zZIBwST8oXGDmsfUtNU6EjSrdRmWaO5uIX25gS5i3NEoOPmD5wo6d66zUrDU2urz7JexQWUrwSsVTdMWVuVOeFU44I/Hiq+vomoaXqGuhLk3VsogKzfKGRGO6SJBwSckAnqBxXRSqONtb3f4u3/AATanPW54PPG32DUA00sU0IW4U42LhmyDxyT7DrXrvws0SI+G98Hihbe9up2nihsXVhv2FGEkUgyWAYcEEA4NedXsdwlwm+F47tvMCWkjbHnh39weM9TjtWj8OPEn/CPa1M8FoLm2l3faJopFF0jZ+VV8zhVxnKqMmu3H4Z14c0Fqj0HVlyOMXueseItKht9C/s69kkigleK0t9Sto3a5K7SW84oOCSo5xtIOD0zXO+KrvXLnS7TR92kWT3du1xNBbPEEYbuAAwLFiqAkjByT0HFbmm/EnQxbWss0N6sBd/MnnlQvBjcysUbDMCOmBx068V5z4/0nwnq90fE2malp0ejyqsjxxTvHcS3ZLHKx9QTnJJwAd3NeFPDSTs4v7rjwk5Ka9pp1V+50fw++H+ljUY4PE+nCTUjG8sUK3CNbjYw3B1Rixba4yD8pUDIzXTfEjS9O1LRzfXXh+yGqRt9i04zx75HjAJASOM9+QqnO0cnGa8qstZTRh9o8CWDx3Zm81by5mJfy9oAjfpvRirZyARx1xV3xZ4mn8XzR21wsdkn2WPz5ftUkab97ZSMZ2nPy8gZ9T0rqoYCvUSb0/rsViKj9upyldf15mXqV9Z6zBcNa3sq6lJBBBBp0p+2W20bdwjbbmLAAHzMScEE9q7jwlY3C6XrcNpp91bxrcKsV2ZBHDcbE2Oj7hxsAPzdOO1M8H+HNX+1Q6pa2thHpFuZEaSXIkG3KsscQ+6cjljzk1sWjxx6jNo1nHaXL3llgQTS4aU5+b5ycEBSRtHOea9KUowp+xhrb/gX7duvf0tw1Z80nY0NQv7WW4mh07MUVq8Iu71G2xQyPF8ux85ZQnJPTnrk1wOv6ha2Whz3V1r0EOoi1MFte2JfMjAjdHFuz8mDkEZ5NdX4mbS/CmlGPxI4v7fU43dtPluMyT3TFcqrD7qKqr14GAB6Vx00eoeG9Dsta1LwxPcw/wBoLeaRLdXAkEIKkRJKS3yxgHgcA4B61nQirXXy21+/+reYoNJXMz4ReCLrxTqNnd65pbah4bjlng/tIXTRS5C71BCsDsyNp46t7V7/AKR4e0rRLiR9G0qGymljEbmFWzIAc/Nz8xz/ABHk+tc/4SuvDfiySPUNBW8tTZSbpY7FzFBLLIuX3j/loeTljyCBzW1b6KyaWdPn17XpkErOkq3QSUIT8qGULvIH1/SubEVZSk020u2v9fkYVJ8z1LNtq2m3l01vY6lYXFyhZWgjnVpBtOG+Uc8HrWf4u1uPR9PMapNLf3qvDbJBH5jbwM/dyCeo6Vy3xA8S6V4a1fQbewt5RqujxO8cFvGEgihmATMhIwF6ksDkdP4jTPCUOv3vxHOp6vY2DLCkkpulLAIjKqKI488SnZ8znORgCoVDTneis3r18vnp94Qgl7z2NXwdoEN74L0WHxPpEP2yyma5hjaLyPJdzuOAuOm7GDxx04rnPE19pi+ObbS7bw8fKs4ZIVhggMc0kxAZblSGB2L0D5yST2r1ORwskEe4ZmYog7sQM8DvXjvxnsZZtf8APiit44JreNGcxfvZLhCwVWI+by+VzjFaYd+0qtN73t6v+mOnLmlqb3gL4cWmmQyT6vL9uWXLxxTSCViSQxLuCeM/wqcE9cmun8TeGdN8SXGnT6hLeR/2cXEUNrMYomDAcMB6AcYx+VP8KX9xqfhWxmZIrbUlhSGZWT90koUAlQDyvcDNZOnTeLdP1H/io006+02a4cTXsDeU0I5ERVBwVxtByMgnkms5upOblKXvL+tCeaTZu2tvp+iaHBZWoistLsk2qJHOyJc8lmYk9T1Nc22salq+6Twboqvbx9dQ1hzb20xyQPJC5d14zuGBzV/xTf3F3p0ml+HrSbULm9/dzXMOPs9vCfvlpD8pZhlQBnr7VsQvK8cUVxbyRMkCoQW3AY4ADA81ly2XNJXb7/m1uK9lcxZdEvtUs5LTxLqaz25bcIrBTCjkEkB853KAQAD1xk1grog0fxzcX+o4k0ExC5slW1Mm26QDLOEB2lVBCrghiQeoFd43JPApod0fchKsMcg4q1Vkr9n8iI1GtCtZ30Wp2MN9Zz/aLaZcpKuefUYPII7ggEUHcGbcRt4wB1965Txbo9/YiLV/Ct4umSxTSTag0rK0McMgHnTqjgjzMKP5AcmtybVZLbQY9TvbURyzj/RIE+Y3ZOTEFC55dQCQPu55xS5VvH7uoOF9V1MPxbpum+JruLTGtme8gkC3E5gKoICAXjaQYO4gDaP6VA/he/028huNEvra5jjnknaHUFdWbeoBG9Dg424G4HA4rodCt7uLSYRqhzfys9zcYOdruc7c99oIX8OKuOoycYx9Oa1jUlH3Vsgc2vdTMO91PUtIs7rUNZtbKXTLbDyLp29po4+7bXIDEHsMcc1R8VeJ57DS0TRNH1uTV70qlo81p5cVuSQC8rZIGAc/r0rqXjSRWSSOORGBQo65V1IwQfbFcb4Nmkg8UeINO06e8udJskRDNdXMkkkJH3Yxu/hHOMDHuaFaWttvu/r8xwSab7GxYromgWQWK70qDaFSa+Z40kuX/vO/VmPPep7W9sb1S1hf2N0Op8m4R8frV5wrSCV4YJZVIId4lYg9iCRwfeqF/pem33mG60yweSVPLaUWyLIR0xuAzQnfV7mbsUPGMIfwtqqu8UaLDvJnbbGQGHDH0PT34rz3wlqNtrep6+L3URdPDYxNZ/bIljYSRbyGwv32G7CEckEAdBXU6vogn1nT9BvphN4Vmty1tYrcFZbWaL5gTghmjIB27iwB+lX5/C2gukQk0q28yN1kW4UMs+9TkMZFIYsDzkmtU4KDi3vtZbfj5ar8WawqKmrWMT4UmF9Mu/J852DL5kzyoQ78nJQHcrc8k9QB1Oa627D+ZCI2Ccl3yM7lBUbfbqefp71UsNIbTbUx6PqVzbZeWUieKO48ySTG52Zl3Z46A4qf7PebW+0azcvnBUxWsUew98HaSc+/SueTvJyv+f8AkKrOM5uS6mZrOhaXqkiyanYQ3TqAFaQsMAfQgUVHew64kgNrqltcxRKcQ3NttaY5yA8i8LxxkD65orppKo4+7Ut/29b8zN3WiZqaBbvdvqeszX0jx6rKyLBE4aNYo2KI27HLfLuDDjBxzWnp1pbabFMtlGIzMxeeVjuklYnOXY8n+lTp8kMalFXaAgWIfKox0A7AdKBkduCO1edzOTfb+rfcbSZC8fmJgTTRc/ejO0//AFxVO/0LTdTvrW8vYDJc2ausBLsFj3dSAOM+h7VoFtsgVmVC52ruIG4+g9TWVretm2mi0/Sof7Q1m5cLFbpnYgz8zu/3VAGeD7VrT5nL3N/6v8iNTF8SeFdN0ez1HxFpkSLq9rF9pL3rvNFMyggblz154xxnHFaWkya14rtkn1mybSNGkRHFu+PtE7cZDf3VP3hgdDjntcPiGGxkmfV7K80tTMkKyTYkjkJ4XYVz15z6V0EgkDNvGD3yc1pKrOyUlr0b1+7p8x/CULGzvYNRvZ7rU2u0upfN8h7dUWEABVEZByAFABz169c1prj8/WoSpzxkc9jUi98ZOP1rB6/1/kTe427jVreSQMykLztGd2O2K5a683S9M1XVJwkumzEPJFPhXQEchAmWYDHA4I6eprqL5bdtPuhfQyXFoYm86BSQZUx8yjHPIzXh+naFqmozNdxwjT9FRpJNC0bUCWEoDlsPj5gVzlc84wORXThoKSbbsv628/yNqeu51HifSNN15tOxqmm3Mt3ZxXUj3MyQ5ZfkGI2OU64wOtcvceAri61e2tdIurTUraSAxyzyu6RwyJyqhzj5+208j1rvW0PW9b8P6xY2ei6Pol/PGttdX08yzxXQGWKxhVyqk4LFugPHNXLPwJpWoaLotxA09nI1ojXMQH7q9LoCzSxk4zu5BHoK6qeLdJW5vyfTrb8LdtdDX2iXoecT+G9Rsba2l1SwkhYo2992UTacDcWAOSfrVbSfD2sRTiO4tYoXmLxobi3a3Kgg7iSQS64PReuR616jqvgcTbJ31jUpjasksS5G6TywNkZJ4C7uR6VzV23iHRvEOhaRNqGvXdvqUjXFzNZRFOXBR974IXH+z2wfStljVKOjV/RmirSloipb6XLEVjaZtSdogbm6gVLeKAdGBLMSx7bR161p2z6bot4/maReW115ZcXSFrR8g/cLuhJyCD8mRjFdtN4V0C+ljsbvSobmzsNoiimQmMYGFI7E9c+tS3HhDRZbhDHZyRRRR7Y4Y7h/KU7ichCSA3PB7VzvFxlpK9vu/X9DH2yejOKPj7XW/s+0tkuIPtO8xFnVVK9QA7AtKWJAyep6CtDwt4a1W6n07UJbe0NrbyC6+yXUg2iTOcCMAtHIuSQT3GDip57OztPFfh+2spEa3/tBrQWt6DKTuQedLb4GYyuxgW+7k9jXoR2LI2xAu45OB1+tZ1K0Yr93FK/+bFOoorlitzzv4vtLqX9gWkFnZiC4uRLqH2lD50MMUgbIYD5Y8g7mHJHQVU8UeNruxbSota8Lafe2rYazt7ZWuUuCCUxCzYXOz7oGSc9s16hHNImPJZl5z071gzaJO195+n67fWFqCJI7SKKN0ilG7LLuHfcSR9K5lNOKi9Lev6DpVoRSUo3OD0rU/wCx/GEcq6IumvqKyXMFjC4t5o5Dn9xLuGAzAls9DgDtV7UPjT4cstUl04WOq30sI2TXFkiNEJP4lUluRnvW7418F22u+FrhJ7u4Ot29uTBrMnM6becZGMKeRtHrxTPBPhrQdP0PTbzStL+ySSwoQ1xLuYkKAzqm4qNx5Pv6Guh1aM1zzTbWn9P+n3Jlyy1OSu9Y12a/vfGR0Ca0jt4xpcEM8bGcxZDsCVHKnOQxG3JOegrbtLaeHSH1C51j+wtQv449S1e8t4vLkniPypbQ5JKNhFGRyScgc12WoapolvaXK6trFmbaSNoZo1uhvwRgqNpyGOcDockVyHhLTL/Xfh841uK9ttXS+d7GbVIPMlUIT9naRG6qoYj65NP2qlC9rJWXy+e9rX9bMm6sblnpp13TtP1DVpb+DVFiCuLecxGAk5eP5RwW+USdCdoHGKfF4N8O29xb3EWkW/2mBXVZ3LM7b+GLEn5icdT0rj/hG/iW31/VNG8RG+ijtwbjZNbZiaQnLv8AaD97cx4AyD1r1AgAZ5rOs50puClp5bWZnO8Xa5GqgLGgAVUUKoHYVHcWsF9bTWl1Ck9tOpjkikXKyKf4SKkX77/OCMcL6H/CpoVLSBBIY2Ybd69UJH3h9OtcsnbUlbnnPiHxHB4Z1DRdH8NtBqlsN3m2UEoka12nOwPn5MjOAxPI+td0uXtIZZIjDLIiySQsQzRsR90kcEj2rzv4M6jpvh/w0mkTSx2Nw1zP5t3IBBFcOGIA8xyN77VyMZGD1r0hVMqK8BWWM8b4mDj/AL6GRWtZcknF9Hv3/r7zWr00/wCCQ4PUZ/KmOOB1pzsPNSIBtxPJxxjHXPb0qpFKkWpvZhmJdPOUbCQozz839KhK5jYnJxk8EEYYOMhgeoI9PauYi8CeGUkkaHTPJkcoySpM4a1ZSSrQ5OIyCc4HBxXUsTuOVI9iKaVyT6VcZyjfldgUmji9M8U3K6zZaVrbWhu7nzhJudYprXyjtDzKDtPm5DLjbwe+aueKJdRv3uNH8Kaktlr1oUmlmkj+SJD0BLAg5yPu8j8a17/SdMv7sXN5YWs115Rh85kHmGM/wlu44GM9O1OhMUaCG3iKRAH+Hvnpz1q1KKtKK2+7+vL+nTlF6pFQWmsCSJv7cSVvK2zJNZIsc0mPv/Lhl59O1YenaP4nk8Qanres3WlWU9zax2cEVrI9x5KLn5tnEZJOD82ee1dYWOM7ajYHA68n8BRGbT6fciebSwxuQB6dc9SajUec4jwRnuR6VI3AJ6+3em5KOpC5AIOD3o9CTmfD5vL67uNdK2tpY6jbosdqshmlcoSokZvupwMbVznv0FazqCeevsax9OvodI1A6Ffo9udzSWt+8YjtrgOSwj35wJRlht77c9TitiVSrKCpUn1FaT38unp0CV7ixLgdeajlc4wamXGOtRy7cH1rB7iKVwuUJJ+929KKJe6/lRVoXM0a8VzbyX01kkyfaoYlkdB1VW6fn1x6c1zlx/wkGoeJ7p9LuTpmnWkAgdLy2LCeVs5eMg4O0YIPTsauyWNjpErapHp73V1JNma7ZwZIlfAd8seg9B9BW3LuBAGSV4x2/wDrVzRahrHXTrb56anW3bYzJtE0+9s4otYgGpsoG57n+JsfewD8p+nTpWjbbLSBobdFhhY5ZIwFBPTJx1PSoLnzZbaaOCYwSshVJQoYxsRw2Dwceho06Ce20+GG8vJL6dR+8uZI1jMh/wB1eAPpVttx1fy/rQyuy4VWWNo5UV4mGGQjII6Vg6XHf2HiC9sy93qNksFsschmBe2UtJksh6gkcsDnCgY4roEBI68isnVoNRm1LTG0m9NnMjM1w5txKtxDx+7YHpzznqM8dacHa8X1Gmbe7HBwcnHXApZFZo2CHy5GGA+OnvVa3luTO0N5AGCqGWeJT5bHOCOeh6HFXUVmYYye3T8ql+6SOhiPyKh3EYAz6+tchJ8QdBn8YyaFOqC4snZXur9zDEsgOAiYBOSc/McfjWzp3iLTbvU7myi1GyS6t2b5DdRneq43PwflUHj5sHiuPg8E6Zr/AIti8YaLOWhnuvtEsV2HjjkZcpI0Tx5zkqeTwOSM1cYrX2mn9fr0NqaSfv7HW2ei67HHO0/iVUkkmDRW9tZqbaGDBBh2nBYkHO/IOR+FdGNoWNEBCRoEUegHAqnp+oG+Mqy2b2N5AT5tqzh/LGcIwYcFWAyO/tVskEEnt2Hepk23Z/p+hlJt7i8jkc+tZEejNaa8+sWJtDcSZFwblGMhi2AeVEwOEX5QcY659a1l+8CeOOnenF2Vd3fIxj1pJtbCUiDR9Ti1bSrPUbaOVbO7gS4iaTgkNnjHqMVbDgDKvg+xrk4Yf+EP1iFonuf+EavWeH7KgLxWMrfMJSScouQw44OQMDHPWqAVVhhgwyrAdR7VdSKT93Z7f13E11RyuraffaRqtzrcAjvrCOFlitYv3N3bmRv3nlygHepLFiGwAOecUWFt4lsJ9QlOsnVtEuVSayWcgT2kZ5bLbcucHj6DpWx4kubSy8OapdamJmsIbdjKsJxI46BEP94kgD3NefaTqnjePUFsYblTfuitb6I0DTvp0UrAI95cMMrsBzgZJ9MVpHmqRsrad/6/Hz1N4XauzvvDGsLqOiwy3U9sWad7aGXzADcAH5WI7MR2/HvU/wDbeltcXNvaXiX13aY863sVM8kZzgKQowD16kdKwvD3giPTvt/9v36axHdsZ5rRYBFbGcn5pMA5fACqobptz1rrrWKO0iMVnFFbRvyRCgTJ9Tjr1rOpyJvl1/Bfj/kiJNX0OXuLXWfEt9dWusxX2gaHbIo8q2nAk1Fyxy3mL92PaPudckGquu+HdN8P6ddajp2nae2lxtGzWN1KyJuLgFY5GJCZJB29CRXZKPmGDnPUdea4j4hajL4d12xu/Lg1O/a3K6foksUhlaUPzLGBlTlcg7hkYyD1FaUpSnJRjp5K+v8AXdvQcJO50ujagjtFbWWjx2dgxfDpE0aqy42jayKCTk9PSs2/8XtDr/2C20W+1G0VUa41OCZPKhUnBcjOSqnIJ45VuOOZ5P8AhLtcmguLme38MwKu8WkRF7cu/be7DYq+qrk+9cUPAHinw742OqeDdYtH0y8nMt5a3vybv4iGAGGBYuFAHy5rNckXd2b7Xf57foaQhCd1J2PVSCyBC5KZ3AEkj9ahuporW1luLuaOC2hUyySOcKiKMkk+mKlt5vtNulwYHtmYZaGRldoz/dJUkEj2NZutalo0CPY61cW4WdAr21xHvEiEgcjBG3JAyeKiKbdkv1Oe2pesmjv7WHUNPnjuLCeLdHLEQyPz94MPyxUm3BJ7+tYuleFNE0vUpbyw0p9PmGAkCTMsSHu6xZ2rnntzW4FOT64yKTSvoD8iK5iS5WOOeOKaOJt6LKiuqtzyAQcGsqHw9otuhS1smsVZi+NPuHtgGPVtqHbuOOuO1bRQnJAGfUCoXXt396abSsmLmdzFutDma1aOy8Sa9DdGRX8+5uFuVwOqNGQAQRn371m2F9r2sx6jZwQ2+nX9tcvA80rhmjhDYEqwgE7mXlcnaM55xXVMpHse9YnifRmvdPu59KhVPEBVfstykxt2DgjBLjrgZ4IPpWkZJ+7L+vy09fuKUr7l2ytUsYfsyXF3cLlnD3kpllIJ7seuOgqVgQMZBPqap6HrcOvae91HbS2U8U721xazgB4ZkxuU4JBHIOQf4hV11YE4GAKTTT97ch3T1IHAxwQOnX9ajZBkOQcjpk1PJhRyMfhTHUnAFBOpEfY89eKZJkthfxqXB4GfxNRsuScN8tMZAqOu4O4JySCBjHoP/r0sRRZFMn3R+n+TTpFO0gEAscDjNR9znnv04p9AONGg6zqug2+m+IdStlswzG4gis0LSEMSu0kkDsdwGTntV9ok0K709bC2vptKmVoLiDzGmW0bAKTIDkheoZRx0IrecEAYb61Dgqcg4weCK3dRvfZ9Nt/60Bzb0Zl3Wv6JZTW8F9q1razXH+qWbcm7HqSMDqOpFXTtkyYZEkx1Mbhh+lTTxx3MEttdQQz20gKvHKiurAjBHP8AOuMtvAkOmJKPD+o3WmSSMoUxRo5AHBBJ5ORjkYORnmsUoPd2f3/ktPxKSTWp0U2dmB9MkUVlTapJBqK2GqwS2lwJVhjl8siG5ZlJXDeuB931opP3bXIcGdBr2nS6xot3pscvkrcFEllDbSsO4GTaegbbkDPGansL1bvR4dQMDW1sUZgJCcpGvRjxnoKqeIdOi1HS5BdzGOzgDSTo4JhdCpB8wDBKrnd1HSvMpTq9hrS+F/tK3cWryymCeS9beU2LjaDgKmBlVyc1nSpqrBpS21+XX9H5HbCHNoepJq1hLBJcwxajLaJgC4is3cSHGW2KMsQOASQOTVma/wBMt9KOrT3cY0opuWcHHmdgoBGck8AY61yzeK9Q8OaBqlmvh5YtW0qWK1s7e3JaK43sArk4HfljnkkdK6LSfCVhpl/qdw8dtL9ukEksQhYIsgOSRuYkZYbsZ6jIpSgofHddtndafdo732IaW/QzfC+sa3rCSQy2uk6bqMTMZdOvVlW5SIEbZDg4CncOo5xx1wOntrKSK6e4uJvNnZfLXy12RxocZULk55Gckk0lzpsE+p2upZlhvoPkM8TYM0XP7qTj5kyc47Eda0ByBgj0yKidRP4VYl2I/J2sc5pktubmGe3inEErxMiyFd3lllIDEd8dcVZIIccZXHr1qQEMAAM8c+1Z8z6EpHF+CdG0648NyaJrGj2U9/pji0vibddkrH5gwfALgrhjn2rs4LSO1to7a0hiht4V2wxRKFRVH8IA4AqdFJUKO54461VutU02zuGt7zUbOC4ABMUkoDDnHIGTnPbrVTqSqNv5lN8zuYNqt1od7rVzfWWp3EVzcM8C6bH9oSVSMqzr95HHKnqvcVtXl9aWFq9zqC3ltAg3SObV3EY7l9gOAPXpTn1S0Nm91am6viFzHHa27s0pIyAoIHX1PFRS3GtXi3Frb6XJpizxBBdz3SB03KQxVQDhlzxnvVXc3eSt31t+f/BB66s0URXijljkV4pFDxuDkOpGQwPcEc5p6QZ6ZI9u1ctpd7rujTppV14bX+wrHZHHf2y7/MtwgGAgORIGyxzxgniujn1nT7eK5u7k3dvp9tEJZL24t2jgAJxjJ5JHGeO9DhJPTX01/Lr5EuNthuqRXLaRqkOmzImoS2rx24kGV8wg7c/X34z9K57StcuJdHt00nQdX1W8jkEF3L+6to0lX5ZAWdzllxztyD69cal7dw31zptvpWpbheymOWSylQsyhcgBiCAuGJyOfTvUOk+IfBOlQ22iaZrOlW0dvIbeO1SYnDljkZPVi27nuc81aTUb8rb36/jb00+Y0/d5TH13Q9b8d+HNY0vVbR/DcBuo2syJllluI0Of3u0kLk4PHTjrjJ5+HSvGHhC8GpXl9arocaxWmoTSOrlot3Excnf8nA5JPPAr0qHUb651C6ji8P3qW8Z2RXU8saJP1yQMkgAisnUrLxPqVtdm603SktrRvtFpZG4859QlQZjEjEAIgYAkYycAZHfSnUktJcvL2uuvbXf128jSM38Oxzlz43vxfrdf6Ha6QhWRIxbm6lu4mICszI37oMTwCAScDk8V6FFPCNGS/vkawiSH7RcC7IU2wxk+Yegx39K8XdLvw/8AEFb+48OPLqomEslwbKSKGYsMy3OASDtwSAWAXGRya3PAM/iHx741vtS1pluPCNm8iIJIwbW7+YeWI0z/AMCLNu7DArSeH5o8+iilf/JebfmVUjDSx3ttf2+t3b2+iXtvPYJEDc3ltIsmxyeIhjoxXn2Hoay7/wAO+G28YafENQntPEJsmjiTzHndoCT8x35weuCCCRnriu0hs4LSMx2dvBbRlywjgjWNcnqQFHX1NOaCKWVZWgieVQVWUqN4U9QG6jqeK5FVs/dbS/rcwUknoc14La/ufDvmXtzDeATyLZ3KKE+0WwICOyjO1vvDHsM4JIGnfStZWV7dNb3NwLaMyCOLDyS4GSEFasMMcESwW8UcUMa4jjjXaqD0GOlVNV0+PUtPntZTLGsylPMgfZJGD1KsPunipdROV3tcltNjbdTLbQSGGWHzEEhimTa65GcMOxFcJ4h8G61rUHi5TLbTR3t1EdNs7tiqpGiBXPmL8y7s5xyPl6c132mWv2DT7ayV5Jo7eJYxJPJvkYAdWbuferSg5Y9yOB6U4V5U3eH9a3/Qalyu6PKPA+valaXQ07VIr+3uYYvKj0O5ZJpXjjUfvbacAGRsA5RzzngjFeiaVfadq1vHPpV9BcxSZKAMAxx94FPvAg5yCMjvXmHiGxtV+Pds1zcxlL1rKVVjOHjlXgKT6Pszx1Ga9I8VeEdM120vNtnZWerShni1SKIR3EM38MgdcNkHHfnvW1dx92T05lfb+r+u/rc3nCGnmjRaDByABUTRHHPI+lVPC2pjVtOhtp/O/tuxhjj1GCVCsqSYwW6AMGIJ3LkGtWMN3BHzYxjP51zycou0tznlGzKbW5PBxnvRHCGlRQDyQOPrVwjIwQcdh1qvcw/aILi1V2iaaJ4944KFgRuBHOQTng5qeZiVrnJeB53vl8QvJZrC39rTkzom0XGMKCB2KhAp9SCeua6I2+4Agc9evYdTXn2n+II7LxlpukeH/CVrc30cJs9Xks7hlOnKshGdjDAU7i+7OWyecjnvb2xt7bWoteu70w29hZzQsJSPKRXKkyA9QTtwc5z8uMY53qXjK/R7f0n16G1SCctdBGhypIHIHUnGaqalJHY2L3M0kEQXBzPIET6bjgetSya/oiXcdpNqtvBdyP5ccM4eKRn/ALoDAc9KyL2HTfEmv28d1Z3d9pQs3EfnW0kdrJIxG7fuxlgv3fqelJcyack0vQiNO++yKcPi7w08jJc69pkUqjJjWXeffBXIbp0BzTY/F/hKeRI4PEmls8pAQGXbuz06gfrW/Z+HtDs7QW9jothb26j/AFcUZUEA555559c1Dq2haPqWly6de6XYvaSIV2CIKAPYrgg+lX7Sjf7X4f18r/MbUBtnNaX8ckmnXVtdIjbXNvKsgVvQ4PH40eRuzkcg88/p/KuKufBF/wCGYLb/AIV0kMU8t27Xkl3J+9MTrtVA3AManDYIzkA885v+BvFjanqup+HtUe3j1jT2IAQEPcbTh3PYsPlz6gg84omra03dfj9xfsbwc4vY6KSA8DbgGoGgKjNaDR7d3LMXfd8xzgkAYHt7Vzmqale3WtQ6PoBjSVNz6hfTws0dooxtRQcBpGPoTilFylojBRuVvFOq3ejw2JsdLn1GW7laNYogdyqBlnwBkgf1FU411/UbmRryK10rSg5RbbJa7lTszMDhD04GevtWvbaQLbV7zUmvLi4vbgkFpW+WJCMFI1H3VOASOeQKmlyM7RkY79atSSSste+v9ad7DbSVkYcmj2IuUuDHJJLAS0JmmaQQsRgsoJ4J9fyxRWhKcBjzx1zRTbct3czuz//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of normal lung tissue shows open alveoli with thin, capillary- containing interstitial spaces. An artery (A) is identifiable by its thick, muscular wall; the accompanying bronchus (B) contains mucoid material and is lined by columnar respiratory epithelial cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18168=[""].join("\n");
var outline_f17_47_18168=null;
var title_f17_47_18169="Cardiovascular effects of obstructive sleep apnea";
var content_f17_47_18169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiovascular effects of obstructive sleep apnea",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18169/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18169/contributors\">",
"     Renaud Tamisier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18169/contributors\">",
"     J Woodrow Weiss, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18169/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18169/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18169/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18169/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/47/18169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with obstructive sleep apnea (OSA) experience repetitive episodes of apnea or reduced inspiratory airflow due to upper airway obstruction during sleep. These events are associated with intermittent asphyxia (ie, concomitant hypoxemia and hypercapnia) and usually provoke an arousal from sleep. The arousal is associated with restoration of upper airway patency and ventilation.",
"   </p>",
"   <p>",
"    Intermittent hypoxia and the arousal response are likely the main pathophysiologic factors associated with oscillation of the systemic and pulmonary arterial blood pressures, heart rate, and cardiac function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/1\">",
"     1",
"    </a>",
"    ]. These hemodynamic changes can be dramatic, even among patients who are normotensive when awake. In one study, the post-apneic mean arterial blood pressure",
"    <span class=\"nowrap\">",
"     ([1/3",
"    </span>",
"    x systolic blood pressure] +",
"    <span class=\"nowrap\">",
"     [2/3",
"    </span>",
"    x diastolic blood pressure]) increased to 105 mmHg from a baseline of 95 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/2\">",
"     2",
"    </a>",
"    ]. The evidence suggests that these repetitive hemodynamic oscillations contribute to cardiovascular disease, although the pathophysiology is incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link\">",
"     \"Sleep related breathing disorders in adults: Definitions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review answers three questions, as they pertain to four cardiovascular disorders (systemic hypertension, pulmonary hypertension, coronary artery disease, and cardiac arrhythmias):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Does OSA cause cardiovascular disease?",
"     </li>",
"     <li>",
"      Should a diagnostic evaluation for OSA be performed if cardiovascular disease is detected?",
"     </li>",
"     <li>",
"      In patients with coexisting OSA and cardiovascular disease, should the OSA be treated to improve the cardiovascular disease?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationship between OSA and stroke is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38518?source=see_link\">",
"     \"Sleep related breathing disorders and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYSTEMIC HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence that obstructive sleep apnea (OSA) may be a cause of systemic hypertension includes the increased prevalence and incidence of systemic hypertension among patients with OSA, as well as the dose-response and treatment effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased prevalence and incidence &ndash; Many studies, including numerous population-based studies [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/4-8\">",
"       4-8",
"      </a>",
"      ] and prospective cohort studies [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/9,10\">",
"       9,10",
"      </a>",
"      ], have reported that systemic hypertension is more common among individuals who have OSA than among those who do not, even after adjustment for confounding variables. As an example, a prospective cohort study that followed 1889 individuals for a median of 12 years found a higher incidence of hypertension among those with OSA that was untreated with CPAP (due to refusal, non-adherence, or ineligibility), than among those with OSA that was treated with CPAP or those without OSA (adjusted hazard ratio 1.3 to 2.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/10\">",
"       10",
"      </a>",
"      ]. It is important to recognize that this association has not been universal [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]; the reasons for the conflicting results are uncertain, but differences in the patient populations have been proposed [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dose-response effect &ndash; Studies have found that the severity of OSA corresponds to the likelihood of systemic hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/4-9\">",
"       4-9",
"      </a>",
"      ]. As an example, a prospective cohort study of 709 subjects estimated that patients with an apnea hypopnea index (AHI) of 5 to 14.9 events per hour of sleep had twice the risk of systemic hypertension compared to those with an AHI of zero (adjusted odds ratio 2.03, 95% CI 1.29-3.17), while subjects with an AHI of &ge;15 events per hour of sleep had three times the risk (adjusted odds ratio 2.89, 95% CI 1.46-5.64) (",
"      <a class=\"graphic graphic_figure graphicRef65555 \" href=\"UTD.htm?3/9/3231\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment effect &ndash; Numerous randomized trials and two meta-analyses have reported that effective continuous positive airway pressure (CPAP) therapy reduces systemic blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/14-21\">",
"       14-21",
"      </a>",
"      ], as described below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic hypertension alone is not an indication for diagnostic evaluation of OSA. Instead, systemic hypertension should prompt the clinician to consider whether there is other evidence of OSA and whether diagnostic evaluation is indicated on that basis (",
"    <a class=\"graphic graphic_table graphicRef55633 \" href=\"UTD.htm?12/10/12460\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef80288 \" href=\"UTD.htm?22/5/22622\">",
"     algorithm 1",
"    </a>",
"    ). Indications for diagnostic evaluation of OSA are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'Indications for diagnostic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with resistant systemic hypertension are an exception to this approach. Such patients should undergo diagnostic evaluation because sleep related breathing disorders (which include OSA) are particularly common in this population. In one study, OSA was found in 71 percent of patients with resistant hypertension, compared to 38 percent of patients with controlled systemic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36728?source=see_link&amp;anchor=H17#H17\">",
"     \"Definition, risk factors, and evaluation of resistant hypertension\", section on 'Obstructive sleep apnea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous randomized trials and meta-analyses have found that effective treatment of OSA using positive airway pressure reduces systemic blood pressure, regardless of whether the patients are hypertensive [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/14-19,21,23\">",
"     14-19,21,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three key observations can be made on the basis of these trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First, the reduction in systemic blood pressure due to positive airway pressure therapy is usually small. This was illustrated by a trial that randomly assigned 118 men with OSA to receive therapeutic or subtherapeutic nasal CPAP for one month [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/14\">",
"       14",
"      </a>",
"      ]. The reduction of the 24-hour mean arterial ambulatory blood pressure among patients who received therapeutic CPAP was small, but statistically significant (-2.5 versus +0.8 mmHg).",
"     </li>",
"     <li>",
"      Second, the reduction in systemic blood pressure due to positive airway pressure therapy appears to be less than that due to antihypertensive medication. In a randomized crossover trial of 23 patients with both untreated hypertension and untreated OSA, antihypertensive medication (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"       valsartan",
"      </a>",
"      160 mg per day) lowered mean 24-hour blood pressure significantly more than CPAP therapy (-9 versus -2.1 mmHg) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/24\">",
"       24",
"      </a>",
"      ]. Moreover, for patients whose blood pressure was not controlled with CPAP or Valsartan, an extended trial of treatment that combined the two therapies showed further significant reduction in blood pressure.",
"     </li>",
"     <li>",
"      Third, the finding that positive airway pressure therapy reduces systemic blood pressure has not been universal [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/25-28\">",
"       25-28",
"      </a>",
"      ]. The conflicting results may be related to methodological differences among the trials, including different study populations, co-interventions, sample sizes, outcome measures (single time point or 24-hour blood pressure), and durations of follow-up. Some of the more common or important methodological differences include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Baseline hypertension &ndash; Most studies enrolled patients with OSA, regardless of whether or not they had baseline hypertension. Among three studies that only enrolled patients with baseline hypertension and OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/20,25,26\">",
"       20,25,26",
"      </a>",
"      ], two failed to find a reduction of systemic blood pressure after the initiation of CPAP [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. This suggests that hypertensive changes may become resistant to the benefits of CPAP therapy at some point.",
"     </li>",
"     <li>",
"      Use of antihypertensive medications &ndash; Studies have differed in terms of whether antihypertensive medications were allowed during the study and, if so, how they were initiated, maintained, or discontinued [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/29\">",
"       29",
"      </a>",
"      ]. Studies have also differed in terms of how antihypertensive therapy was accounted for in the analysis, which may contribute to the conflicting results.",
"     </li>",
"     <li>",
"      Excessive daytime sleepiness &ndash; Most studies enrolled patients with OSA who had excessive daytime sleepiness. However, three out of four randomized trials that evaluated patients with OSA who did not have excessive daytime sleepiness found no reduction in the blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/26,28\">",
"       26,28",
"      </a>",
"      ] or incidence of hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/30\">",
"       30",
"      </a>",
"      ] following the initiation of CPAP. The fourth trial found only a small reduction in the diastolic blood pressure and may have been confounded by the inclusion of patients with OSA-related sleepiness that was not severe enough to be defined as excessive daytime sleepiness [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/20\">",
"       20",
"      </a>",
"      ]. Taken together, these trials suggest that blood pressure reduction achieved by CPAP therapy is less in non-sleepy patients than in sleepy patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      OSA severity &ndash; The decrease in blood pressure in response to treatment with CPAP has been shown to be related to the severity of sleep apnea (as measured by the degree of nocturnal hypoxemia), with a greater decrease in blood pressure among those with more severe OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/14\">",
"       14",
"      </a>",
"      ]. The severity of hypoxemia varies among studies and may influence the results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of the randomized trials and meta-analyses had important methodologic problems. Positive airway pressure is the most effective therapy for sleep apnea; as a result, it was the only therapy employed in most of the randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/14-19,23\">",
"     14-19,23",
"    </a>",
"    ]. It seems reasonable to assume that elimination or reduction of obstructive events has the same effect on blood pressure regardless of the intervention used, but this is unproven.",
"   </p>",
"   <p>",
"    Taken together, the evidence indicates that treatment of OSA with positive airway pressure reduces systemic blood pressure in many patients. However, the reduction is usually modest and may not occur in patients with long-standing systemic hypertension or without excessive sleepiness. Despite this small reduction, it should be noted that a decrease of only 2 mmHg in blood pressure is enough to significantly reduce cardiovascular risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PULMONARY HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) may be associated with mild pulmonary hypertension when there is coexisting daytime hypoxemia (eg, chronic lung disease), even after adjustment for confounding variables [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. This was illustrated by an observational study that enrolled 50 consecutive patients with OSA, then compared patients with cor pulmonale to patients with normal right heart function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/32\">",
"     32",
"    </a>",
"    ]. Cor pulmonale only occurred in patients who had both nocturnal and daytime hypoxemia (not in patients who had nocturnal hypoxemia alone). The severity of the OSA was similar in both groups.",
"   </p>",
"   <p>",
"    The presence of pulmonary hypertension may have prognostic importance in patients with OSA. An observational study of 83 patients with OSA (defined as clinical suspicion plus an apnea hypopnea index &gt;5",
"    <span class=\"nowrap\">",
"     events/hour)",
"    </span>",
"    who underwent pulmonary artery catheterization for unspecified reasons found that one-, four-, and eight-year survival rates were lower among patients with pulmonary hypertension (93, 75, and 43 percent, respectively) than among those without pulmonary hypertension (100, 90, and 76 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/36\">",
"     36",
"    </a>",
"    ]. The study defined pulmonary hypertension as a mean pulmonary arterial pressure &gt;25 mmHg at rest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension alone is not an indication for diagnostic evaluation of OSA. Instead, pulmonary hypertension should prompt the clinician to consider whether there is other evidence of OSA and whether diagnostic evaluation is indicated on that basis (",
"    <a class=\"graphic graphic_table graphicRef55633 \" href=\"UTD.htm?12/10/12460\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef80288 \" href=\"UTD.htm?22/5/22622\">",
"     algorithm 1",
"    </a>",
"    ). Indications for diagnostic evaluation of OSA are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'Indications for diagnostic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive airway pressure therapy reduces pulmonary artery systolic pressure in patients with OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. In one trial, 23 patients with OSA were randomly assigned to receive therapeutic or subtherapeutic continuous positive airway pressure (CPAP) for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/35\">",
"     35",
"    </a>",
"    ]. Therapeutic CPAP reduced the estimated pulmonary artery systolic pressure from 29 to 24 mmHg. The extent of reduction was greatest among patients who had OSA plus pulmonary hypertension. The impact of other therapies (eg, oral appliances, pharmacotherapy, surgery, tracheostomy) on pulmonary hypertension is unknown.",
"   </p>",
"   <p>",
"    While treatment targeting OSA with positive airway pressure reduces pulmonary arterial systolic pressure in many patients, the reduction is modest and evidence of improved patient-important outcomes (eg, mortality) is lacking. Therapy directed at the pulmonary hypertension is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CORONARY ARTERY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that severe (but probably not mild) OSA is associated with cardiovascular morbidity related to coronary artery disease. As an example, a prospective cohort study followed 1651 men for a mean of 10 years following polysomnography [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients with untreated severe OSA (mean apnea hypopnea index [AHI] of 42 events per hour of sleep) had a higher incidence of fatal and non-fatal cardiovascular events than untreated patients with mild-moderate OSA, patients treated with continuous positive airway pressure (CPAP), simple snorers, and healthy participants, even after adjustment for confounding variables. Cardiovascular events included myocardial infarction, acute coronary syndrome, and stroke. These findings have been supported by numerous subsequent studies that also found increased cardiovascular events (including mortality) among patients with untreated severe OSA, compared to patients without OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. It is important to keep in mind that such an association does not necessarily indicate a causal relationship.",
"   </p>",
"   <p>",
"    It is not surprising that severe OSA may be associated with vascular morbidity because it is associated with multiple vascular risk factors, including decreased high density lipoproteins [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/43\">",
"     43",
"    </a>",
"    ], increased C-reactive protein [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], increased homocysteine [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/44\">",
"     44",
"    </a>",
"    ], and elevated blood glucose [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OSA may also exacerbate pre-existing coronary artery disease. In a prospective cohort study, polysomnography was performed on 89 consecutive patients who had undergone a percutaneous coronary intervention for acute coronary syndrome (53 with acute MI and 36 with unstable angina) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/47\">",
"     47",
"    </a>",
"    ]. OSA (defined as an AHI &ge;10 events per hour of sleep) was detected in 51 patients (57 percent). During a mean follow up of 227 days, the incidence of major adverse cardiac events (cardiac death, reinfarction, target vessel revascularization) was higher among patients with OSA than those without OSA (adjusted HR 11.6, 95% CI 2.2-62.2).",
"   </p>",
"   <p>",
"    It is conceivable that mild OSA exerts a protective effect, possibly through preconditioning induced by the apneic events. This was suggested by a study that found that patients with total coronary occlusion of at least one vessel and symptoms suggestive of OSA expressed more collateral coronary vessels if they had OSA (defined as an apnea hypopnea index &gt;10 events per hour by overnight polysomnography) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/48\">",
"     48",
"    </a>",
"    ]. These findings need to be confirmed via additional investigation. A potential limitation of this study is that even those patients with an AHI &lt;10 events per hour (ie, the non-OSA group) spent a significant portion of their total sleep time with an SpO",
"    <sub>",
"     2",
"    </sub>",
"    &lt;90 percent, suggesting that they may not be representative of most control populations. The different severities of OSA are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of obstructive sleep apnea in adults\", section on 'Disease spectrum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the evidence above suggests that untreated severe OSA is associated with the development of adverse cardiovascular events (eg, myocardial infarction, acute coronary syndrome), the reverse may also be true; that is, myocardial infarction may be associated with worsening of sleep-disordered breathing. This was demonstrated by a prospective cohort study of 2721 individuals (mean age 62 years) without known cardiovascular disease who were followed for a mean of five years, which included polysomnography performed at baseline and at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/49\">",
"     49",
"    </a>",
"    ]. Fifty seven subjects (2 percent) had a myocardial infarction during the study. The adjusted AHI increased a mean of 6.37 respiratory events per hour of sleep among those who had a myocardial infarction, compared with only 2.71 respiratory events per hour of sleep among those who had not had a myocardial infarction. It was not determined whether the increased respiratory event rate among individuals who had a myocardial infarction only was due to an increase in obstructive events, central events, or both, although among patients who developed either a myocardial infarction or heart failure, the rates of both obstructive and central respiratory events increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery disease alone is not an indication for diagnostic evaluation of OSA. Instead, coronary artery disease should prompt the clinician to consider whether there is other evidence of OSA and whether diagnostic evaluation is indicated on that basis (",
"    <a class=\"graphic graphic_table graphicRef55633 \" href=\"UTD.htm?12/10/12460\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef80288 \" href=\"UTD.htm?22/5/22622\">",
"     algorithm 1",
"    </a>",
"    ). Indications for diagnostic evaluation of OSA are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'Indications for diagnostic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of OSA with positive airway pressure may reduce the incidence of cardiovascular events, including events related to coronary artery disease. This was suggested by the following observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study followed 1651 men for a mean of 10 years following polysomnography [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/38\">",
"       38",
"      </a>",
"      ]. Patients with OSA who were treated with CPAP (mean AHI of 42 events per hour of sleep prior to therapy) had a lower incidence of fatal and non-fatal cardiovascular events than patients with untreated severe OSA (mean AHI of 43 events per hour of sleep). In fact, the incidence of fatal and non-fatal cardiovascular events among patients treated with CPAP did not differ significantly from that in individuals without OSA. Cardiovascular events included myocardial infarction, acute coronary syndrome, and stroke.",
"     </li>",
"     <li>",
"      A prospective cohort study followed 449 patients with mild or moderate OSA for a median of six years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/50\">",
"       50",
"      </a>",
"      ]. Treatment of OSA (primarily CPAP) was associated with a reduction of the likelihood of a cardiovascular event (adjusted HR 0.36, 95% CI 0.21-0.62), compared to no treatment. Cardiovascular events were defined as myocardial infarction, stroke, or acute coronary syndrome requiring a revascularization procedure. An important limitation of this study was that combining patients with mild and moderate OSA made it impossible to determine whether treatment benefited only patients with moderate OSA, mild OSA, or both.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these studies, the untreated group included both patients who did not accept CPAP therapy and patients who were non-adherent with CPAP therapy.",
"   </p>",
"   <p>",
"    The severity of OSA that warrants treatment for the purpose of preventing cardiovascular events related to coronary artery disease needs to be determined and the potential benefits of therapy need to be verified by controlled clinical trials before routine administration of positive airway pressure to patients with OSA is warranted for this sole purpose. The impact of other therapies (eg, oral appliances, pharmacotherapy, surgery, tracheostomy) on the same outcomes is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CARDIAC ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) is associated with nocturnal cardiac arrhythmias. Although it is unknown whether the relationship is causal, there may be a temporal relationship with arrhythmias occurring more frequently after a respiratory event [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an observational study, 228 patients with a sleep related breathing disorder (respiratory disturbance index [RDI] &ge;30 events per hour of sleep) were compared to 338 control subjects (RDI &lt;5 events per hour of sleep) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/52\">",
"     52",
"    </a>",
"    ]. The sleep related breathing disorder group had a higher prevalence of nocturnal atrial fibrillation (4.8 versus 0.9 percent), nonsustained ventricular tachycardia (5.3 versus 1.2 percent), and complex ventricular ectopy (25 versus 14.5 percent). These relationships persisted after adjustment for confounding variables. Examples of complex ventricular ectopy include nonsustained ventricular tachycardia, bigeminy, trigeminy, and quadrigeminy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H13#H13\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Respiratory disturbance index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bradycardia and asystole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradycardia and asystole during sleep are the most prominent and significant rhythm disturbances associated with OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/53-57\">",
"     53-57",
"    </a>",
"    ]. In extreme cases, ventricular asystole can last longer than 10 seconds. The contribution of asystole to the increase in mortality associated with OSA is unclear.",
"   </p>",
"   <p>",
"    OSA also appears to be associated with bradyarrhythmias that occur during waking hours. In an observational study, 98 patients who had a cardiac pacemaker for sinus node dysfunction, atrioventricular block, or heart failure underwent polysomnography [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/58\">",
"     58",
"    </a>",
"    ]. Nearly 60 percent were found to have OSA, when defined as an apnea hypopnea index &ge;10 events per hour of sleep. As a comparison, only 20 percent of the general population has OSA, when defined as an apnea hypopnea index &ge;5 events per hour of sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bradycardia and asystole in patients with OSA probably result from enhanced vagal tone, rather than structural disease of the conduction system [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/57\">",
"     57",
"    </a>",
"    ]. In one study, 15 patients with OSA and asystole who underwent electrophysiology exams all had normal (or only slightly abnormal) sinus and atrioventricular (AV) node function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/61\">",
"     61",
"    </a>",
"    ]. Activation of the parasympathetic nervous system may result from hypoventilation, hypoxemia, respiratory acidosis, or vigorous inspiratory effort against a closed airway (Mueller's maneuver).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of atrial fibrillation (AF) in patients with OSA is low, but higher than that in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/52,62,63\">",
"     52,62,63",
"    </a>",
"    ]. Conversely, the prevalence of OSA among patients with AF is strikingly high, with estimates ranging from 32 to 82 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/62,64-66\">",
"     62,64-66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link&amp;anchor=H17#H17\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Other types of cardiopulmonary disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    OSA may also be associated with recurrent AF. In an observational study of 130 patients who had been electrically cardioverted from AF, the rate of recurrent AF in patients with untreated OSA, with treated OSA, and without OSA was 82, 42, and 53 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We believe that all patients who are observed to have nocturnal cardiac arrhythmias (with or without daytime arrhythmias) should undergo diagnostic evaluation for possible OSA. The evaluation should consist of an objective sleep assessment that includes an ECG tracing, so that respiratory events during sleep may be correlated with cardiac arrhythmias. Such an assessment is particularly important for patients who have a chronic pacemaker for any reason, because sleep related breathing disorders are prevalent in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/58\">",
"     58",
"    </a>",
"    ]. The diagnostic evaluation of potential OSA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'Indications for diagnostic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy with positive airway pressure abolishes nocturnal ventricular asystole and bradycardia in most patients with OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/53,61,68\">",
"     53,61,68",
"    </a>",
"    ]. In a prospective cohort study, a loop recorder capable of monitoring the heart rhythm for 16 months was implanted in 23 patients with moderate or severe OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/53\">",
"     53",
"    </a>",
"    ]. Recording was performed for two months prior to the initiation of continuous positive airway pressure (CPAP) and then for 14 months after initiation of CPAP. Nocturnal ventricular bradycardia or asystole were noted in 47 percent of patients prior to the initiation of CPAP. This decreased by eight weeks. No nocturnal arrhythmias were detected during the final six months.",
"   </p>",
"   <p>",
"    There are several important gaps in our knowledge about the impact of OSA therapy on nocturnal arrhythmias:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It is unknown whether nocturnal arrhythmia suppression improves mortality",
"     </li>",
"     <li>",
"      There are few data about the impact of therapy on arrhythmias other than ventricular bradycardia or asystole",
"     </li>",
"     <li>",
"      The effect of therapies other than positive airway pressure (eg, oral appliances, pharmacotherapy, surgery, tracheostomy) on nocturnal arrhythmias is unknown",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of cardiac arrhythmias has been evaluated as a potential therapy for OSA. In a study of 15 patients with OSA and permanent pacemakers (placed previously for symptomatic bradycardia), atrial overdrive pacing at a rate 15 beats per minute faster than the patient's average nocturnal heart rate resulted in fewer hypopneas (three versus nine events per hour of sleep) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/69\">",
"     69",
"    </a>",
"    ]. However, these results were not reproduced in three larger studies with longer follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. As a result, OSA is not considered an indication for permanent pacemaker placement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27159755\">",
"    <span class=\"h1\">",
"     HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is well known that obstructive sleep apnea (OSA) complicates heart failure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The high prevalence of sleep disordered breathing (SDB, referring to OSA and central sleep apnea collectively) among patients with heart failure was illustrated by an observational study of 700 patients with heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/73\">",
"       73",
"      </a>",
"      ]. SDB was present among 76 percent of the patients, including 40 percent with central sleep apnea and 36 percent with OSA. The frequency of central sleep apnea was related to more severe heart failure, but the frequency of OSA was not.",
"     </li>",
"     <li>",
"      The increased frequency of respiratory events during sleep among patients who develop heart failure was demonstrated by a prospective cohort study that followed 2721 individuals (mean age 62 years) without known cardiovascular disease for a mean of five years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/49\">",
"       49",
"      </a>",
"      ]. This included polysomnography performed at baseline and at five years. Fifty seven subjects (2 percent) developed heart failure during the study. The AHI increased a mean of 4.55 respiratory events per hour of sleep among those who developed heart failure, compared with only 2.75 respiratory events per hour of sleep among those who did not develop heart failure. It was not determined whether the increased respiratory event rate among individuals who developed heart failure was due to an increase in obstructive events, central events, or both; however, among patients who developed either a myocardial infarction or heart failure, the rates of both obstructive and central respiratory events increased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it is only beginning to be recognized that OSA may be a risk factor for the development of heart failure. This was suggested by a prospective cohort study of 1927 men and 2495 women without baseline heart failure who were followed for a median of 8.7 years after baseline polysomnography [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18169/abstract/41\">",
"     41",
"    </a>",
"    ]. Among men, OSA appeared to be associated with an increased risk of developing heart failure, even after adjustment for potential confounders. The increased risk appeared to be highest among men with severe OSA, defined as an apnea hypopnea index &gt;30 events per hour of sleep. OSA was not associated with heart failure among women.",
"   </p>",
"   <p>",
"    The combination of OSA and heart failure is discussed in detail separately, including diagnosis and management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive sleep apnea (OSA) is a disorder characterized by repetitive episodes of apnea or reduced inspiratory airflow due to upper airway obstruction during sleep, despite an increase in respiratory effort. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      OSA appears to be related to several cardiovascular diseases, even after adjustment for confounding variables. These include systemic hypertension, mild pulmonary hypertension (when there is coexisting daytime hypoxemia), coronary artery disease, nocturnal cardiac arrhythmias, and, possibly, heart failure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Systemic hypertension'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pulmonary hypertension'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Coronary artery disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Cardiac arrhythmias'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27159755\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolated systemic hypertension, pulmonary hypertension, or coronary artery disease is not an indication for diagnostic evaluation for possible OSA. However, these disorders should prompt the clinician to consider whether there is alternative evidence of OSA and whether diagnostic evaluation is indicated on that basis (",
"      <a class=\"graphic graphic_table graphicRef55633 \" href=\"UTD.htm?12/10/12460\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef80288 \" href=\"UTD.htm?22/5/22622\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Systemic hypertension'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pulmonary hypertension'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Coronary artery disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Cardiac arrhythmias'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27159755\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exceptions include patients with nocturnal cardiac arrhythmias, nocturnal angina, or difficult-to-treat systemic hypertension. All such patients should be evaluated for possible OSA. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Systemic hypertension'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Cardiac arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following recommendations address whether OSA-specific therapy should be initiated in patients who have an abnormal AHI and cardiovascular disease alone (ie, no other clinical or physiological sequelae attributable to OSA). A more comprehensive list of indications to treat OSA is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of obstructive sleep apnea in adults\", section on 'Indications for treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link&amp;anchor=H25#H25\">",
"       \"Management of obstructive sleep apnea in adults\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with severe OSA (an apnea hypopnea index [AHI] of &gt;30 events per hour of sleep), we suggest treatment of the OSA to improve or prevent cardiovascular morbidity and mortality (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Prospective cohort studies have confirmed that treatment of severe OSA reduces cardiovascular events with a large effect, although these studies did not separately analyze patients who had no clinical or physiological sequelae attributable to OSA. It is unclear whether this is mediated by treatment-related reduction of systemic blood pressure. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Coronary artery disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have OSA of any severity and coexisting refractory systemic hypertension or cardiac arrhythmias, we suggest treatment of the OSA to improve the cardiovascular disease (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Examples of cardiac arrhythmias include atrial fibrillation, atrioventricular block, nocturnal bradycardia, and nocturnal ventricular asystole. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Systemic hypertension'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27159755\">",
"       'Heart failure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Cardiac arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have OSA and coexisting pulmonary hypertension, there is no evidence to justify treating the OSA to improve the pulmonary hypertension, since the increase in pulmonary arterial pressure due to sleep apnea is slight. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pulmonary hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients whose OSA is being treated with continuous positive airway pressure (CPAP), attention should be directed toward maintaining the average use of CPAP above four hours per night to protect against incident cardiovascular diseases and worsening of existing cardiovascular conditions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The relationship between OSA and heart failure is discussed in detail separately, including diagnosis and management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link\">",
"       \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/1\">",
"      Podszus T, Mayer J, Penzel T, et al. Nocturnal hemodynamics in patients with sleep apnea. Eur J Respir Dis Suppl 1986; 146:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/2\">",
"      Somers VK, Dyken ME, Skinner JL. Autonomic and hemodynamic responses and interactions during the Mueller maneuver in humans. J Auton Nerv Syst 1993; 44:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/3\">",
"      Parish JM, Somers VK. Obstructive sleep apnea and cardiovascular disease. Mayo Clin Proc 2004; 79:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/4\">",
"      Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ 2000; 320:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/5\">",
"      Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/6\">",
"      Young T, Peppard P, Palta M, et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med 1997; 157:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/7\">",
"      Grote L, Ploch T, Heitmann J, et al. Sleep-related breathing disorder is an independent risk factor for systemic hypertension. Am J Respir Crit Care Med 1999; 160:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/8\">",
"      Bixler EO, Vgontzas AN, Lin HM, et al. Association of hypertension and sleep-disordered breathing. Arch Intern Med 2000; 160:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/9\">",
"      Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/10\">",
"      Marin JM, Agusti A, Villar I, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA 2012; 307:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/11\">",
"      O'Connor GT, Caffo B, Newman AB, et al. Prospective study of sleep-disordered breathing and hypertension: the Sleep Heart Health Study. Am J Respir Crit Care Med 2009; 179:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/12\">",
"      Cano-Pumarega I, Dur&aacute;n-Cantolla J, Aizpuru F, et al. Obstructive sleep apnea and systemic hypertension: longitudinal study in the general population: the Vitoria Sleep Cohort. Am J Respir Crit Care Med 2011; 184:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/13\">",
"      Logan A. Sleep-disordered breathing and hypertension. Am J Respir Crit Care Med 2009; 179:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/14\">",
"      Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002; 359:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/15\">",
"      Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med 2001; 163:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/16\">",
"      Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003; 107:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/17\">",
"      Dimsdale JE, Loredo JS, Profant J. Effect of continuous positive airway pressure on blood pressure : a placebo trial. Hypertension 2000; 35:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/18\">",
"      Haentjens P, Van Meerhaeghe A, Moscariello A, et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med 2007; 167:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/19\">",
"      Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 2007; 50:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/20\">",
"      Barb&eacute; F, Dur&aacute;n-Cantolla J, Capote F, et al. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010; 181:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/21\">",
"      Sharma SK, Agrawal S, Damodaran D, et al. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N Engl J Med 2011; 365:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/22\">",
"      Gon&ccedil;alves SC, Martinez D, Gus M, et al. Obstructive sleep apnea and resistant hypertension: a case-control study. Chest 2007; 132:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/23\">",
"      Alajmi M, Mulgrew AT, Fox J, et al. Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials. Lung 2007; 185:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/24\">",
"      P&eacute;pin JL, Tamisier R, Barone-Rochette G, et al. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010; 182:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/25\">",
"      Campos-Rodriguez F, Grilo-Reina A, Perez-Ronchel J, et al. Effect of continuous positive airway pressure on ambulatory BP in patients with sleep apnea and hypertension: a placebo-controlled trial. Chest 2006; 129:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/26\">",
"      Robinson GV, Smith DM, Langford BA, et al. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. Eur Respir J 2006; 27:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/27\">",
"      Mansfield DR, Gollogly NC, Kaye DM, et al. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med 2004; 169:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/28\">",
"      Barb&eacute; F, Mayoralas LR, Duran J, et al. Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness. a randomized, controlled trial. Ann Intern Med 2001; 134:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/29\">",
"      Parati G, Lombardi C. Control of hypertension in nonsleepy patients with obstructive sleep apnea. Am J Respir Crit Care Med 2010; 181:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/30\">",
"      Barb&eacute; F, Dur&aacute;n-Cantolla J, S&aacute;nchez-de-la-Torre M, et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA 2012; 307:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/31\">",
"      Fletcher EC, Schaaf JW, Miller J, Fletcher JG. Long-term cardiopulmonary sequelae in patients with sleep apnea and chronic lung disease. Am Rev Respir Dis 1987; 135:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/32\">",
"      Bradley TD, Rutherford R, Grossman RF, et al. Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis 1985; 131:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/33\">",
"      Sajkov D, Cowie RJ, Thornton AT, et al. Pulmonary hypertension and hypoxemia in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1994; 149:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/34\">",
"      Guidry UC, Mendes LA, Evans JC, et al. Echocardiographic features of the right heart in sleep-disordered breathing: the Framingham Heart Study. Am J Respir Crit Care Med 2001; 164:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/35\">",
"      Arias MA, Garc&iacute;a-R&iacute;o F, Alonso-Fern&aacute;ndez A, et al. Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J 2006; 27:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/36\">",
"      Minai OA, Ricaurte B, Kaw R, et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 2009; 104:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/37\">",
"      Sajkov D, McEvoy RD. Obstructive sleep apnea and pulmonary hypertension. Prog Cardiovasc Dis 2009; 51:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/38\">",
"      Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/39\">",
"      Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 2009; 6:e1000132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/40\">",
"      Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008; 31:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/41\">",
"      Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation 2010; 122:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/42\">",
"      Mart&iacute;nez-Garc&iacute;a MA, Campos-Rodr&iacute;guez F, Catal&aacute;n-Serra P, et al. Cardiovascular mortality in obstructive sleep apnea in the elderly: role of long-term continuous positive airway pressure treatment: a prospective observational study. Am J Respir Crit Care Med 2012; 186:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/43\">",
"      B&ouml;rgel J, Sanner BM, Bittlinsky A, et al. Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur Respir J 2006; 27:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/44\">",
"      Can M, A&ccedil;ikg&ouml;z S, Mungan G, et al. Serum cardiovascular risk factors in obstructive sleep apnea. Chest 2006; 129:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/45\">",
"      Zouaoui Boudjeltia K, Van Meerhaeghe A, Doumit S, et al. Sleep apnoea-hypopnoea index is an independent predictor of high-sensitivity C-reactive protein elevation. Respiration 2006; 73:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/46\">",
"      Reichmuth KJ, Austin D, Skatrud JB, Young T. Association of sleep apnea and type II diabetes: a population-based study. Am J Respir Crit Care Med 2005; 172:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/47\">",
"      Yumino D, Tsurumi Y, Takagi A, et al. Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. Am J Cardiol 2007; 99:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/48\">",
"      Steiner S, Schueller PO, Schulze V, Strauer BE. Occurrence of coronary collateral vessels in patients with sleep apnea and total coronary occlusion. Chest 2010; 137:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/49\">",
"      Chami HA, Resnick HE, Quan SF, Gottlieb DJ. Association of incident cardiovascular disease with progression of sleep-disordered breathing. Circulation 2011; 123:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/50\">",
"      Buchner NJ, Sanner BM, Borgel J, Rump LC. Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. Am J Respir Crit Care Med 2007; 176:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/51\">",
"      Monahan K, Storfer-Isser A, Mehra R, et al. Triggering of nocturnal arrhythmias by sleep-disordered breathing events. J Am Coll Cardiol 2009; 54:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/52\">",
"      Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med 2006; 173:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/53\">",
"      Simantirakis EN, Schiza SI, Marketou ME, et al. Severe bradyarrhythmias in patients with sleep apnoea: the effect of continuous positive airway pressure treatment: a long-term evaluation using an insertable loop recorder. Eur Heart J 2004; 25:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/54\">",
"      Tilkian AG, Guilleminault C, Schroeder JS, et al. Sleep-induced apnea syndrome. Prevalence of cardiac arrhythmias and their reversal after tracheostomy. Am J Med 1977; 63:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/55\">",
"      Miller WP. Cardiac arrhythmias and conduction disturbances in the sleep apnea syndrome. Prevalence and significance. Am J Med 1982; 73:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/56\">",
"      Zwillich C, Devlin T, White D, et al. Bradycardia during sleep apnea. Characteristics and mechanism. J Clin Invest 1982; 69:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/57\">",
"      Alonso-Fern&aacute;ndez A, Garc&iacute;a-R&iacute;o F, Racionero MA, et al. Cardiac rhythm disturbances and ST-segment depression episodes in patients with obstructive sleep apnea-hypopnea syndrome and its mechanisms. Chest 2005; 127:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/58\">",
"      Garrigue S, P&eacute;pin JL, Defaye P, et al. High prevalence of sleep apnea syndrome in patients with long-term pacing: the European Multicenter Polysomnographic Study. Circulation 2007; 115:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/59\">",
"      Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA 2004; 291:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/60\">",
"      Netzer NC, Hoegel JJ, Loube D, et al. Prevalence of symptoms and risk of sleep apnea in primary care. Chest 2003; 124:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/61\">",
"      Grimm W, Hoffmann J, Menz V, et al. Electrophysiologic evaluation of sinus node function and atrioventricular conduction in patients with prolonged ventricular asystole during obstructive sleep apnea. Am J Cardiol 1996; 77:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/62\">",
"      Gami AS, Friedman PA, Chung MK, et al. Therapy Insight: interactions between atrial fibrillation and obstructive sleep apnea. Nat Clin Pract Cardiovasc Med 2005; 2:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/63\">",
"      Guilleminault C, Connolly SJ, Winkle RA. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. Am J Cardiol 1983; 52:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/64\">",
"      Porthan KM, Melin JH, Kupila JT, et al. Prevalence of sleep apnea syndrome in lone atrial fibrillation: a case-control study. Chest 2004; 125:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/65\">",
"      Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004; 110:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/66\">",
"      Braga B, Poyares D, Cintra F, et al. Sleep-disordered breathing and chronic atrial fibrillation. Sleep Med 2009; 10:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/67\">",
"      Kanagala R, Murali NS, Friedman PA, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation 2003; 107:2589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/68\">",
"      Becker H, Brandenburg U, Conradt R, et al. [Influence of nCPAP therapy on bradycardic arrhythmias in sleep apnea]. Pneumologie 1993; 47 Suppl 4:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/69\">",
"      Garrigue S, Bordier P, Ja&iuml;s P, et al. Benefit of atrial pacing in sleep apnea syndrome. N Engl J Med 2002; 346:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/70\">",
"      P&eacute;pin JL, Defaye P, Garrigue S, et al. Overdrive atrial pacing does not improve obstructive sleep apnoea syndrome. Eur Respir J 2005; 25:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/71\">",
"      L&uuml;thje L, Unterberg-Buchwald C, Dajani D, et al. Atrial overdrive pacing in patients with sleep apnea with implanted pacemaker. Am J Respir Crit Care Med 2005; 172:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/72\">",
"      Simantirakis EN, Schiza SE, Chrysostomakis SI, et al. Atrial overdrive pacing for the obstructive sleep apnea-hypopnea syndrome. N Engl J Med 2005; 353:2568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18169/abstract/73\">",
"      Oldenburg O, Lamp B, Faber L, et al. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients. Eur J Heart Fail 2007; 9:251.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7705 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-198.199.123.20-28C064E6EE-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18169=[""].join("\n");
var outline_f17_47_18169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYSTEMIC HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PULMONARY HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CORONARY ARTERY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CARDIAC ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bradycardia and asystole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27159755\">",
"      HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7705\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7705|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/5/22622\" title=\"algorithm 1\">",
"      OSA diagnosis algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7705|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/9/3231\" title=\"figure 1\">",
"      Hypertension and AHI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7705|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/10/12460\" title=\"table 1\">",
"      Clinical features OSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=related_link\">",
"      Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36728?source=related_link\">",
"      Definition, risk factors, and evaluation of resistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38518?source=related_link\">",
"      Sleep related breathing disorders and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_47_18170="Overview of neutropenia";
var content_f17_47_18170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of neutropenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18170/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18170/contributors\">",
"     Thomas D Coates, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18170/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18170/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18170/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/47/18170/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/47/18170/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/47/18170/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic review will provide an overview of the causes, clinical manifestations, diagnosis, and management of neutropenia when it occurs as an",
"    <strong>",
"     isolated or predominant feature",
"    </strong>",
"    . Neutropenia is also a common manifestation of bone marrow defects associated with reductions in red cells and platelets, such as aplastic anemia, leukemia, myelodysplasia, megaloblastic anemia due to vitamin B12 or folate deficiency, and the administration of chemotherapy. These disorders are reviewed separately.",
"   </p>",
"   <p>",
"    Laboratory evaluation of neutropenia and neutrophil function, as well as various disorders associated with neutropenia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=see_link\">",
"     \"Laboratory evaluation of neutropenia and neutrophil dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=see_link\">",
"     \"Cyclic neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link\">",
"     \"Immune neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10473?source=see_link\">",
"     \"Infectious causes of neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link\">",
"     \"Drug-induced neutropenia and agranulocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44039?source=see_link\">",
"     \"Hematologic manifestations of HIV infection: Neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absolute neutrophil count (ANC) is equal to the product of the white blood cell count (WBC) and the fraction of polymorphonuclear cells (PMNs) and band forms noted on the differential analysis:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;ANC = WBC",
"    <span class=\"nowrap\">",
"     (cells/microL)",
"    </span>",
"    x percent (PMNs &nbsp;+ &nbsp;bands) &divide; 100",
"   </p>",
"   <p>",
"    Neutrophilic metamyelocytes and younger forms are not included in this calculation (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). An ANC",
"    <span class=\"nowrap\">",
"     &lt;1500/microL",
"    </span>",
"    (&lt;1.5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L)",
"    </span>",
"    is the generally accepted definition of neutropenia for adults, as well as the threshold for neutrophil toxicity and infectious risk following chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef64984 \" href=\"UTD.htm?25/21/25948\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63903 \" href=\"UTD.htm?10/19/10555\">",
"     table 2",
"    </a>",
"    ). The normal range for the ANC varies somewhat with age. The lower limit of normal is",
"    <span class=\"nowrap\">",
"     5000/microL",
"    </span>",
"    <span class=\"nowrap\">",
"     (5.0&times;10",
"     <sup>",
"      9",
"     </sup>",
"     /L)",
"    </span>",
"    for the first week of life, then falls to",
"    <span class=\"nowrap\">",
"     1000/microL",
"    </span>",
"    <span class=\"nowrap\">",
"     (1.0&times;10",
"     <sup>",
"      9",
"     </sup>",
"     /L)",
"    </span>",
"    between two weeks and one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutropenia is often categorized as mild, moderate or severe, based upon the level of ANC. Mild neutropenia corresponds to an absolute neutrophil count between 1000 and",
"    <span class=\"nowrap\">",
"     1500/microL,",
"    </span>",
"    moderate between 500 and",
"    <span class=\"nowrap\">",
"     1000/microL,",
"    </span>",
"    and severe with less than",
"    <span class=\"nowrap\">",
"     500/microL.",
"    </span>",
"    The risk of infection begins to increase at an ANC below",
"    <span class=\"nowrap\">",
"     1000/microL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef63903 \" href=\"UTD.htm?10/19/10555\">",
"     table 2",
"    </a>",
"    ). However, the risk is also dependent upon the adequacy of the marrow reserve pool of granulocytes. (See",
"    <a class=\"local\" href=\"#H2412659\">",
"     'Infection propensity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Leukopenia and granulocytopenia are generally used interchangeably with neutropenia, although they are somewhat different:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukopenia refers to a low total white blood cell count that may be due to any cause (eg, lymphopenia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neutropenia); however, almost all leukopenic patients are neutropenic since the number of neutrophils is so much larger than the number of lymphocytes.",
"     </li>",
"     <li>",
"      Granulocytopenia refers to a reduced absolute number of all circulating cells of the granulocyte series (eg, neutrophils, eosinophils, and basophils); however, almost all granulocytopenic patients are neutropenic since the number of neutrophils is so much larger than the number of eosinophils and basophils.",
"     </li>",
"     <li>",
"      Agranulocytosis literally means the absence of granulocytes, but the term is often incorrectly used to indicate severe neutropenia (ie, ANC",
"      <span class=\"nowrap\">",
"       &lt;500/microL).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2412651\">",
"    <span class=\"h1\">",
"     PROPENSITY TO INFECTION AND SIGNIFICANCE OF NEUTROPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two fundamental issues to consider in the neutropenic patient:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the patient at increased risk for infection because of neutropenia?",
"     </li>",
"     <li>",
"      Does the presence of neutropenia indicate a serious underlying disorder that is secondarily affecting the neutrophil count?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since most physicians&rsquo; exposure to neutropenia is through experience with malignancy or severe marrow failure syndromes, it is important to point out that, for most commonly encountered cases of neutropenia, the patient&rsquo;s propensity to infection may have little relation to the degree of neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2412659\">",
"    <span class=\"h2\">",
"     Infection propensity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only about 3 percent of the body&rsquo;s neutrophils are circulating in the peripheral blood. The vast majority of neutrophils are in the bone marrow reserve pool and the remainder is in the tissue and marginated pool attached to the lining of blood vessels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=see_link\">",
"     \"Normal neutrophil development and kinetics\"",
"    </a>",
"    .) Thus, a standard complete blood count (CBC) done on peripheral blood is, in effect, sampling the very smallest compartment of neutrophils and does not accurately reflect the body&rsquo;s capacity to protect against bacterial infection. The most important issue is whether adequate neutrophils get to the site of infection, not how many are sampled en route from the marrow to the tissue. While one can infer tissue supply of neutrophils from the clinical history and certain physical findings (",
"    <a class=\"graphic graphic_table graphicRef62992 \" href=\"UTD.htm?37/10/38060\">",
"     table 3",
"    </a>",
"    ), there is no good clinical laboratory test available to quantitate tissue neutrophil delivery.",
"   </p>",
"   <p>",
"    Adequacy of the marrow reserve pool is the most critical determinant of propensity to infection in a neutropenic patient, although having a normal marrow does not guarantee protection against infection (see below). By &ldquo;adequate marrow reserve&rdquo; we mean normal marrow cellularity and normal maturation of the neutrophil series. We would consider low marrow cellularity or myeloid arrest at the myelocyte or metamyelocyte stage to imply decreased reserve. The risk of infection based on ANC is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef71724 \" href=\"UTD.htm?6/49/6941\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the neutropenic febrile patient, management decisions must be made without information about the adequacy of the bone marrow reserve. Bone marrow aspiration and biopsy are the only ways to directly evaluate marrow reserve. The table lists clinical signs that infer marrow reserve (",
"    <a class=\"graphic graphic_table graphicRef62992 \" href=\"UTD.htm?37/10/38060\">",
"     table 3",
"    </a>",
"    ). If the bone marrow reserve pool is significantly depleted, there is a rough relationship between the absolute neutrophil count and propensity to infection (",
"    <a class=\"graphic graphic_table graphicRef63903 \" href=\"UTD.htm?10/19/10555\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, and importantly, if the bone marrow reserve pool is completely adequate, there is no relationship between the degree of neutropenia and propensity to infection. If the marrow reserve pool is normal, patients with an ANC of zero may be at no increased risk of serious infection because of the neutropenia. Essentially, patients with normal marrow reserve are able to deliver neutrophils to the site of infection, and those with no marrow reserve are not.",
"   </p>",
"   <p>",
"    Most physicians are aware of the extreme danger present in patients with significant fever and very low absolute neutrophil counts based upon their experiences during training with patients who have received chemotherapy or who have bone marrow failure syndromes. These patients have no bone marrow reserve. Patients with immune mediated neutropenia but normal bone marrow reserve are on the other end of the spectrum and are at no increased risk of infection because of the neutropenia. Note that we are careful to say &ldquo;no increased risk of infection because of the neutropenia&rdquo; and not &ldquo;no increased risk of infection&rdquo;. Neutropenia can be the presenting finding in common variable immunodeficiency, other immunodeficiency states, and collagen vascular diseases, all of which can have adequate marrow reserve yet put the patient at increased risk for infection for reasons other than the neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link\">",
"     \"Immune neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Various neutropenia syndromes are presented in the table according to marrow reserve (",
"    <a class=\"graphic graphic_table graphicRef71724 \" href=\"UTD.htm?6/49/6941\">",
"     table 4",
"    </a>",
"    ). Some disorders appear in more than one category. For example, post-infectious neutropenia usually has normal marrow reserve, but not always. Classification of neutropenias by marrow reserve status offers a mechanistic link to propensity to infection and has some bearing on treatment. Patients with decreased reserve are likely to benefit from treatment with granulocyte colony stimulating factor, whereas this agent is not of benefit for patients with normal marrow. The clinical symptoms noted in the table (",
"    <a class=\"graphic graphic_table graphicRef62992 \" href=\"UTD.htm?37/10/38060\">",
"     table 3",
"    </a>",
"    ) can give the clinician some idea of the ability to deliver neutrophils to tissue and thus adequacy of marrow reserve. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a neutropenic patient has a frank abscess or purulent exudate, he or she can get neutrophils to tissue and likely has a normal marrow.",
"     </li>",
"     <li>",
"      The presence of mucosal ulcerations and severe gingivitis suggests inability to deliver neutrophils. However, immune disorders can directly cause similar lesions in the presence of normal reserve neutropenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link\">",
"       \"Immune neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2412809\">",
"    <span class=\"h2\">",
"     Significance of neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Separate from the issue of propensity to infection, neutropenia can be a sign of an underlying systemic disorder (",
"    <a class=\"graphic graphic_table graphicRef69186 \" href=\"UTD.htm?5/19/5437\">",
"     table 5",
"    </a>",
"    ). When neutropenia is discovered during the evaluation of a febrile patient, propensity to infection dominates. However, neutropenia is often discovered on a blood count done for some other reason. The approach to such patients is outlined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE OF NEUTROPENIA  IN NORMAL SUBJECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect of race and ethnic origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above definition of neutropenia (ie, an ANC",
"    <span class=\"nowrap\">",
"     &lt;1500/microL)",
"    </span>",
"    is applicable for all ages and ethnic groups except newborn infants who have an elevated ANC for the first few days of life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] and certain populations (eg, African Americans, Yemenite Jews, Ethiopians, certain Arabs), who normally have slightly lower WBC and ANC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the 1999 to 2004 United States National Health and Nutritional Examination Survey (NHANES) indicated a prevalence of neutropenia for the following population groups [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Black participants &mdash; 4.5 percent",
"     </li>",
"     <li>",
"      White participants &mdash; 0.79 percent",
"     </li>",
"     <li>",
"      Mexican-American participants &mdash; 0.38 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This issue was also studied in a group of 261 healthy women of varying ethnicities recruited in New York City. The incidence of neutropenia (ANC &lt;1500) according to their country of origin was [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      United States Black &mdash; 10.5 percent",
"     </li>",
"     <li>",
"      Haiti &mdash; 8.2 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Barbados/Trinidad-Tobago",
"      </span>",
"      &mdash; 6.4 percent",
"     </li>",
"     <li>",
"      Jamaica &mdash; 2.7 percent",
"     </li>",
"     <li>",
"      Dominican Republic &mdash; zero percent",
"     </li>",
"     <li>",
"      United States or Europe White &mdash; zero percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Neutropenia in African Americans",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two reasons for a lower ANC in African Americans: those with an ANC below",
"    <span class=\"nowrap\">",
"     2000/microL",
"    </span>",
"    have defective granulocyte release from an otherwise normal bone marrow; the majority with ANC above",
"    <span class=\"nowrap\">",
"     2000/microL",
"    </span>",
"    have a compromised bone marrow reserve of PMNs as assessed by measuring the maximum ANC increment after the administration of hydrocortisone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/4\">",
"     4",
"    </a>",
"    ], or following endurance exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/9\">",
"     9",
"    </a>",
"    ]. However, bone marrow aspirates are normal and progenitor release is increased. Furthermore, there is no propensity to infections, indicating that the neutropenia is benign [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/4,10,11\">",
"     4,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases, neutropenia has been traced to a common West African allele, a single nucleotide polymorphisms in the Duffy",
"    <span class=\"nowrap\">",
"     antigen/receptor",
"    </span>",
"    chemokine gene (DARC), which acts as a receptor for certain pro-inflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Presence of this Duffy null state protects against malaria and has been shown to provide a survival advantage in leukopenic HIV-infected persons of African ancestry [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link&amp;anchor=H45#H45\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'Duffy blood group system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Benign familial (ethnic) neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Those patients with what has been called benign familial neutropenia or benign familial leukopenia may not generate a leukocytosis during infection but are otherwise normal; they generate a fever and tachycardia during infection similar to controls, do not have an increased incidence of infection, and do not have an increased risk for febrile neutropenia secondary to myelosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/5,6,10\">",
"     5,6,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given that benign familial neutropenia has been reported in several ethnic groups, including Yemenite Jews, Blacks of South African extraction, West Indians, and Arab Jordanians, this condition may not be distinct from that described above, and may best be termed \"benign ethnic neutropenia\" [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. The bone marrow reserves of these patients are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/4,10,11\">",
"     4,10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=see_link\">",
"     \"Normal neutrophil development and kinetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND ETIOLOGY OF ISOLATED NEUTROPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of isolated neutropenia can be classified by mechanism or by etiologic agent. Neutropenia results from four basic mechanisms: decreased production, ineffective granulopoiesis, shift of circulating PMNs to vascular endothelium or tissue pools, or enhanced peripheral destruction. Confirmation of one of these mechanisms requires leukokinetic studies employing bone marrow cultures, radionuclide tagging of blood PMNs, and other monitoring devices not readily available outside the research laboratory. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=see_link\">",
"     \"Normal neutrophil development and kinetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The classification of neutropenia according to marrow reserve status is useful when thinking about mechanism of neutropenia and propensity to infection. However, classification based on whether the neutropenia is acquired or congenital and grouped by known causes or associations provides a practical means to approach the differential diagnosis of these disorders in a clinical setting (",
"    <a class=\"graphic graphic_table graphicRef69186 \" href=\"UTD.htm?5/19/5437\">",
"     table 5",
"    </a>",
"    ). That said, there is great overlap in the disorders listed, which is why we favor a classification based on marrow reserve. There are several named disorders that lead to neutropenia with normal cellularity, late myeloid arrest, and little or no propensity to infection. These likely represent various interactions between subtle genetic differences and environmental factors. Apoptosis of marrow precursors is now recognized as a common mechanism for many acquired and congenital neutropenias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=see_link\">",
"     \"Normal neutrophil development and kinetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acquired neutropenias",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many acquired causes of neutropenia, with infection, drugs, and immune disorders being the most common. As with all neutropenias, the danger to the patient depends on the marrow status (",
"    <a class=\"graphic graphic_table graphicRef71724 \" href=\"UTD.htm?6/49/6941\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Postinfectious neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious neutropenias may represent the most common cause of acquired isolated neutropenia. A number of bacterial, viral, parasitic and rickettsial infections are responsible. In most instances, particularly with viral infections, the neutropenia is short-lived and rarely results in bacterial superinfection. Mechanisms include redistribution, sequestration and aggregation, and destruction by circulating antibodies. Hepatitis B virus, Epstein-Barr virus and human immunodeficiency virus can be associated with more severe and protracted neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10473?source=see_link\">",
"     \"Infectious causes of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Drug-induced neutropenia and agranulocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced neutropenia occurs as an adverse idiosyncratic reaction and is the second most common cause of neutropenia. The true incidence of drug-induced neutropenia is not known; the reported incidence of the rare, more severe, agranulocytosis ranges from approximately 1 to 10 cases per million population per year. The usual definition excludes known cytotoxic agents and requires that the drug have been administered within four weeks of the onset of neutropenia. The drugs with the highest risk of inducing severe neutropenia include clozapine, the thionamides (antithyroid drugs), and sulfasalazine&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef65507 \" href=\"UTD.htm?39/4/40013\">",
"     table 6",
"    </a>",
"    ). These drugs appear to cause neutropenia either by immune-mediated destruction of circulating neutrophils by drug-dependent or drug-induced antibodies or by direct toxic effects upon marrow granulocytic precursors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link\">",
"     \"Drug-induced neutropenia and agranulocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2412865\">",
"    <span class=\"h3\">",
"     Nutritional neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia and marrow failure can be seen with severe vitamin B12 deficiency, folate deficiency, and copper deficiency. B12 and folate deficiency, as well as inborn errors of B12 metabolism, are well known to be associated with neutropenia and anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      B12 and folate deficiency are best detected by measuring methylmalonic acid (MMA) and homocysteine (HcY). Both are elevated with B12 deficiency and HcY alone is elevated in folate deficiency. This is important because serum levels of B12 and folate can be normal in the face of deficiency as detected by MMA and HcY [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=see_link&amp;anchor=H5#H5\">",
"       \"Diagnosis and treatment of vitamin B12 and folate deficiency\", section on 'Laboratory evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Copper deficiency and subsequent low ceruloplasmin is a well-recognized cause of isolated neutropenia as well as pancytopenia. While not often thought of, it is not uncommon in children with short gut syndromes receiving parenteral nutrition, patients with malabsorption, and post-gastric bypass surgery. It can cause a marrow picture indistinguishable from myelodysplasia. Particularly in young children completely supported via parenteral nutrition, copper is often removed from the intravenous solution and not reintroduced, leading to deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/17-20\">",
"       17-20",
"      </a>",
"      ]. Critically ill patients who have prolonged hospitalizations should be screened for these deficiencies if they present with neutropenia, even if they are receiving parenteral nutrition. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of dietary trace minerals\", section on 'Copper'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6138?source=see_link&amp;anchor=H30#H30\">",
"       \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\", section on 'Copper deficiency'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Primary immune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antineutrophil antibodies mediate neutrophil destruction either by splenic sequestration of opsonized cells or by complement-mediated neutrophil lysis. Immune neutropenia can occur as a myeloid specific syndrome or in association with other cytopenias. Antineutrophil antibodies are involved in the pathophysiology of the neutropenia caused by some infections, drug exposure, and immune deficiencies. In addition, there are specific primary immune disorders characterized by neutropenia and antineutrophil antibody production.",
"   </p>",
"   <p>",
"    Assessment of immune neutropenias can be particularly problematic because the propensity to infection may be more related to the underlying immune disorder than to the neutropenia. Thus, while immune disorders may have antibody-mediated neutropenia, they may also be associated with vasculitis, leading to mucosal ulcers. We have seen the oral symptoms completely resolve with treatment of the underlying vasculitis with no change in the ANC, proving that the mucositis and the neutropenia are not related. Usually, immune neutropenias have normal marrow reserve (",
"    <a class=\"graphic graphic_table graphicRef71724 \" href=\"UTD.htm?6/49/6941\">",
"     table 4",
"    </a>",
"    ). These disorders are discussed in detail elsewhere and will only be summarized here (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link\">",
"     \"Immune neutropenia\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Isoimmune neonatal neutropenia",
"      </strong>",
"      &mdash; Moderate to severe neutropenia can occur in newborn infants secondary to transplacental passage of IgG antibodies directed against neutrophil specific antigens inherited from the father of the infant. The pathogenesis of this disorder is identical to that of Rh hemolytic disease. The neutropenia is usually noted in an otherwise normal infant and these patients typically do well.",
"     </li>",
"     <li>",
"      <strong>",
"       Chronic autoimmune neutropenia",
"      </strong>",
"      &mdash; Autoimmune neutropenia occurs primarily in infants and children under age four and is also called chronic benign neutropenia of infancy and childhood. Most patients present with recurrent infections. Specific treatment of neutropenia is not required. Many patients remain free of infections and maintain a normal lifestyle with no or minimal medical intervention. Spontaneous remission with disappearance of autoantibodies is common.",
"     </li>",
"     <li>",
"      <strong>",
"       Chronic idiopathic neutropenia",
"      </strong>",
"      &mdash; The term chronic idiopathic neutropenia, also known as benign chronic neutropenia, is used to describe chronic neutropenia for which there is no obvious cause. In contrast to autoimmune neutropenia, which is primarily a disease of infants and young children, chronic idiopathic neutropenia tends to occur in late childhood or adulthood and does not undergo spontaneous remission. Serologic abnormalities and evidence of antibody production have been found in 30 to 40 percent. These patients most often have a benign course despite the degree of neutropenia. The presence of normal marrow reserve may explain the lack of significant infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link&amp;anchor=H9#H9\">",
"       \"Immune neutropenia\", section on 'Chronic idiopathic neutropenia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pure white cell aplasia",
"      </strong>",
"      &mdash; Pure white cell aplasia is a rare disorder characterized by complete disappearance of granulocytopoietic tissue from the bone marrow. It is often associated with thymoma and is due to the presence of antibody mediated GM-CFU inhibitory activity. Such individuals have no marrow reserve and are at risk for infection because of the neutropenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link&amp;anchor=H12#H12\">",
"       \"Immune neutropenia\", section on 'Pure white cell aplasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other autoimmune disorders",
"      </strong>",
"      &mdash; Other immune disorders that are associated with neutropenia include T-gamma lymphocytosis (large granular lymphocyte syndrome) and Felty's syndrome. In the former disorder, there is infiltration of the bone marrow with large granular lymphocytes (LGL), most often due to a clonal expansion of cytotoxic T-cells and often associated with rheumatoid arthritis. LGL disease has markedly decreased marrow reserve as well as autoimmune vasculitic components. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=see_link\">",
"       \"Large granular lymphocyte leukemia in rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=see_link\">",
"       \"Treatment of large granular lymphocyte leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Complement activation",
"      </strong>",
"      &mdash; The exposure of blood to artificial membranes, as in dialysis and extracorporeal membrane oxygenation, may result in complement activation in vivo. The complement is typically produced by the classic complement activation pathway and induces neutrophil aggregation and adherence to endothelial surfaces, often in the lung. Neutropenia and cardiopulmonary symptoms typically occur shortly after exposure to the membrane. This complication can be prevented during hemodialysis by using biocompatible membranes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=see_link\">",
"       \"Reactions to the hemodialysis membrane\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hypersplenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enlargement of the spleen from any etiology can result in neutropenia, due to splenic trapping [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/21\">",
"     21",
"    </a>",
"    ]. The severity of neutropenia is related to the size of the spleen and rarely is sufficient to result in severe infection. Anecdotal information is available indicating the ability of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to improve absolute neutrophil counts in patients with severe hypersplenism-associated neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, this treatment is not indicated in this situation and has been associated with splenic enlargement and rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Bone marrow disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of diseases affecting the bone marrow are associated with neutropenia (",
"    <a class=\"graphic graphic_table graphicRef69186 \" href=\"UTD.htm?5/19/5437\">",
"     table 5",
"    </a>",
"    ). In most cases, such as aplastic anemia, the leukemias, myelodysplasia, and postchemotherapy, the neutropenia is not an isolated defect, and is associated with varying degrees of anemia and thrombocytopenia. Examination of the peripheral smear and a bone marrow aspirate with biopsy are indicated when more than one cell line is involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Congenital neutropenias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare primary neutropenias occur and, when associated with severe recurrent infections as in the severe congenital neutropenias, can be treated successfully with hematopoietic growth factors. These syndromes include severe infantile agranulocytosis, myelokathexis, Shwachman-Diamond-Oski syndrome, Chediak-Higashi syndrome, and reticular dysgenesis. The diagnosis is made by examination of the bone marrow, which reveals myeloid hypoplasia. Congenital neutropenia can also be seen with certain inborn errors of metabolism such as glycogen storage disease and with some of the primary immune deficiency states. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33400?source=see_link\">",
"     \"Shwachman-Diamond syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cyclic neutropenia is characterized by recurrent mouth infections and regular oscillations in the numbers of blood neutrophils, monocytes, eosinophils, lymphocytes and reticulocytes at approximately 21-day intervals. It usually presents in childhood, as a familial syndrome, but there is a subset of patients with onset in adulthood. Treatment is largely supportive and G-CSF has been effective in preventing infection and reducing symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=see_link\">",
"     \"Cyclic neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Myeloperoxidase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many clinical laboratories, neutrophils are identified on the white blood cell differential by virtue of their positivity for myeloperoxidase. Patients with myeloperoxidase deficiency may then be erroneously considered as having severe neutropenia. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14280?source=see_link&amp;anchor=H2#H2\">",
"     \"Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency\", section on 'Myeloperoxidase deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=see_link&amp;anchor=H28#H28\">",
"     \"Automated hematology instrumentation\", section on 'Siemens Advia (and H series)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent infections are the only significant consequence of neutropenia. However, the classic signs of infection may be less evident in patients with neutropenia. This is particularly true in patients with bone marrow hypoplasia who are unable to respond to infection. In this setting, radiographs may not demonstrate pneumonia, or the patient may not exhibit abnormal tenderness with an early ruptured viscus.",
"   </p>",
"   <p>",
"    The propensity to infection in neutropenic patients has been discussed and is related to the degree of neutropenia (",
"    <a class=\"graphic graphic_table graphicRef63903 \" href=\"UTD.htm?10/19/10555\">",
"     table 2",
"    </a>",
"    ) and the cause of the neutropenia (",
"    <a class=\"graphic graphic_table graphicRef71724 \" href=\"UTD.htm?6/49/6941\">",
"     table 4",
"    </a>",
"    ). Common sites of infection include the oral cavity and mucous membranes, the skin, and, with severe, persistent neutropenia, systemic infections of the lungs and bloodstream may occur. Endogenous bacterial flora are the most common pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Risk of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a classic study in patients with leukemia published in 1966, which applies to neutropenia with decreased marrow reserve, the relationship between the frequency of infection and both the severity and duration of neutropenia was evaluated during 733 episodes of moderate neutropenia (ANC less than",
"    <span class=\"nowrap\">",
"     1000/microL)",
"    </span>",
"    and 125 episodes of severe neutropenia (ANC less than",
"    <span class=\"nowrap\">",
"     100/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/25\">",
"     25",
"    </a>",
"    ]. Identified infections occurred in 80 percent of patients with severe neutropenia within two weeks of onset and in 100 percent at three weeks.",
"   </p>",
"   <p>",
"    These relationships can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with an ANC",
"      <span class=\"nowrap\">",
"       &lt;500/microL",
"      </span>",
"      due to chemotherapy, marrow failure, or marrow exhaustion are at high risk for overwhelming bacterial infection [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]. This is particularly true in cancer patients with an ANC",
"      <span class=\"nowrap\">",
"       &lt;100/microL",
"      </span>",
"      for more than five days [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/28\">",
"       28",
"      </a>",
"      ]. The source of microbial invasion of the blood is chemotherapy-induced mucositis and breaks in the gastrointestinal lining.",
"     </li>",
"     <li>",
"      Efforts have been made to identify febrile neutropenic patients with a lower risk of bacteremia. In one pediatric study of 161 patients experiencing 509 episodes of fever and neutropenia, presentation with chills or hypotension, the requirement for fluid resuscitation, or the diagnosis of leukemia or lymphoma were associated with a higher probability of positive blood cultures [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/29\">",
"       29",
"      </a>",
"      ]. Children without initial signs of sepsis whose fever resolved on antibiotic therapy and whose ANC was",
"      <span class=\"nowrap\">",
"       &ge;100/microL",
"      </span>",
"      after a 48-hour period in hospital had a low risk of complications.",
"     </li>",
"     <li>",
"      The risk is lower in patients with AIDS who may develop neutropenia in whom drug toxicity or autoimmunity may be responsible for the neutropenia. The risk for bacterial infection becomes significant when the ANC is less than 750 to",
"      <span class=\"nowrap\">",
"       1000/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. In one series of 2047 HIV-infected patients, the risk for developing a bacterial infection requiring hospitalization occurred at ANCs below",
"      <span class=\"nowrap\">",
"       750/microL",
"      </span>",
"      and increased progressively as the ANC fell below this level (",
"      <a class=\"graphic graphic_figure graphicRef61584 \" href=\"UTD.htm?34/18/35117\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10473?source=see_link&amp;anchor=H13#H13\">",
"       \"Infectious causes of neutropenia\", section on 'Human immunodeficiency virus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with the benign chronic neutropenia may have an ANC below",
"      <span class=\"nowrap\">",
"       200/microL",
"      </span>",
"      for months or years and remain free of serious infections [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/32\">",
"       32",
"      </a>",
"      ]. Similarly, some adults with immune neutropenia have severe depression of the ANC but never suffer episodes of infection [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/33\">",
"       33",
"      </a>",
"      ]. In both situations, the bone marrow generally shows normal granulocyte maturation up to either the metamyelocyte or band form stage with a paucity of PMNs. This bone marrow picture is referred to as a \"maturational arrest\".",
"     </li>",
"     <li>",
"      Well-appearing children with transient neutropenia, particularly of short duration, are also at low risk for infection. In one study of 119 children, infectious complications occurred in 4 of the 36 patients who had neutropenia for more than 30 days (two with stomatitis, one with cellulitis, and one with pneumonia) but in none with a shorter duration of neutropenia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to differences in bone marrow reserve, several other factors may contribute to the variability in infectious risk. Many patients with chronic forms of neutropenia have normal or increased blood monocyte counts. Monocytes are functioning phagocytes such as the neutrophil and band forms and probably contribute to the lack of correlation between the ANC and infection risk [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Neutropenia related to underlying immunodeficiency may have normal marrow reserve yet increased risk because of inability to make protective antibodies or mucosal barrier damage secondary to vasculitis.",
"   </p>",
"   <p>",
"    Another difference is that the delivery of neutrophils to tissues in chronic severe neutropenia appears to be greater than in acute chemotherapy-induced neutropenia of equal degree [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/28,37\">",
"     28,37",
"    </a>",
"    ]. Furthermore, recovery of neutrophils is evident at tissue sites before the blood [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/37\">",
"     37",
"    </a>",
"    ]. These observations indicate that the ANC does not always accurately reflect neutrophil availability at tissue or organ sites of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Specific pathogens associated with neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific pathogens isolated from infected neutropenic patients are almost exclusively pyogenic or enteric bacteria or certain fungi (eg, Candida species). They are usually endogenous bacteria including Staphylococcus aureus from the skin and Gram-negative organisms from the gastrointestinal and urinary tract. Isolated neutropenia does not increase the susceptibility to viral or parasitic infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\", section on 'Immunocompromised patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common sites of infection include the oral cavity and mucous membranes, the skin, and perirectal and genital areas. With persistent severe neutropenia, systemic infection occurs associated with bacteremia, and infections of the lung and gastrointestinal tract. Patients receiving broad spectrum antibiotics for two weeks or more while neutropenic are more prone to infection with enteric bacteria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fungi, while patients with indwelling catheters or other foreign bodies are more likely to become infected with coagulase-negative staphylococci.",
"   </p>",
"   <p>",
"    One study evaluated the distribution of organisms for 909 episodes of bacteremia and associated outcome among 799 neutropenic febrile cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/28\">",
"     28",
"    </a>",
"    ]. Among the bacteremic episodes, 46 percent were due to Gram-positive organisms, 42 percent to Gram-negative organisms, and 12 percent were polymicrobial. Infection at a site other than blood alone was observed in 242 episodes; the sites of involvement included lung (about 40 percent), skin and soft tissue (about 30 percent), urinary tract, sinuses and oropharynx, skeletal, enteric tract, meninges, and endocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/28\">",
"     28",
"    </a>",
"    ]. In general, the initial and ultimate response rates were good when the infection was due to a single type of organism and less favorable when the infection was due to more than one type of microbe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the approach to the patient with neutropenia is confirmation of the diagnosis. Review of a Wright&mdash;Giemsa stained peripheral blood smear will confirm the reduced number of neutrophils. In all cases in which the white blood cell differential count has been generated by automatic counters, it should be repeated manually. Pseudoneutropenia can occur if blood is left standing for a prolonged period of time and in the presence of paraproteinemia and certain anticoagulants that can cause cellular clumping.",
"   </p>",
"   <p>",
"    Because most acquired cases of neutropenia are transient, monitoring of the blood counts for 8 to 12 weeks is often the best approach if there are no other important clinical factors present. An approach for following such patients is shown in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef66041 \" href=\"UTD.htm?31/49/32543\">",
"     algorithm 1",
"    </a>",
"    ). This algorithm works for patients of all ages, including adults. For isolated mild or severe neutropenia in the absence any abnormal clinical findings, obtaining serial blood counts at increasing intervals is the most reasonable approach. We recommend monitoring the sedimentation rate as well. Elevation of the sedimentation rate in the absence of other findings in a neutropenic patient can indicate deep-seated inflammation and may indicate a more serious type of neutropenia. According to this schema, if the patient develops clinical symptoms related to neutropenia or changes in other cell lines in the blood count, a full evaluation should be undertaken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Infants and young children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of neutropenia in infants and young children includes isoimmune neonatal neutropenia, autoimmune neutropenia, severe congenital neutropenia (SCN), Shwachman Diamond-Oski syndrome, and cyclic neutropenia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient mild to moderate neutropenia can be caused by a variety of common viral infections during childhood, including respiratory syncytial virus (RSV), influenza A and B, parvovirus, Epstein-Barr virus (EBV), and human herpes virus 6 (HHV6). In most cases, neutropenia occurs during the first few days of the viral illness and persists for three to eight days [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Postinfectious neutropenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isoimmune neutropenia occurs only in newborns and presents as moderate to severe neutropenia. The disorder is due to antineutrophil antibodies transferred from the mother. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link\">",
"       \"Immune neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autoimmune neutropenia (&ldquo;benign neutropenia&rdquo;) is not associated with recurrent severe infections and typically occurs between the ages 5 to 15 months, although the range extends from one month to adulthood. Although unusual, a small number of patients with autoimmune neutropenia present with features characteristic of SCN and the differential diagnosis is ultimately made by bone marrow aspiration and genetic studies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link\">",
"       \"Immune neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe congenital neutropenia (SCN) is very rare and characterized by severe infections in the first month of life, the absence of spontaneous remissions, and maturation arrest of myelopoiesis at the promyelocyte stage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"       \"Congenital neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Shwachman Diamond-Oski syndrome is very rare and is characterized by pancreatic insufficiency, metaphyseal dysostosis, neutropenia with or without thrombocytopenia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"       \"Congenital neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cyclic neutropenia is very rare and classically occurs as neutropenic periods of three to six days approximately every 21 days. The diagnosis is made by monitoring the ANC three times per week for six to eight weeks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=see_link\">",
"       \"Cyclic neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Children or adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;If anemia, particularly normocytic or macrocytic anemia, or thrombocytopenia is found in the child or adult with neutropenia, hematological consultation should be requested immediately and examination of the peripheral smear along with a bone marrow aspiration should be performed unless the cause is clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Neutropenia in the absence of recurrent or protracted infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most causes of neutropenia are benign, especially if the ANC is above",
"    <span class=\"nowrap\">",
"     800/microL.",
"    </span>",
"    Thus, a period of observation is indicated if the patient is asymptomatic and there are no other significant clinical features, particularly if there is a recent history of viral infection or a medication has been taken that is known to be associated with neutropenia (",
"    <a class=\"graphic graphic_table graphicRef69186 \" href=\"UTD.htm?5/19/5437\">",
"     table 5",
"    </a>",
"    ). Examination of the oral cavity is important, since the presence of gingivitis or tooth abscess suggests the presence of symptomatic neutropenia (",
"    <a class=\"graphic graphic_algorithm graphicRef66041 \" href=\"UTD.htm?31/49/32543\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If the neutropenia resolves, the patient should be followed for one year with complete blood count being obtained whenever fever occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Moderate to severe neutropenia with recurrent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow aspiration with evaluation of cellularity and morphology should permit identification of late myeloid arrest or myeloid hypoplasia. Late arrest is seen in idiopathic or autoimmune neutropenia, most often associated with antineutrophil antibodies, and in collagen vascular diseases, some drug-induced neutropenias, and chronic infection. Myeloid hypoplasia characterizes toxic drug-induced neutropenias, pure white cell aplasia, T-gamma lymphocytosis (large granular lymphocyte syndrome), severe congenital neutropenia, and myelodysplastic syndrome.",
"   </p>",
"   <p>",
"    The diagnostic evaluation of isolated neutropenia is listed in the table (",
"    <a class=\"graphic graphic_table graphicRef51687 \" href=\"UTD.htm?41/55/42875\">",
"     table 7",
"    </a>",
"    ). While bone marrow aspiration is often thought of as the first step, we prefer to delay this test unless there is a clear indication to do it immediately. It is only diagnostic in the case of the progranulocyte maturation arrest seen in the rare case of Kostmann syndrome or marrow infiltration. Most other disorders require other confirmatory testing. Thus, we prefer to do tests for collagen vascular disease and nutritional disorders first, prior to marrow examination.",
"   </p>",
"   <p>",
"    Patients who have episodic infections should have twice weekly measurement of the ANC for at least six weeks to confirm the diagnosis of cyclic neutropenia. Patients with cyclic neutropenia have decreased marrow cellularity one week before the nadir of their neutropenia. This is a rare syndrome and usually associated with symptoms every 21 days and should not be considered unless there is good clinical reason or family history. Bone marrow aspiration is not helpful in this disorder; tests for the ELANE gene are positive over 90 percent of the time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=see_link\">",
"     \"Cyclic neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted in the table (",
"    <a class=\"graphic graphic_table graphicRef51687 \" href=\"UTD.htm?41/55/42875\">",
"     table 7",
"    </a>",
"    ), the following laboratory studies may be indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antinuclear antibodies and complement to screen for collagen vascular disease",
"     </li>",
"     <li>",
"      Antineutrophil antibodies to screen for immune neutropenia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=see_link\">",
"       \"Laboratory evaluation of neutropenia and neutrophil dysfunction\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Immunoglobulins and immune evaluation to screen for defects of cellular or humoral immunity (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"       \"Laboratory evaluation of the immune system\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Screen for HIV infection (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"       \"Diagnostic assays for HIV infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Methylmalonic acid and homocysteine levels to assess vitamin B12 and folate status (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=see_link\">",
"       \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Serum copper and ceruloplasmin levels to assess for copper deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     GENERAL ASPECTS OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical management of neutropenic states depends upon the cause and degree of the neutropenia, as well as the presence of associated disease states. Patients with severe neutropenia and little marrow reserve may have sepsis, while patients with hypercellular marrow tend to have chronic infections or no infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link\">",
"     \"Fever in children with chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link&amp;anchor=H736498253#H736498253\">",
"     \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients with chronic neutropenia with decreased marrow reserve should receive regular dental care. Chronic gingivitis and recurrent stomatitis can be major sources of morbidity. Antibiotic mouthwashes, such as Peridex, can be used to decrease gingivitis. Prophylactic antibiotics are of no value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Patients with bone marrow hypoplasia and/or severe infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;This group includes patients with chemotherapy-induced neutropenia or bone marrow granulocyte hypoplasia. There are multiple causes of the latter problem, such as aplastic anemia, severe congenital neutropenia, Shwachman Diamond-Oski syndrome, pure white cell aplasia, large granulocyte lymphocyte syndrome, and drug-induced (toxic-form) agranulocytosis. The general approach involves preventive measures to limit the number and severity of infections and aggressive treatment of infections that occur. Patients should also receive aggressive antibacterial therapy for fever, even in the absence of signs of infection.",
"   </p>",
"   <p>",
"    G-CSF should be given to patients with decreased marrow reserve and an inadequate response to antibiotics. Treatment with G-CSF is indicated in most cases of severe congenital neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The organisms that cause infections in patients with severe neutropenia usually come from the gastrointestinal tract or skin and can result in the rapid onset of overwhelming sepsis. Thus, febrile patients with neutropenia related to marrow suppression should be treated immediately, following culture of body fluids, with broad-spectrum parenteral antibiotics for coverage of both Gram-positive and Gram-negative bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, patients with an ANC",
"    <span class=\"nowrap\">",
"     &gt;1000/microL",
"    </span>",
"    can be managed on an outpatient basis while those with an ANC of",
"    <span class=\"nowrap\">",
"     &lt;500/microL",
"    </span>",
"    and marrow aplasia may require inpatient treatment with parenteral antibiotics (",
"    <a class=\"graphic graphic_table graphicRef63903 \" href=\"UTD.htm?10/19/10555\">",
"     table 2",
"    </a>",
"    ). Routine reverse isolation procedures are of no benefit and serve to decrease contact with medical personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When a patient first presents with high fever and has a very low ANC, one must assume that the patient is high risk and has inadequate marrow reserve. The schema in the algorithm is an accepted approach to such patients (",
"    <a class=\"graphic graphic_algorithm graphicRef81789 \" href=\"UTD.htm?16/11/16575\">",
"     algorithm 2",
"    </a>",
"    ). Specific antibiotic regimens for such patients can be found elsewhere in UpToDate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link\">",
"     \"Fever in children with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is now recognized that even in post-chemotherapy patients, outpatient management of fever may be acceptable under certain limited circumstances. If there is any question, the patient should be admitted for observation and treatment.",
"   </p>",
"   <p>",
"    If the patient is",
"    <strong>",
"     known",
"    </strong>",
"    to be in a low risk group (",
"    <a class=\"graphic graphic_table graphicRef71724 \" href=\"UTD.htm?6/49/6941\">",
"     table 4",
"    </a>",
"    ),",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    can be managed as any other patient. Unlike the &ldquo;low risk&rdquo; group as defined for oncology patients, these patients may not require any antibiotics at all. &ldquo;Low risk&rdquo; febrile oncology patients by definition have decreased marrow reserve and therefore are excluded from our low risk group. Otherwise, the oncology risk classification and treatment approaches are useful for non-oncological neutropenia cases as well [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring of the C-reactive protein level and sedimentation rate daily or every other day can be very helpful in these patients, particularly in patients with established severe chronic neutropenia. Often, cultures are negative and treatment is purely empiric. A rapid response can indicate that the appropriate antibiotics have been selected, and poor response or increase in ESR after a response can indicate that a change in antibiotics is necessary.",
"   </p>",
"   <p>",
"    Antibiotics should be continued for several days after the fever has subsided and the sedimentation rate has normalized. If the ANC has risen above",
"    <span class=\"nowrap\">",
"     500/microL",
"    </span>",
"    on several measures, the antibiotics may be discontinued as long as no source of infection is apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/38\">",
"     38",
"    </a>",
"    ]. If fever persists or there is no clear response to treatment, other therapies should be considered.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If fever and neutropenia persist beyond seven days in the immunosuppressed patient, antifungal treatment should be considered. This approach has support in post-chemotherapy patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/38\">",
"       38",
"      </a>",
"      ]; however, it should not be used in patients with benign forms of neutropenia.",
"     </li>",
"     <li>",
"      Granulocyte transfusions have been given, if available, to patients with Gram-negative sepsis who have not shown a clinical response to antibiotics within 24 to 48 hours. Enthusiasm for the use of granulocyte transfusions has waned due in part to difficulties in procurement, to better antibiotics, and to the use of bone marrow growth factors. However, better methods of procurement and their rapid efficacy makes them a useful part of the armamentarium for treating neutropenic patients with sepsis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4393?source=see_link\">",
"       \"Granulocyte transfusions\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Myeloid growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of recombinant granulocyte colony-stimulating factor (G-CSF, filgrastim) can correct the neutropenia and reduce infectious morbidity in infected patients with a variety of causes of severe neutropenia. Included in this group are severe congenital neutropenia, cyclic neutropenia, and AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/42-49\">",
"     42-49",
"    </a>",
"    ]. GM-CSF has also been used successfully in neutropenic patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/48\">",
"     48",
"    </a>",
"    ] but appears to be less effective than G-CSF in patients with cyclic neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential efficacy of the appropriate use of G-CSF can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter, phase III trial randomized 123 patients with severe chronic neutropenia and recurrent infection to either immediate treatment with filgrastim (3.45 to 11.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per day) or a four-month observation period followed by filgrastim treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/43\">",
"       43",
"      </a>",
"      ]. On treatment, 108 patients had a median ANC greater than or equal to",
"      <span class=\"nowrap\">",
"       1500/microL",
"      </span>",
"      and bone marrow aspirates showed increased proportions of maturing neutrophils. Filgrastim therapy was associated with a reduction in the incidence and duration of infection-related events of approximately 50 percent.",
"     </li>",
"     <li>",
"      Another multicenter trial randomized 258 HIV-infected patients with a CD4 cell count below",
"      <span class=\"nowrap\">",
"       200/microL",
"      </span>",
"      and an ANC between 750 and",
"      <span class=\"nowrap\">",
"       1000/microL",
"      </span>",
"      to placebo or increasing doses of daily or intermittent filgrastim to maintain an ANC between 2000 and",
"      <span class=\"nowrap\">",
"       10,000/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/47\">",
"       47",
"      </a>",
"      ]. The incidence of severe neutropenia or death was much lower in the treated patients (10 versus 34 percent) who also had 31 percent fewer bacterial infections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, G-CSF therapy is not indicated for all causes of neutropenia. It is helpful in patients with neutropenia associated with early myeloid arrest and its use should be reserved for patients with demonstrated infectious morbidity related to the neutropenia. The literature is misleading with respect to the use of G-CSF in neutropenias, as there are a number of reports of patients even with benign neutropenia who were given G-CSF and recovered, when in fact they may have recovered spontaneously despite this treatment.",
"   </p>",
"   <p>",
"    A more complete discussion of the use of G-CSF in patients with chemotherapy-induced neutropenia (eg, use as primary or secondary prophylaxis, neutropenia without fever, neutropenic fever) is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Chemotherapy-induced neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link\">",
"     \"Fever in children with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation has been used successfully in certain instances of severe neutropenia, such as infantile agranulocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/50\">",
"     50",
"    </a>",
"    ]. It should be considered if an appropriate donor is available and no therapeutic response is achieved with G-CSF or GM-CSF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Patients with adequate marrow reserves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with late marrow arrests and a normocellular marrow have an adequate bone marrow supply of neutrophils and usually handle infections reasonably well. Children in whom the diagnosis of chronic benign neutropenia of infancy has been confirmed can be treated as normal children. Less aggressive therapy is also warranted in adults with an adequate bone marrow reserve and a several month history of severe neutropenia without serious infection. However, the subsequent course is not known when these patients are first encountered. As a result, they should initially be treated as other patients with severe forms of neutropenia.",
"   </p>",
"   <p>",
"    Long-term follow-up of patients with severe combined neutropenia and Shwachman-Diamond-Oski syndrome receiving G-CSF has indicated a 25 to 36 percent cumulative incidence of acute myeloid leukemia or myelodysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/47/18170/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. It is unclear whether G-CSF is a risk factor, since patients with both disorders have developed",
"    <span class=\"nowrap\">",
"     AML/MDS",
"    </span>",
"    prior to the use of G-CSF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link&amp;anchor=H12#H12\">",
"     \"Congenital neutropenia\", section on 'G-CSF receptor mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/59/25521?source=see_link\">",
"       \"Patient information: Neutropenia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22394841\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Definition",
"      </strong>",
"      &mdash; An absolute neutrophil count (ANC)",
"      <span class=\"nowrap\">",
"       &lt;1500/microL",
"      </span>",
"      defines neutropenia (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) for all ages and ethnic groups except newborn infants who have a transiently elevated ANC, and certain populations (eg, African Americans, Yemenite Jews, Ethiopians, certain Arabs), who normally have a slightly lower ANC. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Effect of race and ethnic origin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Overview",
"      </strong>",
"      &mdash; A peripheral blood white blood cell count (WBC) samples the smallest compartment of neutrophils and does not accurately reflect the body&rsquo;s capacity to deliver neutrophils to tissues and protect against bacterial infection. Examination of the bone marrow, which contains most of the body&rsquo;s neutrophils, can determine this most effectively. (See",
"      <a class=\"local\" href=\"#H2412651\">",
"       'Propensity to infection and significance of neutropenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Etiology",
"      </strong>",
"      &mdash; Neutropenia can be either acquired or congenital (",
"      <a class=\"graphic graphic_table graphicRef69186 \" href=\"UTD.htm?5/19/5437\">",
"       table 5",
"      </a>",
"      ). Infection, drugs, and immune disorders are the most common acquired causes while congenital causes are rare and confined mostly to infants and children. The danger to the patient depends on the etiology, bone marrow status (",
"      <a class=\"graphic graphic_table graphicRef71724 \" href=\"UTD.htm?6/49/6941\">",
"       table 4",
"      </a>",
"      ), and the ANC (",
"      <a class=\"graphic graphic_table graphicRef63903 \" href=\"UTD.htm?10/19/10555\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Classification and etiology of isolated neutropenia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Clinical Presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Diagnosis and management",
"      </strong>",
"      &mdash; The approach to the subject with isolated neutropenia is shown in the algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef66041 \" href=\"UTD.htm?31/49/32543\">",
"       algorithm 1",
"      </a>",
"      ). Management includes the prevention of infection, regular dental care, use of antibiotic mouthwashes, aggressive antibacterial therapy for fever, and the judicious use of myeloid growth factors in selected patients. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnostic approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'General aspects of treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/1\">",
"      Segel GB, Halterman JS. Neutropenia in pediatric practice. Pediatr Rev 2008; 29:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/2\">",
"      Manroe BL, Weinberg AG, Rosenfeld CR, Browne R. The neonatal blood count in health and disease. I. Reference values for neutrophilic cells. J Pediatr 1979; 95:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/3\">",
"      Xanthou M. Leucocyte blood picture in healthy full-term and premature babies during neonatal period. Arch Dis Child 1970; 45:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/4\">",
"      Mason BA, Lessin L, Schechter GP. Marrow granulocyte reserves in black Americans. Hydrocortisone-induced granulocytosis in the \"benign\" neutropenia of the black. Am J Med 1979; 67:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/5\">",
"      Shoenfeld Y, Alkan ML, Asaly A, et al. Benign familial leukopenia and neutropenia in different ethnic groups. Eur J Haematol 1988; 41:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/6\">",
"      Shoenfeld Y, Ben-Tal O, Berliner S, Pinkhas J. The outcome of bacterial infection in subjects with benign familial leukopenia (BFL). Biomed Pharmacother 1985; 39:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/7\">",
"      Hsieh MM, Everhart JE, Byrd-Holt DD, et al. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med 2007; 146:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/8\">",
"      Grann VR, Bowman N, Joseph C, et al. Neutropenia in 6 ethnic groups from the Caribbean and the U.S. Cancer 2008; 113:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/9\">",
"      Bain BJ, Phillips D, Thomson K, et al. Investigation of the effect of marathon running on leucocyte counts of subjects of different ethnic origins: relevance to the aetiology of ethnic neutropenia. Br J Haematol 2000; 108:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/10\">",
"      Hsieh MM, Tisdale JF, Rodgers GP, et al. Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy? J Clin Oncol 2010; 28:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/11\">",
"      Mintz U, Sachs L. Normal granulocyte colony-forming cells in the bone marrow of Yemenite Jews with genetic neutropenia. Blood 1973; 41:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/12\">",
"      Nalls MA, Wilson JG, Patterson NJ, et al. Admixture mapping of white cell count: genetic locus responsible for lower white blood cell count in the Health ABC and Jackson Heart studies. Am J Hum Genet 2008; 82:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/13\">",
"      Grann VR, Ziv E, Joseph CK, et al. Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean. Br J Haematol 2008; 143:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/14\">",
"      Kulkarni H, Marconi VC, He W, et al. The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry. Blood 2009; 114:2783.",
"     </a>",
"    </li>",
"    <li>",
"     Manoli I, Venditti CP. Methylmalonic acidemia. In: GeneReviews, Pagon RA, Bird RD, Dolan CR, Stephens K.  (Eds), Seattle 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/16\">",
"      Carmel R. How I treat cobalamin (vitamin B12) deficiency. Blood 2008; 112:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/17\">",
"      Jabbour N, DiGiuseppe JA, Usmani S, Tannenbaum S. Copper deficiency as a cause of reversible anemia and neutropenia. Conn Med 2010; 74:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/18\">",
"      Halfdanarson TR, Kumar N, Hogan WJ, Murray JA. Copper deficiency in celiac disease. J Clin Gastroenterol 2009; 43:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/19\">",
"      Griffith DP, Liff DA, Ziegler TR, et al. Acquired copper deficiency: a potentially serious and preventable complication following gastric bypass surgery. Obesity (Silver Spring) 2009; 17:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/20\">",
"      Haddad AS, Subbiah V, Lichtin AE, et al. Hypocupremia and bone marrow failure. Haematologica 2008; 93:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/21\">",
"      Schaffner A, Fehr J. Granulocyte demargination by epinephrine in evaluation of hypersplenic states. Scand J Haematol 1981; 27:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/22\">",
"      Gurakar A, Fagiuoli S, Gavaler JS, et al. The use of granulocyte-macrophage colony-stimulating factor to enhance hematologic parameters of patients with cirrhosis and hypersplenism. J Hepatol 1994; 21:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/23\">",
"      Ishizone S, Makuuchi M, Kawasaki S, et al. Effect of granulocyte colony-stimulating factor on neutropenia in liver transplant recipients with hypersplenism. J Pediatr Surg 1994; 29:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/24\">",
"      Tigue CC, McKoy JM, Evens AM, et al. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007; 40:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/25\">",
"      Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/26\">",
"      Brown AE. Neutropenia, fever, and infection. Am J Med 1984; 76:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/27\">",
"      Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986; 80:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/28\">",
"      Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/29\">",
"      Lucas KG, Brown AE, Armstrong D, et al. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996; 77:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/30\">",
"      Jacobson MA, Liu RC, Davies D, Cohen PT. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection. Arch Intern Med 1997; 157:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/31\">",
"      Moore RD, Keruly JC, Chaisson RE. Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arch Intern Med 1995; 155:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/32\">",
"      Lalezari P, Khorshidi M, Petrosova M. Autoimmune neutropenia of infancy. J Pediatr 1986; 109:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/33\">",
"      Logue GL, Shimm DS. Autoimmune granulocytopenia. Annu Rev Med 1980; 31:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/34\">",
"      Alario AJ, O'Shea JS. Risk of infectious complications in well-appearing children with transient neutropenia. Am J Dis Child 1989; 143:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/35\">",
"      Kyle RA. Natural history of chronic idiopathic neutropenia. N Engl J Med 1980; 302:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/36\">",
"      Dale DC, Guerry D 4th, Wewerka JR, et al. Chronic neutropenia. Medicine (Baltimore) 1979; 58:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/37\">",
"      Wright DG, Meierovics AI, Foxley JM. Assessing the delivery of neutrophils to tissues in neutropenia. Blood 1986; 67:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/38\">",
"      Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997; 25:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/39\">",
"      Gurwith M, Brunton JL, Lank B, et al. Granulocytopenia in hospitalized patients. II. A prospective comparison of two antibiotic regimens in the empiric therapy of febrile patients. Am J Med 1978; 64:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/40\">",
"      Single protective isolation in patients with granulocytopenia. N Engl J Med 1981; 304:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/41\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/42\">",
"      Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/43\">",
"      Roe TF, Coates TD, Thomas DW, et al. Brief report: treatment of chronic inflammatory bowel disease in glycogen storage disease type Ib with colony-stimulating factors. N Engl J Med 1992; 326:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/44\">",
"      Bonilla MA, Dale D, Zeidler C, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol 1994; 88:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/45\">",
"      Hammond WP 4th, Price TH, Souza LM, Dale DC. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med 1989; 320:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/46\">",
"      Wright DG, Kenney RF, Oette DH, et al. Contrasting effects of recombinant human granulocyte-macrophage colony-stimulating factor (CSF) and granulocyte CSF treatment on the cycling of blood elements in childhood-onset cyclic neutropenia. Blood 1994; 84:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/47\">",
"      Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS 1998; 12:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/48\">",
"      Manfredi R, Mastroianni A, Coronado O, Chiodo F. Recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in leukopenic patients with advanced HIV disease. J Chemother 1996; 8:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/49\">",
"      Lehrnbecher T, Welte K. Haematopoietic growth factors in children with neutropenia. Br J Haematol 2002; 116:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/50\">",
"      Rappeport JM, Parkman R, Newburger P, et al. Correction of infantile agranulocytosis (Kostmann's syndrome) by allogeneic bone marrow transplantation. Am J Med 1980; 68:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/51\">",
"      Donadieu J, Fenneteau O, Beaupain B, et al. Congenital neutropenia: diagnosis, molecular bases and patient management. Orphanet J Rare Dis 2011; 6:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/47/18170/abstract/52\">",
"      Rosenberg PS, Alter BP, Link DC, et al. Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. Br J Haematol 2008; 140:210.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8375 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18170=[""].join("\n");
var outline_f17_47_18170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22394841\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2412651\">",
"      PROPENSITY TO INFECTION AND SIGNIFICANCE OF NEUTROPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2412659\">",
"      Infection propensity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2412809\">",
"      Significance of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE OF NEUTROPENIA  IN NORMAL SUBJECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect of race and ethnic origin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Neutropenia in African Americans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Benign familial (ethnic) neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLASSIFICATION AND ETIOLOGY OF ISOLATED NEUTROPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acquired neutropenias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Postinfectious neutropenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2412865\">",
"      - Nutritional neutropenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Primary immune disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Bone marrow disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Congenital neutropenias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Myeloperoxidase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Risk of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Specific pathogens associated with neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Infants and young children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Children or adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Neutropenia in the absence of recurrent or protracted infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Moderate to severe neutropenia with recurrent infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      GENERAL ASPECTS OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Patients with bone marrow hypoplasia and/or severe infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Myeloid growth factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Patients with adequate marrow reserves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22394841\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8375\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8375|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/49/32543\" title=\"algorithm 1\">",
"      Diagnostic approach to isolated neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?16/11/16575\" title=\"algorithm 2\">",
"      Treatment of fever and neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8375|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/18/35117\" title=\"figure 1\">",
"      ANC hospitalization infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8375|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/21/25948\" title=\"table 1\">",
"      Hematologic toxicity grades NCI CTCAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/19/10555\" title=\"table 2\">",
"      Neutropenia and infectious risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/10/38060\" title=\"table 3\">",
"      Signs and symptoms of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/49/6941\" title=\"table 4\">",
"      Infection risk by type of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/19/5437\" title=\"table 5\">",
"      Classification of neutropenias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/4/40013\" title=\"table 6\">",
"      Drugs and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/55/42875\" title=\"table 7\">",
"      Diagnostic laboratory evaluation for neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=related_link\" title=\"calculator 1\">",
"      Calculator: Absolute neutrophil count",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=related_link\">",
"      Automated hematology instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6138?source=related_link\">",
"      Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=related_link\">",
"      Cyclic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=related_link\">",
"      Epidemiology and pathogenesis of candidemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=related_link\">",
"      Evaluation and management of fever in children with non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=related_link\">",
"      Fever in children with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4393?source=related_link\">",
"      Granulocyte transfusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44039?source=related_link\">",
"      Hematologic manifestations of HIV infection: Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=related_link\">",
"      Immune neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10473?source=related_link\">",
"      Infectious causes of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=related_link\">",
"      Laboratory evaluation of neutropenia and neutrophil dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=related_link\">",
"      Large granular lymphocyte leukemia in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14280?source=related_link\">",
"      Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=related_link\">",
"      Normal neutrophil development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=related_link\">",
"      Overview of dietary trace minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/59/25521?source=related_link\">",
"      Patient information: Neutropenia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=related_link\">",
"      Reactions to the hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=related_link\">",
"      Risk assessment of adults with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33400?source=related_link\">",
"      Shwachman-Diamond syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=related_link\">",
"      Treatment of large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_47_18171="Classification local anesthetic";
var content_f17_47_18171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F57120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F57120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of local anesthetics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Group I. Benzoic acid esters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzocaine (Americaine, Lanocaine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloroprocaine (Nesacaine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Procaine (Novocaine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proparacaine (Alcaine, Ophthetic, Paracain)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tetracaine (Pontocaine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Group II. Amides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Articaine (Septocaine, Zorcaine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bupivacaine (Marcaine, Sensorcaine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levobupivacaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dibucaine (Nupercainal)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etidocaine (Duranest)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lidocaine (Xylocaine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mepivacaine (Carbocaine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prilocaine (Citanest)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ropivacaine (Naropin)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18171=[""].join("\n");
var outline_f17_47_18171=null;
var title_f17_47_18172="Etiology epistaxis children";
var content_f17_47_18172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of epistaxis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Local",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trauma",
"       </td>",
"       <td>",
"        Nose-picking*; foreign body; blunt or penetrating facial trauma; child abuse, postoperative; nasotracheal intubation; nasogastric tube placement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mucosal irritation",
"       </td>",
"       <td>",
"        Dry air*; allergic rhinitis; inhaled irritants/drugs (inhaled corticosteroids*, tobacco, cocaine heroin, volatile inhalants of abuse); upper respiratory infection or systemic infection with nasal congestion; localized skin or soft tissue infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anatomic",
"       </td>",
"       <td>",
"        Septal deviation or unilateral choanal atresia causing asymmetric airflow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tumors",
"       </td>",
"       <td>",
"        Hemangioma, juvenile nasopharyngeal angiofibroma (particularly in adolescent males), pyogenic granuloma, rhabdomyosarcoma, nasopharyngeal carcinoma, inverting papilloma",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Other",
"       </td>",
"       <td>",
"        Increased nasal venous pressure secondary to paroxysmal coughing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        Systemic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bleeding disorders",
"       </td>",
"       <td>",
"        Inherited or acquired coagulation disorders, platelet disorders, blood vessel disorders (eg, hereditary hemorrhagic telangiectasia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medications",
"       </td>",
"       <td>",
"        Aspirin, ibuprofen, anticoagulants (including rodenticides), valproic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Granulomatous disorders",
"       </td>",
"       <td>",
"        Granulomatosis with polyangiitis (Wegener's), sarcoidosis, tuberculosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Hypertension",
"       </td>",
"       <td>",
"        Primary hypertension, secondary hypertension (renal disease, corticosteroids), increased venous pressure (exertion, superior vena cava syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recurrent",
"       </td>",
"       <td>",
"        Usually related recurrent/chronic nasal trauma or irritation, but may be the presenting symptom of bleeding disorder, hereditary hemorrhagic telangiectasia, nasopharyngeal carcinoma, posttraumatic pseudoaneurysm of internal carotid artery",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Most common causes.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18172=[""].join("\n");
var outline_f17_47_18172=null;
var title_f17_47_18173="Calculation Fick cardiac output";
var content_f17_47_18173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Calculation of AV oxygen difference and cardiac output using the Fick method",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 120px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oxygen consumption is estimated from a nomogram based on age, sex, height, and weight. In addition, oxygen consumption can be measured directly using exhaled breath analysis.",
"    <div class=\"footnotes\">",
"     Hgb: serum hemoglobin (g/dL)",
"     <br>",
"      SaO2: arterial oxygen saturation (percent) measured from arterial blood",
"      <br>",
"       SvO2: mixed venous oxygen saturation (percent) measured from the pulmonary artery in the absence of a shunt or calculated using MvO2 = [3 SVC saturation + IVC saturation] divided by 4 if a left to right shunt is present.",
"       <br>",
"        Constant values: 1.34 mL O2 per gram Hgb; 10 dL per L.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18173=[""].join("\n");
var outline_f17_47_18173=null;
var title_f17_47_18174="Syndromic immunodeficiency";
var content_f17_47_18174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F75043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F75043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Syndromic immunodeficiencies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Name of syndrome",
"      </td>",
"      <td class=\"subtitle1\">",
"       Primary defect",
"      </td>",
"      <td class=\"subtitle1\">",
"       Immune defect",
"      </td>",
"      <td class=\"subtitle1\">",
"       Associated features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Griscelli syndrome, type 2",
"      </td>",
"      <td>",
"       Specific organ dysfunction",
"      </td>",
"      <td>",
"       T, B, NK, Ph",
"      </td>",
"      <td>",
"       Partial albinism, frequent pyogenic infections, lymphohistiocytosis, episodic thrombocytopenia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hoyeraal-Hreidarsson syndrome",
"      </td>",
"      <td>",
"       Specific organ dysfunction",
"      </td>",
"      <td>",
"       T, B, Ph",
"      </td>",
"      <td>",
"       Cerebellar hypoplasia, absent corpus callosum, microcephaly, growth failure, pancytopenia, fungal sepsis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypohydrotic/anhidrotic ectodermal dysplasia with immunodeficiency",
"      </td>",
"      <td>",
"       Specific organ dysfunction",
"      </td>",
"      <td>",
"       T, B",
"      </td>",
"      <td>",
"       Alopecia, hypo/anhydrosis, tooth anomalies, hypogammaglobulinemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       ICF syndrome",
"      </td>",
"      <td>",
"       Chromosomal instability and/or defective DNA repair",
"      </td>",
"      <td>",
"       T, B",
"      </td>",
"      <td>",
"       Mental retardation, chromosomal instability, facial dysmorphism; sinopulmonary, gastrointestinal, cutaneous infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nigmegen breakage syndrome",
"      </td>",
"      <td>",
"       Chromosomal instability and/or defective DNA repair",
"      </td>",
"      <td>",
"       T, B",
"      </td>",
"      <td>",
"       Microcephaly, mental retardation, prenatal onset short stature, bird-like facies, malignancy (lymphoma), sinopulmonary and urinary tract infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       OLEDAID syndrome",
"      </td>",
"      <td>",
"       Specific organ dysfunction",
"      </td>",
"      <td>",
"       B",
"      </td>",
"      <td>",
"       Anhidrotic ectodermal dysplasia, osteopetrosis, lymphadema",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Omenn syndrome",
"      </td>",
"      <td>",
"       Specific organ dysfunction",
"      </td>",
"      <td>",
"       T, B",
"      </td>",
"      <td>",
"       Erthyematous dermatitis, eosinophilia, lymphadenopathy, hemophagocytosis, severe combined immunodeficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Roifman syndrome",
"      </td>",
"      <td>",
"       Growth deficiency",
"      </td>",
"      <td>",
"       B",
"      </td>",
"      <td>",
"       Spondyloepiphyseal dysplasia, retinal dystrophy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Roifman-Costa syndrome",
"      </td>",
"      <td>",
"       Growth deficiency",
"      </td>",
"      <td>",
"       B, T",
"      </td>",
"      <td>",
"       Spondylometaphyseal dysplasia, autoimmune conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Schimke immunoosseous dysplasia",
"      </td>",
"      <td>",
"       Growth deficiency",
"      </td>",
"      <td>",
"       T, B",
"      </td>",
"      <td>",
"       Spondyloepiphyseal dysplasia, progressive neuropathy, episodic lymphopenia, pigmentary skin changes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Short-limb skeletal dysplacia with immunodeficiency",
"      </td>",
"      <td>",
"       Growth deficiency",
"      </td>",
"      <td>",
"       T, B",
"      </td>",
"      <td>",
"       Short-limb skeletal dysplasia, metaphyseal dysplasia; may be associated with adenosine deaminase deficiency or Omenn syndrome; heterogeneous",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trichohepatoenteric syndrome",
"      </td>",
"      <td>",
"       Specific organ dysfunction",
"      </td>",
"      <td>",
"       B, Ph",
"      </td>",
"      <td>",
"       Severe infantile diarrhea, hepatic cirrhosis, Trichorrhxis nodosa, characteristic facies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       WHIM syndrome",
"      </td>",
"      <td>",
"       Specific organ dysfunction",
"      </td>",
"      <td>",
"       T, B, Ph",
"      </td>",
"      <td>",
"       Warts, hypogammaglobulinemia, infection, myelokathexis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bloom syndrome",
"      </td>",
"      <td>",
"       Chromosomal instability and/or defective DNA repair",
"      </td>",
"      <td>",
"       T, B, NK",
"      </td>",
"      <td>",
"       Short stature, telangiectatic erythema of face, sensitivity to sunlight, pneumonia, otitis media, risk for leukemia/lymphoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Branched chain amino acidemias",
"      </td>",
"      <td>",
"       Inborn errors of metabolism",
"      </td>",
"      <td>",
"       T, B, Ph",
"      </td>",
"      <td>",
"       Methylmalonic propionic, and isovaleric acidemias, acidosis, vomiting, ketosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Deletion of short arm of chromosome 4 (4p16) (Wolf-Hirschhorn syndrome)",
"      </td>",
"      <td>",
"       Chromosomal abnormalities of number or structure",
"      </td>",
"      <td>",
"       B",
"      </td>",
"      <td>",
"       Growth and developmental deficiency, \"Greek helmet\"-like facies, microcephaly, coloboma, respiratory infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Kabuki syndrome",
"      </td>",
"      <td>",
"       Growth deficiency",
"      </td>",
"      <td>",
"       B",
"      </td>",
"      <td>",
"       Long palpebral fissures, prominent eyelashes, skeletal anomalies, congenital heart disease, increased risk of autoimmune diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lysinuric protein intolerance",
"      </td>",
"      <td>",
"       Inborn errors of metabolism",
"      </td>",
"      <td>",
"       T, B, Ph, NK",
"      </td>",
"      <td>",
"       Dibasic aminoaciduria, hepatomegaly, failure to thrive, severe varicella infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acrodermatitis enteropathica",
"      </td>",
"      <td>",
"       Specific organ dysfunction",
"      </td>",
"      <td>",
"       T, B, Ph",
"      </td>",
"      <td>",
"       Vesiculobullous dermatitis, alopecia, diarrhea; caused by zinc deficiency, may be associated with opportunistis infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Congenital disorders of glycosylation, Types Ia, Ig, Ik",
"      </td>",
"      <td>",
"       Inborn errors of metabolism",
"      </td>",
"      <td>",
"       B, Ph",
"      </td>",
"      <td>",
"       Decreased glycosylation hypotonia, poor growth, other organ systems may be involved depending on the type",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dyskeratosis congenita",
"      </td>",
"      <td>",
"       Specific organ dysfunction",
"      </td>",
"      <td>",
"       T, B, Ph",
"      </td>",
"      <td>",
"       Atrophy and pigmentation of skin, nail dystrophy, leukoplakia of oral mucosa; risk of cancer of the mouth, anus, skin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Familial intestinal polyatresia",
"      </td>",
"      <td>",
"       Specific organ dysfunction",
"      </td>",
"      <td>",
"       T, B",
"      </td>",
"      <td>",
"       Multiple atresias from pylorus to rectum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Missing or abnormal X chromosome (Turner syndrome; XO, isoX, ring X)",
"      </td>",
"      <td>",
"       Chromosomal abnormalities of number or structure",
"      </td>",
"      <td>",
"       T, B",
"      </td>",
"      <td>",
"       Short stature, webbed neck, broad chest, ovarian dysgenesis, congenital lymphedema, pulmonary/ear infections, autoimmune disease (eg, thyroid disease, celiac disease, arthritis), gonadoblastoma (if Y chromosome material present)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myotonic dystrophy",
"      </td>",
"      <td>",
"       Specific organ dysfunction",
"      </td>",
"      <td>",
"       B",
"      </td>",
"      <td>",
"       Myotonia, muscle wasting, cataract, hypogonadism, cardiac arrhythmia; caused by triplet repeat expansion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Netherton syndrome",
"      </td>",
"      <td>",
"       Specific organ dysfunction",
"      </td>",
"      <td>",
"       T, B, Ph",
"      </td>",
"      <td>",
"       Trichorrhexis invaginata (bamboo hair), ichthyosiform dermatitis, atopic diathesis, skin infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trisomy 21 (Down syndrome)",
"      </td>",
"      <td>",
"       Chromosomal abnormalities of number or structure",
"      </td>",
"      <td>",
"       T, B, Ph, NK",
"      </td>",
"      <td>",
"       Hypotonia, flat facies, upslanting palperbral fissures, mental retardation, sinopulmonary infections, risk of leukemia, autoimmune thyroiditis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CHARGE association",
"      </td>",
"      <td>",
"       Growth deficiency",
"      </td>",
"      <td>",
"       T, B",
"      </td>",
"      <td>",
"       Coloboma, heart defect, atresia choanae, retarded growth and development, genital hypoplasia, ear anomalies/deafness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Growth hormone pathway defects",
"      </td>",
"      <td>",
"       Growth deficiency",
"      </td>",
"      <td>",
"       B, T, NK",
"      </td>",
"      <td>",
"       Defects in growth hormone synthesis or sensitivity deficiency, sinopulmonary infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Incontinentia pigmenti",
"      </td>",
"      <td>",
"       Specific organ dysfunction",
"      </td>",
"      <td>",
"       T, B, Ph",
"      </td>",
"      <td>",
"       Erythematous vesiculobullous eruptions, central nervous system involvement, swirling of macules or hyperpigmentation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rubinstein-Taybi syndrome",
"      </td>",
"      <td>",
"       Growth deficiency",
"      </td>",
"      <td>",
"       T, B",
"      </td>",
"      <td>",
"       Broad thumbs and halluces, prominent nasal septum below ala nasi, cryptorchidism, mental retardation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     B: B-cell defect; NK: NK cell defect; Ph: phagocyte defect; T: T-cell defect.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ming, JE, Stiehm, ER. Genetic syndromic immunodeficiencies with antibody defects. Immunol Allergy Clin North Am 2008; 28:715.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18174=[""].join("\n");
var outline_f17_47_18174=null;
var title_f17_47_18175="Esophageal coin erosion 2";
var content_f17_47_18175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulceration at site of foreign body (coin) removal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 5-year-old child with three weeks of dysphagia with vomiting. A coin in the esophagus was discovered on upper GI radiograph. Both sides of the esophagus, particularly the right side, showed significant inflammation. Ulceration is evident at the site of coin removal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karen Murray, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_47_18175=[""].join("\n");
var outline_f17_47_18175=null;
